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1.1. Introduction
In this introduction some general aspects of psoriasis will be highlighted. For the 
readability of this thesis, a short summary of the pathogenesis of psoriasis in adults 
(and probably in paediatric patients) will be described below. Thereafter, this introduction 
will focus on the known literature of paediatric psoriasis with respect to epidemiology, 
clinical features, treatments and quality of life. 
1.2. History of psoriasis
Psoriasis is a chronic, immune-mediated inflammatory skin disease. The history of 
psoriasis goes back to the ages of the bible, and up until 200 years ago people mistook 
this common disease for leprosy. In 1808, Robert Willan described psoriasis as an 
independent entity and distinguished this disorder from leprosy.1 The foundation for 
the classification of psoriasis in its current form dates back to Ferdinand van Hebra, 
using Robert Willans notes, in 1841.
1.3. Pathogenesis
Psoriasis is a multifactorial disease and has both environmental and genetic causes 
in its aetiology. In addition, both the innate and the adaptive immune system are thought 
to play an important role in the pathogenesis.2 Evidence for a genetic component 
comes from population studies, showing that the incidence of psoriasis is greater in 
first and second degree relatives of patients than in the general population. The risk 
of psoriasis is two or three times higher in monozygotic twins compared to dizygotic 
twins.2-4
Many genetic associations have been established in epidemiological and genetic 
psoriasis studies.5-7 These studies did not distinguish for age at onset of psoriasis. In 
the past decades studies demonstrated the strongest linkage and association for 
PSORS1 locus on chromosome 6p21.3, covering much of the human major histo-
compatibility complex. Human lymphocyte antigen(HLA)-C*06 is the most likely 
susceptibility gene in the PSORS1 region, which probably accounts for 35% to 50% 
of the heritability of the disease.2,8 More recently, genome-wide association studies 
(GWAS) have been conducted to find susceptibility loci for psoriasis.9-13 Nowadays, 
36 susceptibility loci are associated with psoriasis.13 For most of these loci, single 
nucleotide polymorphisms (SNPs) have been identified in or near candidate genes. 
So far, studies have shown that variants in the innate (for example; interferon induced 
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activate the epidermal innate immune system and drive expression and secretion of 
antimicrobial proteins (such as defensins, SLPI, S100 proteins and LL-37) and 
chemokines/cytokines (such as IL-8, CXCL10, IL-1b, and TNF-α).23,24 Disturbances of 
the skin barrier will also initiate a repair response, which includes upregulation of 
regular skin barrier proteins (such as involucrin, transglutaminase-1) but will also 
induce de novo expression of structural proteins involved in repair, regeneration, and 
temporal barrier recovery (such as keratins 6 and 17, SPRRs, SKALP/elafin, and 
members of the LCE3 group). A superficial injury and exposure to PAMPs and 
cytokines in a genetically predisposed person could lead to inflammatory responses, 
increased production of β-defensins in individuals with high copy numbers, and 
insufficient or delayed skin barrier repair in individuals who are heterozygous or 
homozygous for LCE3C_LCE3B-del.14,25-27 This will affect the innate and adaptive 
immune system in several ways. Secretion of mediators such as IL-8, CXCL10, and 
β-defensins will attract neutrophils, T cells, and dendritic cells to the epidermal 
compartment. Incomplete barrier repair will allow sustained penetration of PAMPs or 
even larger (protein) antigens that will be taken up by Langerhans cells and dendritic 
cells and presented to T- cells. T-cell activation will be initiated, which could be 
facilitated by genetic predispositions such as HLA-C*06 or polymorphisms in genes 
of the IL-23 pathway. Activated T cells will secrete Th1 and Th17 cytokines (IFN-γ, 
TNF-α IL-17, IL-23, IL-22), which will further activate the keratinocytes.28 This model creates 
a vicious circle: activated keratinocytes produce chemokines and antimicrobial 
proteins that attract immunocompetent cells. Keratinocytes will continue to proliferate, 
and differentiate incompletely. In addition, skin barrier repair may be incomplete in 
individuals carrying heterozygous or homozygous deletions of the LCE3B and LCE3C 
genes. The incomplete barrier of lesional psoriatic skin will continuously allow PAMPs 
and protein antigens to enter the skin and activate immuno competent cells. Chronicity 
of psoriasis could be explained because of the absence of a negative feedback in 
this process.22 
In paediatric psoriasis, up to almost 75% reported a positive family history of psoriasis, 
however large continental differences are reported.29-33 Most of the genetic studies 
did not distinguish for age at disease onset, besides a few studies on HLA-C*06 and 
ERAP1.34-38 HLA-C*06 was detected to be associated with early onset psoriasis.34-37 
One study demonstrated an association between ERAP1 and a psoriasis onset 
between 10 and 20 years.38 In this thesis, the associations between known genetic 
risk factors for psoriasis and age of onset of psoriasis is investigated. In addition, 
associations between observed clinical parameters and known genetic risk factors of 
psoriasis in a well-defined cohort of paediatric psoriasis patients is described.
with helicase C domain 1 (IFIH1)) and adaptive immune system (for example; HLA-C*06 
and endoplasmic reticulum aminopeptidase 1 (ERAP1)), the Th17 pathway (for example; 
TRAF3-interacting protein 2 (TRAF3IP2), interleukin(IL)-23 receptor (IL23R) and inter-
leukin-12B (IL12B)) and the skin barrier function (for example; deletion of late cornified 
envelope 3B and 3C (LCE3C_LCE3B-del)) are genetically linked with psoriasis.9,10,12,14-19 
Recent studies have shown genetic (epistatic) interactions between HLA-C*06 and 
LCE3C_LCE3B-del, and between HLA-C*06 and ERAP1.10,14,20,21 On the basis of these 
genetic findings, it is a challenge to explain the observed epistasis in molecular or 
cellular terms.
Figure 1 demonstrates a schematic overview of the suggested pathogenesis of 
psoriasis.22 The epidermis is exposed to trauma and infections. Therefore, environmental 
antigens and microbial components will enter the epidermis (collectively named 
pathogen-associated molecular patterns (PAMPs)). These PAMPs can activate 
keratino cytes and immunocompetent cells via pattern recognition receptors and also 
Figure 1  Pathogenesis of psoriasis.
(adapted from: Bergboer JGM, Zeeuwen PLJM, Schalkwijk J. Genetics of Psoriasis: Evidence for epistatic 
interaction between skin barrier abnormalities and immune deviation.22)
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reddish and scaly papules on the trunk and extremities. It is described that this 
subtype of psoriasis can be self-limiting, resolving within a few months of onset, 
however some patients may develop classic plaque type psoriasis.3,64 Frequency 
rates of guttate psoriasis in children vary between approximately 5% to 30%. 
29-33,53,54,56-59,65 Pustular psoriasis and erythrodermic psoriasis are two rare subtypes of 
psoriasis in children.30,31,53,58 Four distinct patterns of pustular psoriasis have been 
described: generalized or von Zumbusch, annular, exanthematic, and localized.66 
Psoriatic arthritis (PsA) is an inflammatory, seronegative spondyloarthropathy that is 
associated with psoriasis. Paediatric PsA, a subtype of juvenile idiopathic arthritis, 
may be difficult to diagnose because of similarities in clinical presentation with 
rheumatoid arthritis. The exact incidence of PsA in children is unknown, possibly 
because skin disease may follow articular disease, and early cases may not be 
diagnosed. In cohort studies of children with psoriasis PsA is reported between 
0.7% and 3.6%, an outlier is a multicenter study from the United States with 10.5% 
PsA.30,32,53,58,59,65 
Koebner phenomenon, the appearance of psoriasis lesions in the uninvolved skin of 
psoriasis patients as a consequence of trauma, is reported in approximately a quarter 
of psoriasis patients.67 Seasonal influences in psoriasis are well known, mostly 
exacerbations of the disease are reported during the winter.32,58 Some degree of 
pruritus is often described in children with psoriasis.29,32,56,58 Clinical manifestations of 
nail involvement of psoriasis can be recognized as pitting, distal onycholysis, 
subungual hyperkeratosis, oil drop discoloration, leukonychia, splinter haemorrhages 
and red spots in the lunula.68,69 Nail involvement was detected in up to 40% of children 
with psoriasis.29-33,53,54,56,58,59,65 Pitting was the most common nail change seen.30,58 
Patients with nail psoriasis are more often diagnosed with PsA.3,69 
1.6. Treatment 
Management of paediatric psoriasis is a great challenge because there is currently 
no cure for psoriasis. In general, treatment modalities are the same as with adults, 
however most of these modalities are not registered for children. In addition, there is 
still not much evidence on the safety and efficacy of treatments in paediatric psoriasis. 
Especially long-term safety is important in this vulnerable age group, in which 
treatments are started at an early age. The following treatments are used in (paediatric) 
psoriasis: topical corticosteroids, keratolytics, vitamin D3 analogues, calcineurin inhibitors, 
topical coal tar, dithranol, phototherapy, acitretin, ciclosporin, methotrexate, fumaric 
acid esters and biologics. 
1.4. Epidemiology
Psoriasis is affecting between 1 – 4% of the world population.39-41 Epidemiological 
studies have demonstrated variable psoriasis prevalence rates across the globe.42 
Psoriasis tends to occur more frequently in Caucasians than in other races and more 
frequently at higher latitudes than lower latitudes.43 Although it can occur at all ages, 
approximately a third of affected patients with psoriasis recall signs of disease before 
adulthood.44-46 The prevalence in children reported varied between 0% in Taiwan and 
2.1% in Italy.47-52 The total prevalence of psoriasis in children aged <18 years is 
approximately 0.7% and the rate increases linearly with age from 0 to 18 years.50 Most 
studies showed that psoriasis in children occurs almost equally in males and 
females.30-32,50,53-55 However, some described a female predilection.33,56 Henseler and 
Christophers stated in 1985 that two clinical forms could be distinguished based on 
clinical grounds, namely early onset (≤ 40 years of age; positive family history) and 
late onset psoriasis (> 40 years of age; no positive family history).34 
1.5. Clinical features
Psoriasis is clinically a heterogenerous disease with several clinical subtypes. The 
phenotyping of psoriasis has traditionally been based on historical morphologic 
descriptions.57 All of the clinical variants of psoriasis described in adults are 
recognized in childhood.31 The commonest type of psoriasis in children is psoriasis 
vulgaris (also known as plaque type psoriasis), with a reported frequency rates up to 
89%.29-33,53,54,56-59 Characteristic features are lesions with sharply demarcated erythe-
matosquamous plaques which may be thick, thin, large or small. Affected areas are 
usually distributed symmetrically, and occur most commonly on the extensor sides of 
elbows and knees; scalp, lumbosacral region, and umbilicus. Scalp involvement is 
reported up to almost 90% of children with psoriasis.29,33,54,60 Around a quarter of 
children with psoriasis report a history of psoriatic diaper rash.31,61  
Several children showed an overlap with “eczema like” lesions, excoriated, not well- 
circumscribed plaques without typical Auspitz’s sign or psoriatic scaling. Psoriasis in 
children may be confused clinically with atopic dermatitis and, the two conditions 
may co-exist.62 The morphology of paediatric psoriasis has previously been recorded 
to differ from adults and may resemble atopic dermatitis, as plaques in children are 
thinner, lack white scale and are less well defined.31 It has been estimated that 
approximately 5% of paediatric patients show an overlap of both psoriasis and 
eczema.31,62 Another subtype is guttate psoriasis, which often occurs after a 
streptococcal throat infection.63 Guttate psoriasis is a sudden dissemination of small, 
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although the exact mechanism of its effectiveness in treating inflammatory skin 
diseases such as psoriasis is not completely understood, it appears to inhibit DNA 
synthesis and mitosis. There are no age-specific data on safety and efficacy of coal 
tar in paediatric psoriasis.
Dithranol (also known as anthralin or cignolin) has been available since 1916.71,76 The 
mechanism of action is not well understood, but it is known to induce a cascade of 
free radicals in the skin, resulting in anti-proliferative effects and a modulation of 
inflammation in psoriasis.77 Treatment with dithranol in paediatric psoriasis can be 
considered if calcipotriol and topical corticosteroids treatments fail, or if psoriasis is 
moderate to severe.78 In a retrospective study, it was shown to be effective and safe 
in 60 children treated with short contact ditranol therapy.79 Dithranol may cause a 
burning sensation, irritation and staining at the application site or clothing. No serious 
adverse events have been reported.76 In this thesis a prospective study about the 
effectiveness and safety of short-contact dithranol therapy in paediatric psoriasis is 
described. 
Ultraviolet (UV) radiation has long been recognized as beneficial for the control of 
psoriatic skin lesions. Phototherapy with ultraviolet B (UVB) and photochemotherapy 
with ultraviolet A (UVA) following ingestion of or topical application of psoralen is 
used in the management of moderate to severe psoriasis in adult patients.71 Only in 
case of lack of efficacy of topical modalities, treatment with narrowband-UVB can be 
considered in adolescents with psoriasis, but only for a short duration.78 No studies 
are available on the long-term safety of UVB phototherapy in paediatric psoriasis. 
In choosing UV therapy, consideration must be given to the potential of UV radiation 
to accelerate photodamage and increase the risk of cutaneous malignancy. Because 
of the photocarcinogenicity of PUVA, its use in the paediatric age group is contra-
indicated.70
Acitretin is a synthetic retinoid (derivatives of vitamin A). In children with psoriasis, 
retinoids can be considered in cases of pustular and erythrodermic psoriasis.78,80 
Common side effects include cheilitis and dryness of the mucosa (eyes, nasal or 
oral), these side effects are dose-dependent. Acitretin is teratogenic and should be 
avoided in women of childbearing age.71
Ciclosporin is a calcineurin inhibitor, which prevents T-lymphocyte activation from 
being translated into the release of effector cytokines.71 Ciclosporin can induce a 
rapid improvement of psoriasis. Close monitoring is required since renal toxicity and 
hypertension are common and broad immune suppression may occur, permitting 
opportunistic infections.71 Treatment with ciclosporin in paediatric psoriasis should 
Topical corticosteroids have become a mainstay in the treatment of psoriasis and are 
considered as a first-line therapy.70 They have anti-inflammatory, anti-pruritic and  anti- 
proliferative properties. Topical corticosteroids are available in a variety of potencies 
(four classes) and preparations.71 Cutaneous complications of corticosteroids are 
striae, (irreversible) atrophy, perioral dermatitis and telangiectasia.72 Infants and 
younger children are at increased risk of local and systemic side effects, including 
growth retardation and suppression of the pituitary-adrenal axis as a result of their 
higher skin surface to body mass ratio.72 Several approaches have been utilized to 
minimize the side effects of topical corticosteroids, including transitioning to weaker 
potency agents after clinical improvement, intermittent usage, and combination with 
other non-steroidal agents.73  
Keratolytics are agents that decrease intercellular cohesion and allow for desquamation 
of terminally differentiated keratinocytes to occur, thus reducing hyperkeratosis and 
scaling. Examples include salicylic acid and urea. They are often used in combination 
with other topical agents. There are no published studies on the specific use of these 
agents in children.
Calcipotriol and calcitriol are vitamin D3 analogues that inhibit keratinocyte proliferation 
and DNA synthesis and promote keratinocyte differentiation.71 Both calcipotriol and 
calcitriol have not been registered for children.70 Calcipotriol, as single compound 
treatment, is not available in the Netherlands anymore. Vitamin D3 analogues can 
be considered as first choice treatment for paediatric psoriasis, a combination with 
class II or III topical corticosteroid is recommended.70 A two-compound formulation 
ointment and gel of vitamin D3 analogue (calcipotriol) and topical corticosteroid 
(betamethasone dipropionate) has been developed for the treatment of psoriasis in 
adults.74,75 The efficacy and safety of the two compound gel for scalp psoriasis in 
children and adolescents is described in this thesis 
Topical tacrolimus (0.03% and 0.1% ointment) and topical pimecrolimus (1% cream) 
are non-steroidal anti-inflammatory agents that decrease T-cell activation and 
proliferation and decrease production of IL-2 via inhibition of calcineurin.71 They are 
approved only for the treatment of atopic dermatitis but are frequently used off-label 
to treat other inflammatory skin diseases such as psoriasis. They are useful as 
corticosteroid sparing agents. Tacrolimus (0.03% or 0.1%) can be considered in 
paediatric psoriasis for the use on areas such as the face, genitals, and flexures.70 
Irritation of the skin is the most frequently reported side effect.70
Topical coal tar is a complex by-product of coal distillation that has been used 
medicinally for over 150 years due to its anti-pruritic and anti-proliferative effects, and 
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defined as the subjective perception of the impact of health status, including disease 
and treatment, on physical, psychological and social functioning and wellbeing.95 
By measuring QoL, it is possible to ascertain the effects of disease upon individuals 
from the child’s perspective. In the limited data published about the QoL in paediatric 
psoriasis, all studies demonstrated a negative effect on the QoL of those affected.94,96-99 
A cross-sectional study in 2006 showed that the QoL impairment in children with a 
chronic skin disease is at least as much as or even more than experienced by children 
with other chronic diseases, such as diabetes and epilepsy.94 In addition, in the 
child’s opinion, psoriasis and eczema caused the greatest impairment in the QoL of 
children with a chronic skin disease.94 Only a few studies described the negative 
impact on QoL in paediatric psoriasis.96-98,100 A cross-sectional study in 39 patients 
demonstrated a negative influence of psoriasis on the QoL in children by means of 
the Children’s Dermatology Life Quality Index (CDLQI) questionnaire.98 A Swedish 
study showed that paediatric psoriasis impairs the children’s QoL and also affects 
their families.96 No significant gender differences in QoL scores were reported.96,101 
One longitudinal study described the influence of a treatment on QoL of children with 
psoriasis.97 This randomized controlled trial demonstrated an improvement in patients’ 
QoL after 12 weeks of treatment with etanercept. In this thesis a cross-sectional and 
longitudinal, observational study about the influence of paediatric (scalp) psoriasis 
on the QoL in a cohort of patients treated in daily clinical practice is described. In addition, 
a multidisciplinary training program for children and adolescents with psoriasis is 
developed and described.  
1.8. Aims and outline of this thesis
In this thesis, the paediatric psoriasis patient will be approached from a holistic point of 
view. Psoriasis in a child or adolescent encompasses much more than the assessment 
of the psoriasis plaques, and the prescription of medication. Obviously, a safe and 
effective treatment of psoriasis in this age group is important and, as mentioned 
above, prospective data are sparse. Therefore, the prospective exploration of different 
treatments in a daily clinical practice setting in paediatric psoriasis is one of the main 
aims in this thesis. However, there is more to paediatric psoriasis. Little is known 
about the genetics of paediatric psoriasis, and about the association between the 
genotype and the phenotype in these children. Last but not least, the impact of 
psoriasis on the QoL of children and adolescents with psoriasis has not been studied 
intensively. In view of these niches in our current knowledge on these important 
aspects we formulated the following aims for this thesis:
  
only be deliberated in exceptional cases, as the evidence is controversial and only 
based on case series and case reports.78,80
Methotrexate (MTX) is a folic acid analogue and competitively inhibits the enzyme 
dihydrofolate reductase and several other folate-dependent enzymes.71 MTX seems 
to be an effective systemic treatment option in moderate to severe paediatric psoriasis 
with a reasonable safety profile.78 The most important side effects of MTX include 
pancytopenia and hepatotoxicity (hepatic fibrosis and cirrhosis). Subjective side effects 
are gastrointestinal complains (nausea, abdominal discomfort) and malaise.71 MTX is 
considered as the first systemic treatment of choice in children with psoriasis.78,80,81
Fumaric acid esters (FAE) are small molecules that are thought to improve psoriasis 
by a broad range of immunomodulatory effects.82,83 FAE are not licensed in the 
Netherlands. FAE can be considered in children with psoriasis in case MTX is 
ineffective or contraindicated.80 Most frequently subjective side effects are gastroin-
testinal complaints (abdominal cramps, diarrhoea) and flushing of the skin.84 In this 
thesis, a retrospective analysis of the effectiveness and safety of FAE of 14 paediatric 
psoriasis patients is described.
Biologics used for psoriasis are therapeutic proteins produced by recombinant DNA 
technology, which selectively interfere in the pathogenesis of psoriasis. The biologic 
that has been licensed at this moment for the use in children with psoriasis is 
etanercept (Enbrel®). Etanercept is a fully human dimeric fusion protein and inhibits 
the activity of tumor necrosis factor(TNF)-α by competitively binding to this pro-
inflammatory cytokine and preventing interactions with its cell surface receptors.83 
Etanercept can be considered as a third-line drug in severe and/or recalcitrant 
psoriasis when the conventional systemic treatments are ineffective.78,80
In the future, other biologics will get their licence for the use in paediatric psoriasis. 
Case reports are published on the use of adalimumab, ustekinumab and infliximab in 
the treatment of paediatric psoriasis.85-93 However, the number of patients described 
in these studies are too low to draw firm conclusions about the efficacy and safety of 
these biologics in paediatric psoriasis. 
1.7. Quality of life
A chronic disease in childhood can affect physical appearance and growth, resulting 
in reduced activity, pain, the need for regular therapy and sometimes unpleasant 
procedures, and possible loss of schooling.94 Health-related quality of life (QoL) is 
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In Chapter 4.2 we presented the development and validation of a questionnaire to 
assess the influence of scalp psoriasis on QoL in children. The development and 
design of a multidisciplinary training program together with the medical psychologist 
for children and adolescents with psoriasis and their parents was described in 
Chapter 4.3.
The results of the subsequent chapters, together with the possible implications for 
future clinical research and care are summarized and discussed in Chapter 5. Finally, 
a summary in Dutch is provided in Chapter 6.
Genetics
1. To explore the genetic features of paediatric-onset psoriasis. 
2. To detect genotype-phenotype associations in children and adolescents with 
psoriasis. 
Treatments
3. To prospectively investigate the effects of different treatments in paediatric 
psoriasis in daily clinical practice. 
Quality of life
4. To achieve more insight in the quality of life of children and adolescents with 
psoriasis.
5. To develop together with the medical psychologist a multidisciplinary training 
program for children and adolescents with psoriasis.  
Several studies to provide answers to the aims formulated above were performed 
and are presented in the following chapters. 
This first chapter of the thesis provides a short introduction. Most genetic studies in 
psoriasis did not distinguish for age at disease onset, therefore Chapter 2 focussed on 
the genetics of paediatric psoriasis. The role of genetic risk factors for specific paediatric 
onset psoriasis were examined in Chapter 2.1. In Chapter 2.2 we investigated 
associations between observed clinical parameters and known genetic risk factors of 
psoriasis in a well-defined prospective cohort of paediatric patients with plaque psoriasis. 
We examined a possible role of LCE3C_LCE3B-del in the Koebner phenomenon in 
psoriasis patients in Chapter 2.3. 
Because there is still not much real clinical practice data providing evidence for 
treatments in paediatric psoriasis, the goal of Chapter 3 was to investigate the effects 
of different treatments in paediatric psoriasis in daily clinical practice. In Chapter 3.1 
the effectiveness and safety of calcipotriol/betamethasone dipropionate scalp 
formulation was prospectively described in children with scalp psoriasis until 48 
weeks of follow-up. In Chapter 3.2 we investigated prospectively the effectiveness 
and safety of short-contact dithranol therapy in paediatric psoriasis in daily clinical 
practice. In addition, the effectiveness, safety, duration of treatment and number of 
visits between regular day care and day care with telemedicine were compared. We 
retrospectively described case series in Chapter 3.3 about the effectiveness and 
safety of fumaric acid esters in 14 children and adolescents with psoriasis.
Chapter 4 focussed on the impact of paediatric psoriasis on the quality of life. 
In Chapter 4.1 we investigated the CDLQI questionnaire in paediatric psoriasis and 
evaluated the influence of treatments in daily clinical practice on this questionnaire. 
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Introduction 
Psoriasis is a common, chronic skin disorder, affecting around 2% of the population1. 
The disease is caused by both environmental and genetic factors, like HLA-C*06.1 
In recent years, independent genome-wide association studies (GWAS) and candidate 
gene approaches identified other genetic susceptibility factors for psoriasis. These 
were mainly single nucleotide polymorphisms (SNPs).2-6
Previous studies have already demonstrated a strong association with HLA-C*06 
in type I psoriasis, which is defined as disease onset before the age of 40 and a 
positive family history.7 Recently, Xu et al. demonstrated an association between 
LCE3C_LCE3B-del and type I psoriasis.8 These studies were based on the observed 
age of onset peaks in psoriasis. The occurrence of such a distribution, however, has 
recently been discussed.9 Besides two studies on HLA-C*06, limited data about the 
association of psoriasis risk genes and age of disease onset are available.7,10 Therefore, 
we investigated the possible association of known psoriasis risk genes in paediatric 
onset (<18 years) and adult onset (≥ 18 years) psoriasis. 
We analysed seven genetic risk factors for psoriasis in well-defined cohorts of 
paediatric onset and adult onset psoriasis. We chose variants that play a (putative) 
role in the various pathways underlying the pathophysiology of psoriasis. Several 
studies showed that variants in the innate (IFIH1) and adaptive immune system 
(HLA-C*06 and ERAP1), the Th17 pathway (TRAF3IP2, IL23R and IL12B) and the skin 
barrier function (LCE3C_LCE3B-del) are genetically linked with psoriasis.3-6,8,11-13 
Materials and methods
Sample collection
DNA samples from psoriasis patients (n=217) were obtained from individuals referred 
to the outpatient clinic of the Department of Dermatology of the Radboud University 
Nijmegen Medical Center. Only patients with psoriasis vulgaris were included in this 
study. The 450 control samples were obtained from the Nijmegen Biomedical Study 
(NBS).14 For the LCE and HLA analysis, we used another control group consisting of 
386 samples, which were used in our previous studies.4,15 Only self-reported data 
were available for all controls, and individuals reported to have psoriasis were 
excluded from this study. All patients and controls were of European descent. For 
cohort characteristics see Table 1.
Abstract
Background
Recent genome-wide association studies have identified several genetic risk factors 
for psoriasis, but data on their association with age at onset are lacking. 
Objective 
To compare the association between known risk alleles and psoriasis in well-defined 
cohorts with paediatric- and adult onset psoriasis. 
Methods 
Based on previous studies we selected seven genes and loci associated with 
psoriasis. Psoriasis patients with paediatric onset (< 18 years) and adult onset 
psoriasis (≥ 18 years) and controls were genotyped. Genotype frequencies were 
compared between controls (n=450) and all cases (n=217), and between controls 
and cases stratified for confirmed age at onset (paediatric onset n=80, adult onset 
n=85).
Results 
Paediatric onset psoriasis showed a significant association with single nucleotide 
polymorphism (SNP) in the ERAP1 (P = 0.042) and IL23R loci (P = 0.042), 
LCE3C_LCE3B deletion (P = 0.003) and HLA-C*06 (P = 1.72 x 10-19) when compared 
with the control group. A significant association of these four genes was also 
demonstrated when all psoriasis cases were compared with controls. In adult onset 
psoriasis a significant association was found for HLA-C*06 (P = 5.11 x 10-06) and for 
LCE3C_LCE3B deletion (P = 0.042). No associations were found for the IFIH1, 
IL12B and TRAF3IP2 loci.
Conclusion
Notwithstanding the small cohort sizes, we demonstrated an association with 
established and recently discovered genetic risk factors in paediatric onset psoriasis 
including genes involved in epidermal barrier function and adaptive immunity. Our 
data suggest that heritable factors may play a more important role in paediatric onset 
psoriasis than in adult onset psoriasis.
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Genotyping
As quality control on the SNP typing 5% of the samples were analysed in duplicate; 
all genotypes were concordant. The SNPs were successfully genotyped in the 
psoriasis and control samples with genotyping success rates between 98.4% and 
99.6%. Genotype cluster plots were evaluated prior to analysis to ensure satisfactory 
assay performance. For the LCE3C_LCE3B-del genotyping a polymerase chain 
reaction (PCR) using three different primers was performed as earlier described.4 
Briefly, 10 ng DNA template was amplified with one universal forward primer and two 
different reverse primers, one spanning the breakpoint of the deletion and one 
located in the possible deleted region generating PCR products of 199 and 240 bp, 
respectively. These were visualized on an agarose gel. HLA-C*06:02 was determined 
by PCR with sequence specific primers for C*06:02.4 Using this method the HLA-C*06 
gene itself is identified rather than a tagging SNP. This method does not allow 
distinction between homozygotes and heterozygotes. 
Statistical analysis
The observed genotype frequencies were compared with the expected Hardy- 
Weinberg distribution by a χ2- test, for none of the variants deviations from Hardy- 
Weinberg equilibrium were found both in the control and the psoriasis group. Power 
was calculated using the Genetic Power Calculator (http://pngu.mgh.harvard.edu/~ 
purcell/gpc/cc2.html).16 Input for the power calculations, like allele frequency and 
genotypic relative risk per genotype, were derived from previous studies.4,12,13 Powers 
shown in Table 2 were derived from the values given for additive models, except for 
HLA-C*06 in which numbers derived from dominant models were used.
Table 1 Cohort characteristics
Controls All  
psoriasis
Paediatric onset  
psoriasis
Adult onset 
psoriasis
N, numbers 450 217 80 85
Boys, n (%) 176 (39.1) 118 (54.2) 29 (36.2) 58 (68.2)
Age, years, mean ± SD 49.6 ± 14.1 40.1 ± 24.6 14.9 ± 9.7 60.7 ± 12.2
Age of onset psoriasis, 
years,  mean ± SD
- 21.3 ± 15.4a 8.2 ± 3.8 33.5 ± 12.5
a Data were available for 165 subjects
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Results 
In our complete psoriasis cohort, we found significant associations between the G 
allele of SNP rs11209026, IL23R (Ptrend = 0.007), the A allele of SNP rs27524, ERAP1 
(Ptrend = 0.019), with LCE3C_LCE3B-del (Ptrend = 0.001) and HLA-C*06 (Ptrend = 3.94 x 10
-19) 
and psoriasis (Table 2). All found associations were in the same directions as 
previously reported. 
Next, we stratified our data into paediatric and adult onset psoriasis and performed 
subgroup analyses. Logistic regression models showed that in the paediatric onset 
psoriasis cohort all found associations in the full cohort were still present. Paediatric 
onset psoriasis was significantly associated with IL23R (Ptrend = 0.042), ERAP1 
(Ptrend = 0.042) LCE3C_LCE3B-del (Ptrend = 0.003) and HLA-C*06 (Ptrend = 1.72 x 10
-19). 
Adult onset psoriasis was associated only with the LCE3C_LCE3B-del (Ptrend = 0.042) 
and HLA-C*06 (Ptrend = 5.11 x 10
-6).  
Moreover, when comparing the paediatric onset psoriasis cohort with the adult onset 
psoriasis cohort, we found a significant difference for HLA-C*06 (P = 2.3 x 10-6), but 
not for the other genes. 
Lastly, we confirmed the known genetic interaction between HLA-C*06 and 
LCE3C_LCE3B-del in our full cohort (P = 0.017).4,12 Furthermore, specifically the 
paediatric onset psoriasis group significantly differed from the control group when 
stratified for HLA-C*06 and LCE3C_LCE3B-del (χ2-test; P = 0.001). The logistic 
regression model, however, showed no significant contribution of the interaction term 
(P = 0.174), probably due to the large effect of the HLA-C*06-component in paediatric 
onset psoriasis. 
Discussion 
In this study, we showed in a small cohort that paediatric onset psoriasis is significantly 
associated with SNPs in ERAP1 (rs27524) and IL23R (rs11209026) loci, and 
LCE3C_LCE3B-del and we confirmed the association for HLA-C*06. Previous studies 
have reported a genetic interaction of ERAP1 and LCE3C_LCE3B-del with 
HLA-C*06.12,17 Given the high HLA-C*06 allele frequency in our paediatric onset 
patients, it is not surprising that the associations with ERAP1 and LCE3C_LCE3B-del 
were detected in such a modestly sized cohort. In adult onset psoriasis significant 
associations were only found for LCE3C_LCE3B -del and HLA-C*06. In our study we 
used a relatively small number of samples compared to large GWAS. It should be 
noted, however, that the subgroup analysis had between 12% and 100% power to 
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Supplemental materialdetect an association. The power in paediatric and adult onset psoriasis groups was 
equal owing to similar group sizes (Table 2). 
In the current study, we have chosen the cut-off point at 18 years of age, which is an 
accepted cut-off point for adulthood in clinical investigations of medicinal products in 
the paediatric population, based on developmental biology and pharmacology.18
ERAP1 encodes an amino peptidase, which regulates the quality of peptides bound 
to MHC class I molecules, such as HLA-Cw6.19 Activation of the interleukin (IL)-23 
receptor (IL23R) stimulates CD4+ T cells into IL-17 producing Th17 cells instead of Th1 
cells.20 The late cornified envelope 3 (LCE3) genes have a role in skin barrier repair.21 
The deletion of LCE3C_LCE3B may lead to a compromised barrier repair response 
upon barrier disruption, which could lead to the penetration of exogenous agents. 
Against a genetic background of HLA-C*06 positivity, these could evoke a response 
of the adaptive immune system. It should be noted, however, that for all associated 
variants a nearby functional variant in linkage disequilibrium with the genotyped 
variant could also contribute to psoriasis. Our data suggest that at least genes 
involved in epidermal barrier function and adaptive immunity play a role in paediatric 
onset psoriasis. 
We hope that this study will stimulate other centres to evaluate their psoriasis patient 
cohorts and define patient groups with reliable and definite age of onset, in order to 
replicate and extend our current study.
 
In conclusion, an association of known genetic risk factors with paediatric onset 
psoriasis, even in a relatively small cohort, was established and our data suggest 
that heritable factors may play a more important role in paediatric onset psoriasis 
than in adult onset psoriasis. Further elucidation of genetic factors and triggering 
environmental factors in an early stage may lead to a better understanding of the 
pathogenesis of psoriasis and could contribute to the development of more targeted 
therapies or even preventive measures for paediatric onset psoriasis.
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Table S1 Numbers of association analysis stratified for age of onset
SNP Gene Allele Population (N)a MAF  
Cases (N)
MAF  
Controls (N)
rs11209026 IL23R G/A All psoriasis (208) 0.04 (17) 0.08 (71)
Adult onset psoriasis (81) 0.06 (9) 0.08 (71)
Paediatric onset psoriasis (78) 0.03(5) 0.08 (71)
rs3213094 IL12B T/C All psoriasis (214) 0.16 (67) 0.17 (155)
Adult onset psoriasis (82) 0.17 (28) 0.17 (155)
Paediatric onset psoriasis (80) 0.14 (22) 0.17 (155)
rs27524 ERAP1 A/G All psoriasis (215) 0.40 (172) 0.33 (295)
Adult onset psoriasis (85) 0.39 (67) 0.33 (295)
Paediatric onset psoriasis (78) 0.42 (65) 0.33 (295)
rs17716942 IFIH1 T/C All psoriasis (217) 0.11 (49) 0.14 (121)
Adult onset psoriasis (85) 0.13 (22) 0.14 (121)
Paediatric onset psoriasis (80) 0.12 (20) 0.14 (121)
rs240993 TRAF3IP2 T/C All psoriasis (216) 0.32 (139) 0.27 (241)
Adult onset psoriasis (85) 0.32 (55) 0.27 (241)
Paediatric onset psoriasis (79) 0.33 (52) 0.27 (241)
direct PCR LCE3C_
LCE3B
DEL/WT All psoriasis (215) 0.30 (128) 0.40 (308)
Adult onset psoriasis (85) 0.31 (53) 0.40 (308)
Paediatric onset psoriasis (78) 0.27 (42) 0.40 (308)
direct PCR HLA-C*06b POS/
NEG
All psoriasis (214) 0.54 (115) 0.17 (63)
Adult onset psoriasis (85) 0.40 (34) 0.17 (63)
Paediatric onset psoriasis (77) 0.78 (60) 0.17 (63)
a   N represents the number of successful genotypes samples. N for controls samples were 444, 444, 447, 
448, 447, 383 and 367 for Il23R, Il12B, ERAP1, IFIH1, TRAF3IP2, LCE3C_LCE3B-del and HLA-C06 
respectively.
b   Numbers in MAF represent individuals instead of allele frequencies.
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Introduction
Psoriasis is a clinically heterogeneous skin disease with a complex genetic background.1-3 
It affects around 2% of the population and in approximately 30% of these patients the 
disease first appears during childhood.1,4 By means of genome-wide association 
studies, the number of genome regions identified to be associated with psoriasis 
jumped recently to 36.5 Different pathways evidently play a role in the pathophysiology 
of psoriasis, as the innate and adaptive immune system, the Th17 pathway and the 
skin barrier function are genetically linked with psoriasis.2,3,6-13 Some studies have 
investigated correlations between genetic risk factors of psoriasis and clinical 
parameters, and these were mainly focused on major histocompatibility (MHC) gene 
HLA-C*06.14-23 In a cohort of adult psoriasis patients a strong association was 
demonstrated between psoriasis severity and single nucleotide polymorphisms 
(SNPs) tagging HLA-C*06 and a deletion of LCE3B and LCE3C (LCE3B_LCE3C-del).22 
Several studies have shown that early age at onset may be associated with distinct 
genetic factors, such as ERAP1 and HLA-C*06.14,17,23,24.Previous studies detected an 
association between HLA-C*06 and early onset psoriasis (onset < 30 or 40 years), 
and a positive family history of psoriasis and early onset of psoriasis,14,16,17,20 suggesting 
an association between HLA-C*06 and family history of psoriasis in patients with 
early onset psoriasis. This association has however, never been investigated. Data 
about associations between clinical parameters and genetic risk factors in paediatric 
psoriasis are lacking. The current study aims to investigate associations between 
observed clinical parameters and known genetic risk factors of psoriasis in a well- 
defined cohort of paediatric patients with plaque psoriasis. 
Materials and methods 
Sample collection
DNA samples were obtained from children with psoriasis referred to the outpatient 
clinic of the Department of Dermatology of the Radboud University Medical Center. 
Only patients of European descent with a primary diagnosis of plaque-type psoriasis, 
before the age of 18 years, were included in this study. Patients with guttate psoriasis 
were excluded. The phenotype classification is based on phenotype at examination 
and not at onset of disease. We obtained clinical data from our prospective observational 
paediatric psoriasis registry in daily clinical practice, called Child-CAPTURE (Continuous 
Assessment of Psoriasis Treatment Use Registry). In this registry, patient characteristics 
including age at onset, family history of psoriasis (up to the third-degree relative) and 
Koebner phenomenon are recorded at the first visit. Psoriasis severity and presence 
of observed nail psoriasis by the physician are recorded every visit.  
Abstract
Background 
Psoriasis is a clinically heterogeneous skin disease with a complex genetic background. 
Data on the association between clinical features in paediatric psoriasis and psoriasis 
risk factors are lacking.
Objective 
This study aims to investigate the associations between observed clinical parameters 
and known genetic risk factors of psoriasis in a well-defined prospective cohort of 
paediatric psoriasis patients. 
Methods 
Children with psoriasis were genotyped for HLA-C*06, LCE3C_LCE3B deletion 
(LCE3C_ LCE3B-del) and single nucleotide polymorphisms (SNPs) tagging ERAP1, 
IFIH1, IL12B, IL23R and TRAF3IP2. Clinical data were obtained from the Child-CAPTURE; 
a prospective registry of children with psoriasis. 
Results 
Significant associations were found for paediatric onset psoriasis (n=151) with ERAP1 
(P = 0.002), IL23R (P = 0.01), LCE3C_LCE3B-del (P = 0.00049) and HLA-C*06 
(P = 3.15 x 10-30). Psoriasis severity was associated with the SNPs tagging IFIH1 and 
ERAP1 (P < 0.05). Age of onset before 10 years was associated with IL12B (P = 0.02). 
Nail psoriasis was more often seen in HLA-C*06 negative patients (P = 0.008). 
Although 67.6% of the cohort has a positive family history and 76.1% is HLA-C*06 
positive, an association between HLA-C*06 and family history could not be found. 
Conclusion 
Psoriasis severity, age at onset and nail psoriasis are, in our well-defined cohort of 
paediatric psoriasis, associated with known genetic risk factors of psoriasis. Remarkably, 
family history is clearly not associated with HLA-C*06 in this specific group. The large 
proportion of patients with a positive family history in HLA-C*06 negative patients 
(and the lack of correlation between the two) indicates that other genes, either alone 
or in epistasis, may have significant effects on heritability.
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common. The individuals who responded with ‘‘often’’ or ‘‘very common’’ were 
considered as Koebner-positive patients and the others as Koebner-negative 
patients, which is in line with our previous study.27 To test for the association with 
psoriasis clinical variables, chi-square tests were executed from the allele frequency 
table (2 x 2 tables). Logistic regression analyses were performed to calculate ORs 
and 95% CIs. The level of significance was considered to be 0.05. Power calculations 
were performed using the Genetic Power calculator.28
Results
Cohort characteristics
The investigated cohort for the replication of the associations between paediatric-on-
set psoriasis and healthy controls consisted of 151 cases and 450 controls, which is 
a doubling of the number of cases compared to our previous study.24 The power to 
detect an association ranged between 18% and 100%. Patient cohort characteristics 
are reported in Table 1. A female preponderance was found  (59%) in the cases, which was 
also present in the control group (60.9%).24 For a total of 139 psoriasis patients clinical data 
were available from our Child-CAPTURE registry (see below). We found no significant 
phenotype differences between patients with an age at onset < 10 years and ≥ 10 years.
The characteristics of the control group of European descent were previously 
described.24 Only self-reported data were available for all controls, and individuals 
reported to have psoriasis were excluded from this study. All participants (or parents, 
if patients were under 18 years) gave written informed consent.  
Genotyping
Genotyping was executed as previously described.24 In short, SNP genotyping was 
performed using Taqman® SNP genotyping assays (assay IDs C_920306_20, 
C_1272298_10, C_3056837_10, C_34244955_10, and C_29927086, for SNPs 
rs240993, rs11209026, rs27524, rs17716942, and rs3213094, respectively) according 
to the manufacturer’s recommendations (Applied Biosystems, Nieuwerkerk aan den 
IJssel, The Netherlands). LCE3C_LCE3B-del genotyping was performed using a 
previous described polymerase chain reaction (PCR).2 HLA-C*06:02 itself (rather 
than a tagging SNP) was determined by PCR with sequence specific primers for 
C*06,2 which does not allow distinction between homozygotes and heterozygotes. 
As quality control on the SNP typing 5% of the samples were analysed in duplicate; 
all genotypes were concordant. The SNPs, LCE3C_LCE3B-del and HLA-C*06:02 
were successfully genotyped in the psoriasis and control samples with genotyping 
success rates between 97.9% and 99.7%, 99.1% and 95.8%, respectively. For SNP 
genotyping, genotype cluster plots were evaluated prior to analysis to ensure 
satisfactory assay performance. 
Statistical analysis
No deviations from Hardy-Weinberg equilibrium were found in the control groups. 
Logistic regression analyses were performed in SPSS software 20.0 (SPSS Inc., 
Chicago, IL, U.S.A.) using co-dominant models. The odds ratio (OR) and 95% 
confidence interval (CI) were calculated using homozygosity for the non-risk variant 
(from previous studies) as a reference for the case-control study. Age at onset was 
analysed comparing two groups; before 10 years and at or after 10 years. Clinical 
severity of psoriasis was assessed by a clinician using three different severity scales: 
Psoriasis Area and Severity Index (PASI; range 0 – 72), Physician Global Assessment 
(PGA; range 0 - 5) and Body Surface Area (BSA; range 0 - 100).25 The highest 
reported psoriasis severity scores for each individual were used. Patients were 
divided in two groups based on psoriasis severity scores; mild-to-moderate and 
severe psoriasis. Mild-to-moderate psoriasis was defined as those patients that have 
never reached PASI ≥ 10, PGA ≥ 3 or BSA ≥ 10. Severe psoriasis was defined as 
those patients that have ever reached PASI ≥ 10, PGA ≥ 3 or BSA ≥ 10. Nail psoriasis 
was scored by using the Nail Psoriasis Severity Index (NAPSI; range 0 - 80).26 Koebner 
phenomenon was assessed based on a 4-point scale, how often a psoriasis plaque 
appeared after skin damage of their non-involved skin: never, rarely, often, or very 
Table 1 Cohort characteristics
Cohort characteristics
Number of cases 151
Boys, n (%) 57 (41.0)
Age, years, mean ± SDa 13.0 ± 4.1
Psoriasis characteristicsa
Age at onset of psoriasis, years, mean ± SD (range) 8.2 ± 4.1 (0 – 17)
Duration of psoriasis, months, mean ± SD (range) 32.9 ± 35.9 (1 – 154)
Time of follow-up, months, mean ± SD (range) 17.8 ± 15.4 (0 – 54)
Family history of psoriasis first-degree relatives, n (%) 53 (38.1)
Family history of psoriasis up to the third degree relatives, n (%) 94 (67.6)
Severe psoriasis, n (%) 77 (55.4)
Nail involvement, n (%) 40 (28.8)
Koebner-positive patients, n (%) 43 (30.9)
a Data were available for 139 subjects. SD, standard deviation.
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Family history of psoriasis 
In 38.1% (n=53) of the patients a first-degree relative stated to have psoriasis. Two 
third of the patients (67.6%, n=94) reported a positive family history of psoriasis up to 
third degree relatives. However, we found no significant associations between family 
history of psoriasis (first and up to third degree relatives) and the allele frequency of 
the psoriasis risk factors. Remarkably, even HLA-C*06 showed no significant 
association with family history of psoriasis (first degree relatives P = 0.92 and up to 
third degree relatives P = 0 .76). In patients with a positive family history up to third 
degree relatives 76.1% were HLA-C*06 positive and in patients with only first-degree 
relatives with psoriasis, 76.5% were HLA-C*06 positive. In patients with a negative 
family history up to third degree relatives 78.6% was HLA-C*06-positive, this was 
77.2% in patients with no first degree relatives with psoriasis (Table 4). 
Psoriasis severity
In our cohort 55.4% (n=77) of the patients were classified as having severe psoriasis. 
Significant associations were demonstrated between severe psoriasis and the risk 
(T) allele of SNP rs17716942 (IFIH1) with an OR of 2.41 (95% CI 1.14 - 5.12, P = 0.019) 
and the risk (A) allele of SNP rs27524 (ERAP1, OR 1.64, 95% CI 1.01 - 2.67, P = 0.047) 
(Table 3). 
Replication of genetic associations with paediatric-onset psoriasis
Logistic regression analysis of our extended cohort demonstrated the same 
associations, albeit with increased significance, with four of the seven tested loci and 
paediatric-onset psoriasis as in our previous study.24 These four genes were IL23R 
(OR 2.42, 95% CI 1.23 - 4.74), ERAP1 (OR 1.55, 95% CI 1.18 - 2.03), LCE3B_LCE3C-del 
(OR 1.67, 95% CI 1.25 - 2.22) and HLA-C*06 (OR 17.1, 95% CI 10.5 - 27.9) (Table 2).
Associations with clinical psoriasis characteristics  
Age at onset of psoriasis
The mean age ± SD at onset of psoriasis in our cohort was 8.2 ± 4.1 years. The group 
of children with an early onset (< 10 years; n=86) had a mean age at onset of 5.5 ± 
2.2 years and the other group  (≥ 10 years; n=53) had a mean age at onset of 12.7 ± 
2.0 years. For IL12B, analysed using SNP rs3213094, we demonstrated a significant 
association between age at onset < 10 years with the risk (T) allele, with an OR of 2.59 
(95% CI 1.14 - 5.88, P = 0.02); 17% of patients with an age at onset < 10 years carried 
this risk allele, compared to 7.5% of the patients with an age at onset ≥ 10 years (Table 3). 
None of the other analysed loci showed significant associations.
Table 2   Association analysis of several known psoriatic risk factors in all patients 
and stratified by age of onset adjusted for sex
SNP Gene Allele a Frequency  
risk allele  
cases
Frequency  
risk allele 
controls
PTrend OR (95% CI)
rs11209026 IL23R G/A 0.97 0.92 0.010 2.42 (1.23 to 4.74)
rs3213094 IL12B T/C 0.13 0.18 0.088 0.72 (0.50 to 1.05)
rs27524 ERAP1 A/G 0.43 0.33 0.002 1.55 (1.18 to 2.03)
rs17716942 IFIH1 T/C 0.88 0.86 0.445 1.16 (0.79 to 1.72)
rs240993 TRAF3IP2 T/C 0.29 0.27 0.132 1.09 (0.82 to 1.45)
direct PCR LCE3C_
LCE3B
DEL/WT 0.72 0.60 0.00049 1.67 (1.25 to 2.22)
direct PCR HLA-C*06 POS/
NEG
0.78 0.17 3.15E-30 17.1 (10.5 to 27.9)
SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval; DEL, deletion; WT, wild 
type; PCR, polymerase chain reaction; POS, positive; NEG, negative. a The first allele called is the allele 
associated with psoriasis. Significant P-values are shown in bold.
Table 3  Significant associations between clinical characteristics and psoriasis  
risk factors
Gene/locus Clinical characteristics Frequency 
risk allele
OR (95% CI) P-value
IL12B/
rs3213094
Age at onset
< 10 years 0.17 2.59 (1.14 - 5.88) 0.020
≥ 10 years 0.08
ERAP1/
rs27524
Psoriasis severity
Mild-to-moderate psoriasis 0.36 1.64 (1.01 - 2.67) 0.047
Severe psoriasis 0.48
IFIH1/
rs17716942
Psoriasis severity
Mild-to-moderate psoriasis 0.83 2.41 (1.14 - 5.12) 0.019
Severe psoriasis 0.92
HLA-C*06/
direct PCR
Nail involvement
Yes 0.61 0.32 (0.14 - 0.76) 0.008
No 0.83
OR, odds ratio; CI, confidence interval; PCR, polymerase chain reaction.
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For analysis of a possible effect of age at onset, we divided the patients into two 
groups with a cut-off point at 10 years of age, which is in line with data previously 
published by Lysell et al.23 They demonstrated, in a Swedish cohort, that ERAP1 
showed an association, albeit weak, with a psoriasis onset between 10 and 20 years. 
Also the strongest association with HLA-C*06 was found for this age group. We did 
not, however, find associations between age at onset and ERAP1 and HLA-C*06 in 
the Dutch paediatric psoriasis patients, which may be due to ethnic variation. In our 
cohort, an age at onset before 10 years was demonstrated to be associated with 
IL12B, which encodes the p40 subunit of interleukin (IL)-23 and IL-12 and is involved 
in both the IL12/Th1 pathway and IL23/Th17 pathway of psoriasis.29,30 
Previous studies detected associations between HLA-C*06 and early onset psoriasis, 
and between a positive family history and early onset of psoriasis in groups of mainly 
adult patients.14,16,17,19 These findings suggest an association between HLA-C*06 and 
a positive family history. In our paediatric cohort, however, with 67.6% of the patients 
having a positive family history up to third degree relatives, including 38.1% with first 
degree relatives with psoriasis, and a total of 77.8% HLA-C*06 positive patients, an 
association between family history and HLA-C*06 was not found. This is due to the 
fact that similar proportions of HLA-C*06 positivity in both the group with a positive 
family history (first degree relatives 76.5% vs up to the third degree relatives 76.1%) 
and a negative family history (first degree relatives 77.2% vs up to the third degree 
relatives 78.6%) were found (Table 4). Although our cohort is relatively small, it is 
highly unlikely that increasing the number of cases would reveal such an association. 
Previous studies reported an association of HLA-C*06 with type 1 psoriasis (early 
onset, positive family history) but not with type 2 (late onset, no positive family 
history).14,16 There are, however, several discrepancies with regard to the age criteria. 
Type 1 psoriasis is variably and loosely defined, depending on the study, as having 
an onset before 30 or 40 years and by a positive family history. Clearly this cannot be 
a comprehensive classification as there are many patients with early onset and 
negative family history and also patients with adult onset that have a positive family 
history. We analysed truly paediatric patients (onset < 18 years), which is by definition 
not type 2 psoriasis, but neither necessarily type 1 because of the requirement of 
positive family history. 
Although the lack of correlation between HLA-C*06 and positive family history comes 
somewhat as a surprise, it is clearly not unprecedented. Gudjonsson et al.,19 
demonstrated in a large mixed cohort of paediatric and adult-onset psoriasis that 
also many of the HLA-C*06 positive patients have a negative family history. Based on 
our own data and those of Gudjonsson et al. we would argue that the historic 
classification of type 1 and 2 psoriasis is no longer meaningful. Classifications based 
Nail involvement
In HLA-C*06 negative patients we found a significant increase of nail involvement 
(OR 0.32, 95% CI 0.14 - 0.76, P = 0.008, Table 3). None of the other psoriasis risk 
alleles showed a positive or negative association with this clinical parameter. 
Koebner-phenomenon
Forty-three patients (30.9%) were Koebner-positive. None of the investigated risk 
factors showed a significant association with Koebnerization in our cohort. 
Discussion
This is the first study to report associations between clinical parameters and genetic 
risk factors in a prospective paediatric psoriasis cohort. We could confirm and 
strengthen, in a larger patient group, our previous findings that paediatric-onset 
psoriasis is associated with HLA-C*06, LCE3C_LCE3B deletion and SNPs in the 
ERAP1 and IL23R loci.24 We performed additional analyses based on clinical data 
from these children and demonstrated that age at onset, psoriasis severity and nail 
psoriasis are associated with different genetic risk factors of psoriasis. Remarkably, 
family history of psoriasis is clearly not associated with HLA-C*06 in this specific 
group.
Table 4  Distribution of family history of psoriasis and HLA-C*06 in our cohort  
of paediatric psoriasis
n (%) HLA-C*06a P-value
Positive
n (%)
Negative
n (%)
Only first degree relatives with psoriasis
     Yes 51 (39.2) 39 (76.5) 12 (23.5) 0.92
     No 79 (60.8) 61 (77.2) 18 (22.8)
Up to third degree relatives with psoriasis
     Yes 88 (67.7) 67 (76.1) 21 (23.9) 0.76
     No 42 (32.3) 33 (78.6) 9 (21.4)
a Data were available for 130 subjects
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on the presence of established genetic risk factors are likely to be more helpful in 
future studies for personalized approaches with respect to prognosis and treatment. 
Even when age of onset is used as a classifier, the distinction between paediatric 
(< 18 years) and adult psoriasis (≥ 18 years) is probably more informative than the 
cut-off point of age 30 or 40 years, which is used in early and late onset psoriasis.
The most striking clinical association in our paediatric cohort with any of the genetic 
risk factors was the observation that nail psoriasis was found more often in HLA-C*06 
negative patients (P < 0.008). This association has been previously reported for a 
larger cohort (unstratified for age) by Gudjonsson et al.19    
Psoriasis severity in adults was previously demonstrated to be associated with 
HLA-C*06 and LCE3C_LCE3B deletion.17,19,20,22 In our paediatric cohort we did not find 
these associations. We did, however, identify an association between psoriasis 
severity and IFIH1 and ERAP1. IFIH1 encodes the interferon-induced with helicase C 
domain 1 (innate immune system), which triggers type I interferon in response to 
microbial infection,31 and variants are associated with type 1 diabetes.32 ERAP1 
encodes an amino peptidase, which regulates the quality of peptides bound to MHC 
class I molecules, such as HLA-C*06.33
 
A limitation of this study is the modest sample size for genetic studies. Considering 
that only children were included, it is, however, the largest cohort described with 
clinical features. In our cohort more than 50% of the patients was defined as severe 
psoriasis which could introduce a selection bias.
In conclusion, our findings suggest that genetic polymorphisms in both innate and 
adaptive immunity play a role in paediatric plaque psoriasis severity and age at onset 
of psoriasis. We confirm earlier associations found in adult psoriasis between 
HLA-C*06 with respect to nail involvement. The large proportion of patients with a 
positive family history in HLA-C*06 negative patients (and the lack of correlation 
between the two) indicates that other genes, either alone or in epistasis,34 may have 
significant effects on heritability. 
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The late cornified envelope (LCE) genes are a group of highly homologous genes 
located on chromosome 1 in the epidermal differentiation complex, which is a 1.6 Mb 
region on the human genome containing a large number of genes involved in 
epidermal differentiation. The epidermal differentiation complex contains a total of 18 
LCE genes, divided over 6 groups.1 Two genes of the LCE3 group, LCE3B and LCE3C, 
are subject to copy number variation due to a commonly deleted segment of 32kb.2 
Individuals can have copy number 0 (homozygous for the deletion), 1 (heterozygous 
for the deletion) or 2 (homozygous for the wild type ancestral haplotype). Deletion of 
LCE3B and LCE3C (LCE3C_LCE3B-del) is a strong and widely replicated risk factor 
for psoriasis.2-5 Recent studies indicate that LCE3C_LCE3B-del may also be a risk 
factor for other (auto)immune diseases,6-8 but it is not associated with atopic 
dermatitis.9 LCE proteins are expressed in a limited number of epithelia and we have 
recently shown that the genes of the LCE3 group, including the psoriasis-associated 
LCE3B and LCE3C genes, show distinct expression patterns under inflammatory 
conditions or upon skin injury.1,2,10,11 Out of all the identified psoriasis-associated risk 
factors, only LCE3C_LCE3B-del and copy number variation in the beta-defensin 
cluster affect expression of putative skin barrier proteins.12 Although the observed 
odds ratios (ORs) in various cohorts are smaller than those published for HLA-Cw6 
(current notation HLA-C*06),13,14 the strongest known psoriasis risk factor, 
LCE3C_LCE3B-del has a large population attributable risk (23%).2 Both the significant 
contribution to the genetic basis of psoriasis and its plausible biological function, 
render LCE3C_LCE3B-del an important risk factor that is amenable to mechanistic 
studies. 
In 1877, Heinrich Koebner described the appearance of psoriatic lesions in uninvolved 
skin of psoriatic patients as a consequence of trauma. Now, it is known that patients 
with other dermatological conditions can koebnerize as well.15 Several causes for this 
phenomenon are known, like trauma, allergic or drug reactions and therapeutics, 
although the pathogenesis is not well understood.15 In previous studies it was shown 
that on average 25% of psoriasis patients will koebnerize on external stimulation of 
the skin.15 We hypothesized that the deletion of the LCE3B and LCE3C genes could 
lead to an inferior barrier function or to an impaired repair function following barrier 
disruption. This would make the skin more susceptible to penetration by microbial or 
other environmental molecules, which could trigger innate or adaptive immune 
responses. Based on our hypothesis that the Koebner reaction may be caused by 
breaching the skin barrier and/or insufficient barrier repair, we investigated a possible 
association of the Koebner phenomenon with LCE3C_LCE3B-del. In a Dutch cohort 
of psoriasis patients that were previously typed for LCE3C_LCE3B-del (by PCR)2 and 
HLA-C*06:02 status (by PCR)2 we assessed their propensity to koebnerize following 
skin injury. The “Commissie mensgebonden onderzoek Arnhem-Nijmegen” approved 
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Our results suggest that the Koebner phenomenon in psoriasis is unlikely to be 
dependent on the LCE3B/C genotype. Therefore, the biological role of LCE3B and 
LCE3C deletion in development and/or maintenance of psoriasis remains to be 
explained. 
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for this study. Patients/parents of the patients gave their informed consent. The 
investigations were conducted according to the Declaration of Helsinki principles. 
Adult patients were approached via written questionnaires. In the case of juvenile 
psoriasis patients we approached the parents by telephone. Both the patients/
parents and the interviewers were unaware of the LCE3C_LCE3B-del and HLA-C*06 
status of the patients. We assessed, on a 4-point scale, how often a psoriasis plaque 
appeared after skin damage of their non-involved skin: never, rarely, often or very 
common. The individuals that responded with often or very common were considered 
as Koebner positive patients and the others as Koebner negative. We approached 
259 patients of whom 192 responded (response rate 74%). Of these, 46 patients 
(24%) were Koebner positive. This percentage is in line with the previously reported 
data.15 We found similar figures for adults (22%, n=24) and children (27%, n=22). 
Table 1 shows an equal distribution over the three LCE3B/C genotypes for the 
Koebner positive and negative group. Logistic regression analysis demonstrates that 
there is no association between LCE3C_LCE3B-del and the Koebner phenomenon in 
psoriasis patients (P = 0.835, OR 1.06, 95% confidence interval (95%CI) 0.64 - 1.74). 
Also for HLA-C*06 we did not observe an association with the Koebner phenomenon 
(P = 0.310, OR 1.43, 95%CI: 0.72 – 2.82). This is in contrast with a previously reported 
association between Koebner effect and HLA-C*06 in Icelandic psoriasis patients. 16 
This discrepancy may have several causes such as the study design (family-based 
versus population-based), ethnic background, inaccurate reporting because of 
self-reported data or lower statistical power of our study (66%, input values were 
derived from Gudjonsson et al.16 significance level 0.05, OR 2.3, allele frequency 0.28, 
dominant model). 
Table 1  No association between LCE3B/C copy number and koebnerization  
in psoriasis patients
LCE3B/C  
copy number
Genotype Koebner 
positive
Koebner 
negative
P-value OR (95% CI)
0 del/del 20 (43%) 66 (45%) 0.835 1.06 (0.64 – 1.74)
1 del/wt 21 (46%) 65 (45%)
2 wt/wt 5 (11%) 15 (10%)
CI, confidence interval; del, deletion; OR, odds ratio; wt, wildtype.
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Introduction
Up to almost 90% of children with psoriasis report some degree of scalp involvement.1-4 
Scalp psoriasis is a challenging element of psoriasis to treat, as it is difficult to apply 
topical treatment at the scalp, resulting in poor compliance.5 A two-compound scalp 
formulation composed of both vitamin D analogue (calcipotriol) and corticosteroid 
(betametasone dipropionate) has been developed specifically for the treatment of 
scalp psoriasis. This scalp formulation was effective in adults and improved the 
quality of life (QoL) of adults with scalp psoriasis.6-13 Literature on the effectiveness of 
treatment of scalp psoriasis in children is lacking. Therefore, this study aims to evaluate, 
in daily clinical practice, the effectiveness and safety of calcipotriol/betamethasone 
dipropionate scalp formulation in children with scalp psoriasis. In addition, the impact 
of this formulation on the QoL of these children was analysed. 
 
Materials and methods
Patient population
Data were extracted from a prospective observational daily clinical practice registry, 
called Child-CAPTURE (Continuous Assessment of Psoriasis Treatment Use Registry). 
All children (<18 years) with psoriasis receiving calcipotriol/betamethasone dipropionate 
scalp formulation between September 2008 and April 2013 were enrolled. Concomitant 
systemic antipsoriatic treatments were excluded, but it was allowed to use topical therapy 
for other parts of the body, such as topical corticosteroids, vitamin D analogues or 
dithranol creme. As this study was performed in daily clinical practice patients were 
treated according to the opinion of the treating dermatologist and visits were not 
planned according to a fixed schedule. At the beginning of treatment, patients were 
advised to use the scalp formulation once daily for the first two weeks and 
subsequently three times a week. Depending on the severity of scaling the scalp was 
pre-treated with 10% salicylic acid in unguentum cetomacrogolis for two nights. 
Because patients were seen in daily clinical practice, a wash-out period was not 
implemented. Data were analysed as separate treatment episodes, which was 
defined as the time between the beginning and the end of treatment. An individual 
patient could have more than one treatment episode. Restart of a treatment after an 
interruption of three months or longer was determined as a new treatment episode. 
At baseline, patient characteristics were recorded including: age, gender, age at 
onset, family history and duration of psoriasis. 
Abstract
Background 
Evidence on efficacy and safety of topical treatments for paediatric scalp psoriasis is 
lacking.
Objective
This study aims to evaluate the effectiveness and safety of calcipotriol/betamethasone 
dipropionate scalp formulation for paediatric scalp psoriasis in daily clinical practice. 
The influence of this formulation on the quality of life (QoL) was assessed as well.
Methods
Data of children treated with the scalp formulation were extracted from a prospective 
observational daily clinical practice registry of children with psoriasis, called Child- 
CAPTURE. Severity was expressed by Psoriasis Scalp Severity Index (PSSI) and the 
impact on the QoL was reflected by the validated Children’s Scalpdex in Psoriasis 
(CSP).
Results
Eighty-four treatment episodes were analysed. Significant improvements of PSSI 
score (18.7 ± 11.8 to 12.7 ± 9.4) was demonstrated in the first 12 weeks and this result 
was well maintained during 48 weeks of follow-up. Three patients (4.1%) developed 
striae of the skin (arms, trunk and legs), which are possibly related to the scalp 
formulation. CSP scores (79.0 to 46.3) declined significantly after three months. 
Conclusion
In a daily clinical practice cohort of children with scalp psoriasis, calcipotriol/beta -
methasone dipropionate scalp formulation was effective with a 32.1% improvement of 
PSSI at week 12 and a maintenance of this effect until 48 weeks of follow-up, in 
combination with improvement of QoL.
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Results
Patients
In total 130 children (146 treatment episodes) were prescribed the calcipotriol/
betamethasone dipropionate scalp formulation. Sixty-two treatment episodes were 
excluded (n=8 concomitant systemic antipsoriatic treatments, n=27 had already 
been prescribed the scalp formulation before the first visit and n=27 no follow-up). 
Thus, 84 treatment episodes (73 patients) were analysed (Table 1). 
Effectiveness 
At the beginning of the study, a mean baseline PSSI of 18.7 ± 11.8 was found. At week 6, 
a 19.2% PSSI improvement (15.1 ± 11.0) was achieved and at week 12 this increased 
to 32.1% PSSI improvement (12.7 ± 9.4). This effect was well maintained until week 48, 
with PSSI rates varying between 13.8 ± 11.5 and 12.8 ± 4.8 (Figure 1). Mixed model 
analysis demonstrated a significant positive effect of the scalp formulation on scalp 
psoriasis over time (P < 0.001). Seventy-two patients had a follow-up of at least 12 weeks. 
The response rate of at least 50% PSSI improvement at week 12 compared to baseline 
was 29.2% (n=21). In 16 children clearance (PSSI = 0) was achieved after a median 
treatment duration of 19 weeks. Analyses of the separate items of the PSSI (erythema, 
Outcome measures
Clinical and QoL data were recorded every time the patient visited our outpatient 
clinic. Safety data were prospectively collected based on side-effects reported by the 
patients and observations of the physician at each visit. Scalp psoriasis severity was 
expressed by the Psoriasis Scalp Severity Index (PSSI; range 0 - 72).14 The PSSI is 
calculated by a 5-point scale (0 = no symptoms, to 4 = very severe) for each 
individual symptom (redness, scaling, and infiltrate). These three scores are added 
and multiplied with a score for the percentage of the scalp involved (0 = 0% to 
6 = 90 – 100%).14 Clinical severity of psoriasis was assessed by a clinician using 
Psoriasis Area and Severity Index (PASI; range 0 – 72).15 
Since March 2011 data about the impact on the QoL of scalp psoriasis was collected 
by the validated Children’s Scalpdex in Psoriasis (CSP; range 0 – 100).16 The CSP 
questionnaire comprises of 22 items that consists of three major constructs: 
‘symptoms’, ‘emotions’ and ‘functioning’. A lower score represents a better QoL. 
Statistics
PSSI scores were analysed at baseline, every 6 weeks until week 24 and thereafter 
every 12 weeks until week 48. The scores were interpolated to the most nearby time 
point. Effectiveness was analysed using the as-treated analysis, in which the analysis 
is performed on the treatment that patients actually received. Subanalyses were 
performed for patients with and without pretreatment with salicylic acid preparations, 
and for patients that treated their scalp psoriasis in the last four weeks before the 
beginning of the scalp formulation versus those who did not. Descriptive statistics 
were used to represent study results as means (± standard deviation; SD). 
Comparisons of numeric variables were analysed with the (un)paired t-test. P < 0.05 
was considered statistically significant. A linear mixed modelling approach was 
applied to investigate the difference in scalp psoriasis severity across multiple visits. 
CSP scores were analysed at baseline, 3 and 6 months after treatment, and were 
converted to the most nearby time point. Changes in the median scale CSP scores 
(interquartile range; IQR) at month 3 and month 6 compared to baseline were 
analysed by using the Wilcoxon rank sum test. Analyses of this questionnaire beyond 
6 months were considered inappropriate, as the number of available questionnaires 
were too low. 
The statistical analyses were performed using SPSS software 20.0 (SPSS Inc., 
Chicago, IL, U.S.A.). The study was approved by the research ethics committee of the 
Radboud University Medical Center and has been carried out in the Netherlands in 
accordance with the applicable rules concerning the review of research ethics 
committees and informed consent.   
Table 1  Patient characteristics
Number of patients, n 73
Number of treatment episodes, n 84
Boys, n (%) 33 (45.2)
Age, years, mean ± SD (range) 10.8 ± 3.7 (4 - 17)
Mean duration of follow-up, weeks ± SD 29.9 ± 21.4
With prescribed treatment in the last four weeks before the beginning 
of the scalp formulation, n (%)
31 (37)
Psoriasis history
Age at onset, years, mean ± SD 7.6 ± 3.9
Duration of psoriasis, months, mean ± SD 37.7 ± 35.3
Family history of psoriasis, n (%) 51 (69.9)
Psoriasis assessments
Baseline PASI, mean ± SD 5.7 ± 3.1
Baseline PSSI, mean ± SD 18.7 ±11.8
Salicylic acid preparations, n (%) 28 (33.3)
PASI, Psoriasis Area and Severity Index; PSSI, Psoriasis Scalp Severity Index.
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Safety
Patients did not report any complaints. In three overweight patients (4.1%) the 
physician observed striae of the skin. The first is a 12-year-old female with striae after 
pubertal growth on both thighs. Another a 13-year-old female had striae on both 
thighs, lower back and buttocks. A 17-year-old male developed striae on his elbows 
and abdomen after extreme increase in bodyweight and waist circumference. There 
were no serious adverse events. 
Quality of life of scalp psoriasis
The total score of the CSP questionnaire showed a significant improvement from 
baseline (median 79.0; IQR 82.9) to 3 months of follow-up (median 46.3; IQR 89.3, 
P < 0.001), with a median CSP score of 59.0 (IQR 69.7) after 6 months. The median 
baseline (n=64) scores were as follows: scale symptoms 41.7 (IQR 31.3), scale 
emotions 26.8 (IQR 35.7) and scale functioning 15.0 (IQR 30.0) (Figure 2). Significant 
improvements from baseline were observed at 3 months (n=47) for all three of the 
scales (scale symptoms 25.0, IQR 25.0, P = 0.009; scale emotions 17.9, IQR 30.4, 
P < 0.001; scale functioning 10.0, IQR 30.0, P = 0.006). The median scale scores 
of the CSP after 6 months (n=38) remained more or less the same compared to 
3 months (scale symptoms 33.3, IQR 27.1, scale emotions 16.1, IQR 27.7, scale 
functioning 15.0, IQR 25.0).  
induration, desquamation and area) demonstrated for all items a significant decline 
in the first 12 weeks (P < 0.05), until week 48 these items remained more or less the 
same. The PASI demonstrated also a significant effect over time (from 5.7 ± 3.1 to 
4.1 ± 2.1, P = 0.038) (Figure 1). 
Twenty-eight treatment episodes were pre-treated with salicylic acid. In subanalysis, 
patients who pre-treated their scalp psoriasis with salicylic acid had a higher baseline 
PSSI than those who did not (26.7 ± 11.0 vs 14.7 ± 10.0, P < 0.001). Both groups 
showed a significant improvement of PSSI at week 12 (with salicylic acid, mean PSSI 
15.8 ± 11.4, 40.1% PSSI improvement, P = 0.012; without salicylic acid, mean PSSI 
11.0 ± 9.1, 25.2% PSSI improvement, P = 0.04). Until week 48, scalp psoriasis 
severity in both groups were more or less the same with PSSI rates varying between 
14.6 ± 12.8 and 11.5 ± 9.1 (Figure 1). Mixed model analysis demonstrated a significant 
positive effect of the scalp formulation on scalp psoriasis for both groups over time 
(P < 0.05).
There were no differences in baseline PSSI nor in effectiveness over time of those 
who used a treatment in the last four weeks before start versus those who did not 
(P > 0.05).
Figure 1  Effectiveness of calcipotriol/betamethasone dipropionate scalp 
formulation: total group, with and without pre-treatment with salicylic acid.
PASI, Psoriasis Area and Severity Index; PSSI, Psoriasis Scalp Severity Index; TE, treatment episode.
Figure 2   The influence of calcipotriol/betamethasone dipropionate scalp 
formulation on the quality of life by means of the Children’s Scalpex in 
Psoriasis median scale scores at baseline, 3 and 6 months.
*P < 0.05.
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Life Quality Index).22 Both studies only investigated short-term improvement of QoL 
until 8 weeks of treatment. 
In conclusion, this prospective daily clinical practice study for paediatric scalp 
psoriasis showed that calcipotriol/betamethasone dipropionate scalp formulation 
was effective and seems well tolerated, with a 32.1% improvement in the first 12 weeks 
and a maintenance of this effect during a 48 weeks of follow-up. In addition, a positive 
influence on the QoL of these children was demonstrated.
Discussion 
This prospective observational study describes in daily clinical practice the 
effectiveness and safety of calcipotriol/betamethasone dipropionate scalp formulation 
in paediatric scalp psoriasis and analysed the influence of this formulation on the 
QoL of these children. The scalp formulation was effective in daily clinical practice 
with a 32.1% PSSI improvement at week 12 and a maintenance of this effect until 48 
weeks of follow-up. Patients pre-treated with salicylic acid for two nights demonstrated 
the highest improvement in the first 12 weeks. This might be due to a fast reduction in 
scaling, but is more probably due to the fact that these patients had a higher PSSI at 
the beginning and could therefore show a greater reduction. The efficacy and safety 
of the scalp formulation in adults with scalp psoriasis has been investigated in many 
studies.6-13 In these randomized, controlled trials, the outcome measures were the 
investigator global assessment and patients were only included after a pre-defined 
wash-out period. In 68 - 83% of the patients, an absent or very mild scalp psoriasis 
was found after 8 weeks of once daily treatment.6-10 In a 52-week follow-up study, 
92.3% of the patients treated with the scalp formulation reported an adequately 
controlled scalp psoriasis.11 Because of the different outcome measures used, and 
different treatment regimes, a direct comparison of our results with prior studies is not 
possible. In addition, no wash-out period was applied and patients may not be nearly 
so motivated to use their medication compared to patients participating in clinical 
trials, which probably leads to poor adherence.17,18 
In our study in three overweight patients (4.1%) striae distensae were observed. These 
striae are possibly related to the scalp formulation, although the overweight in combination 
with an increase in body weight can also cause striae distensae.19,20 In addition, topical 
corticosteroids for other parts of the body were used as well. A long-term study in 
adults reported a proportion of corticosteroid-related events in 2.6% of the patients.11 
Other 8-week randomized, controlled trials in adults reported adverse events rates 
between 3.4% and 7.0%.7-10 The number of patients and adverse events in our study 
were too small to draw firm conclusions about safety. In addition, it should be kept in 
mind that adverse events in this study were based on patients own experience or 
observations of the physician and not actively reported and collected as in 
randomized, controlled trials. In this study no pharmacokinetics was taken into 
account. This might be interesting in a future study. 
A positive influence on the QoL of the scalp formulation was demonstrated. Our 
results confirm two former studies in adults with scalp psoriasis.12,21 However, these 
studies used other instruments to measure quality of life, namely Skindex-16 (16-item 
Short Form Health Survey) and the Scalp Life Quality Index (derived from the Dermatology 
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21 Ortonne JP, Ganslandt C, Tan J et al. Quality of life in patients with scalp psoriasis treated with calcipotriol/
betamethasone dipropionate scalp formulation: a randomized controlled trial. J Eur Acad Dermatol 
Venereol 2009; 23: 919-26.
22 Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine 
clinical use. Clin Exp Dermatol 1994; 19: 210-6.
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Introduction
In one-third of patients with psoriasis, disease onset occurs during childhood.1 Three 
studies have been published on the effectiveness of dithranol in paediatric psoriasis, of 
which two did not use an objective severity score.2-4 Short-contact dithranol therapy 
involves a complex, time consuming treatment schedule, and best results are 
obtained when it is administered in a day care centre setting, with regular visits.5 
Contact by means of telemedicine can reduce this burden. 
This study aims to provide the first prospective observational data on the effectiveness 
and safety of short-contact dithranol therapy in children with psoriasis in daily clinical 
practice. In addition, the effectiveness, safety, duration of treatment and number of 
visits between two groups were compared – regular day care and day care with tele-
medicine. 
Materials and methods
Data were extracted from the prospective observational, daily clinical practice registry 
of children with psoriasis, called Child-CAPTURE (Continuous Assessment of 
Psoriasis Treatment Use REgistry). All children (aged <18 years) with plaque psoriasis 
receiving short-contact dithranol therapy between September 2008 and December 
2012 were analysed. Exclusion criteria are depicted in Figure 1. 
Short-contact dithranol cream was started if topical corticosteroids with or without 
calciportiene treatment failed, or if patients had a moderate-to-severe psoriasis 
(Psoriasis Area and Severity Index (PASI) score around 10 and/or a Children’s 
Dermatology Life Quality Index (CDLQI) score around 10).6 The formulation of 
dithranol cream, can be washed off totally and cleanly is as follows: dithranol (0.05, 
0.1, 0.2, 0.3, 0.4, 0.8, 1, 2, 3 or 5 gram), ascorbic acid 0.1 gram, salicylic acid 1 gram 
and cremor lanette I ad 100 gram.7
As of March 2011 patients were given the possibility to choose between regular day 
care or day care with telemedicine, primarily to reduce the burden of travelling for 
patients living far away. Telemedicine was performed by video calls established 
through the Skype for Windows desktop software (Skype Communications SARL, 
Luxembourg City, Luxembourg).
In the first week, all patients were seen for four days at the day care centre; thereafter 
visits were scheduled two times a week. From the second week, the telemedicine 
Abstract
Background 
Evidence on the effectiveness and safety of short-contact dithranol therapy in 
paediatric psoriasis is sparse and only based on retrospective data. The best results 
are achieved in a time consuming day care setting. 
Objective
To study prospectively the effectiveness and safety of short-contact dithranol therapy 
in paediatric psoriasis. In addition, the effectiveness, safety, duration of treatment 
and number of visits between regular day care and day care with telemedicine were 
compared.
Methods
Data were collected from the prospective observational Child-CAPTURE registry of 
children with psoriasis. Effectiveness was measured as the mean percentage 
improvement in Psoriasis Area and Severity Index (PASI). Safety was assessed by 
recording adverse events. The number of visits and duration of treatment were 
reported. 
Results 
For all patients a mean percentage reduction in PASI score of -69.3% was found, with 
no significant differences between regular day care and day care with telemedicine. 
The only adverse event reported was irritation of the skin. Neither the frequency of 
irritation during treatment nor the mean duration of treatment significantly differ 
between the two groups. Patients with telemedicine had significant less number of 
visits
Conclusion
This first prospective observational study demonstrated that short-contact dithranol 
therapy in paediatric psoriasis is effective and safe. Regular day care and day care 
with telemedicine are equally effective. Telemedicine can be of additional value as it 
is less time consuming. We hope is will therefore make dithranol treatment appropriate 
for a larger number of children with psoriasis. 
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Psoriasis severity was assessed by means of PASI.8 Safety was assessed by counting 
the frequency of irritation as reported in the day care centre patient status. Each 
interruption of dithranol treatment caused by irritation of the skin (burning sensation 
of the skin and erythema) was counted as one event. All other reported adverse 
events were noted. Quality of life was scored with a validated Dutch version of the 
CDLQI.9 
Descriptive statistics were used to provide baseline characteristics. All analyses were 
performed as treated. For differences within or between groups paired samples 
t-tests or independent t-tests were used or, if applicable, Wilcoxon signed-rank tests 
or Mann–Whitney U tests. A P-value of < 0.05 was considered statistically significant. 
All statistical analyses were performed using SPSS software 20.0 (IBM Corp., Armonk, NY, 
U.S.A.). The study was approved by the research ethics committee of the Radboud 
University Nijmegen Medical Center and has been carried out in the Netherlands in 
accordance with the applicable rules concerning the review of research ethics 
committees and informed consent.
Results
Thirty-four patients could be analysed (Figure 1): 17 on regular day care and 17 on 
day care with telemedicine. At baseline, the patients overall had a median PASI of 8.9 
with a mean CDLQI of 9.6 (Table 1). The PASI, CDLQI or demographic characteristics 
did not differ significantly between the two groups, except for a preponderance of 
males (82.4%) in the telemedicine group.
Overall, dithranol treatment resulted in a mean significant change in PASI score of 
-69.3%. Effectiveness between the groups did not significantly differ (-67.2% regular 
day care vs. -71.3% telemedicine P = 0.62). Overall, a significant mean ΔCLDQI 
score of -5.1 was found (-4.1 regular day care vs. -6.1 telemedicine; P = 0.25).
The only adverse event reported was irritation of the skin, with a mean frequency of 
3.6 events and no difference in frequency between the two groups. None of the 
patients and parents reported unwanted staining of their furniture and bathroom. 
The mean treatment duration was 11.4 weeks, without significant difference between 
the groups. The mean number of day care centre visits was 14.5, with patients in the 
telemedicine-assisted group having significantly fewer visits (mean 12.1 versus 16.8, 
P = 0.014). Instead, they made a mean of 7.1 video calls, and more often phone 
contact between the visits. 
group replaced one visit per week by a scheduled video call. Between the visits, 
patients treated themselves daily at home. Patients could always call for extra 
instructions. The application schedule of daily short-contact dithranol therapy is 
published in our previous retrospective study.2 The protocol is available from the 
corresponding author on request. Treatment ended if clearance or almost clearance 
was achieved or if no further results were achieved. To prevent staining of the 
bathroom, patients were advised to wet the bathroom before showering and to clean 
the bathroom with a cleaning agent directly thereafter.
Figure 1  Study flow diagram.
CAPTURE,Continuous Assessment of Psoriasis Treatment Use Registry; RUMC, Radboud University 
Medical Center. a Within 1 month prior to the start and during treatment; b during dithranol treatment;  
c interruption of > 1 week; d to avoid learning bias.
Treatment episodes 
of short-contact 
dithranol therapy in the 
Child-CAPTURE registry n=70
Treatment episodes at RUMC 
day-care centre n=46
Patients included 
in study n=34
Regular day-care 
n=17
Day-care with 
telemedicine n=17
Excluded:
Short-contact dithranol 
therapy in other hospitals 
n=24
Excluded:
Systemic antipsoriatic treatment/phototherapy a n=4
Other topical therapy b n=0
Excessive sun exposure n=1
Interupted treatment c n=1
Missing data n=2
Mutiple treatment episodes d n=4
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Discussion
In this first prospective observational study, the effectiveness and safety of short- 
contact dithranol treatment in paediatric psoriasis was demonstrated. In addition, 
the effectiveness, safety, duration of treatment and number of visits between regular 
day care and day care with telemedicine were compared. Especially in paediatric 
psoriasis there is a need for effective treatments without serious side-effects. Our 
prospective daily clinical practice data showed a significant reduction in PASI score 
of -69.3%. Direct comparison of these results with prior studies is not possible, as 
these failed to report objective severity scores to evaluate outcome.2,3 Our results are 
consistent with percentages reported in a randomized controlled trial involving 
short-contact dithranol therapy in adults, which demonstrated a PASI improvement of 
-63.3%.10 With respect to quality of life, short-contact dithranol therapy resulted in a 
significant decline in CDLQI score, both in the regular day care and day care with 
telemedicine group. 
The maximum biological effect of dithranol is achieved just below the level of irritation of 
the surrounding uninvolved skin.11 Compared to other studies,2,3 the obtained frequency of 
irritation in our study is relatively high. As these studies were retrospectively performed, 
the reported frequency might have been biased or our application time may be too 
long. In children with psoriasis, no studies have been performed that investigated 
which application time schedule of short-contact dithranol therapy is the most 
sufficient. Dithranol staining is a common reported limitation.12,13 In our study, however, 
none of the patients and parents reported unwanted staining of their bathroom or 
furniture, probably because they received clear instructions to prevent this.
This study is the first to compare the effectiveness and safety of short-contact dithranol 
treatment application between regular day care and day care with telemedicine. The most 
important benefit of patients in telemedicine group is the reduction in travel time, which 
results in the possibility to attend school more often. In addition, for the convenience 
of the children, the telemedicine contacts were planned before or after school. 
Patients were given the possibility to choose between the two treatment regimes. 
Obviously, all patients in the telemedicine group lived far away. The preponderance 
of males is considered to be coincidental. We found no significant differences in 
effectiveness, safety and improvement in quality of life between the groups. Additional 
studies are needed to investigate the possibility of decreasing day care visits while 
preserving good results. 
A limitation of the study are the relatively small treatment groups, but considering 
the fact that data and evidence of treatment in children with psoriasis are sparse, we 
think it is still an acceptable number of patients to draw conclusions. In addition, there 
Table 1  Patient and treatment characteristics of regular day care and day care 
with telemedicine
Regular  
day care
Day care with 
telemedicine
All  
treatments
P - value*
Number of patients 17 17 34
Age, years, mean ± SD 
(range)
11.4 ± 3.4
(5 – 17)
10.2 ± 4.0
(3 – 17)
10.8 ± 3.7
(3.0 -17.0)
0.39
Boys/girls, n (%) 6/11
(35.3/64.7)
14/3
(82.4/17.6)
20/14
(58.8/41.2)
0.004
Psoriasis history
Age at onset, years,  
mean ± SD (range)
7.8 ± 4.4
(1 – 15)
7.4 ± 4.0
(3 – 16)
7.6 ± 4.2
(1 - 16)
0.68
Duration of psoriasis,  
months, mean ± SD (range)
43.4 ± 39.2
(1 – 135)
38.7 ± 30.8
(5 – 107)
41.0 ± 34.8
(1 – 135)
0.97
Effectiveness
Baseline PASI, median (IQR) 9.9 (7.6 - 12.0) 8.2 (6.6 – 9.8) 8.9 (6.6 – 11.2) 0.14
End of treatment PASI, 
median (IQR)
2.7 (2.0 – 3.9) 2.0 (0.8 – 3.3) 2.4 (1.1 – 3.8) 0.15
Percentage change in PASI, 
95% CI
-67.2  
(-78.9 to -55.6)
-71.3  
(-83.6 to -58.9)
-69.3  
(-77.3 to -61.2)
0.62
Adverse events
Frequency of irritation during 
treatment, mean ± SD
3.7 ± 1.8 3.5 ± 3.1 3.6 ± 2.5 0.89
Short-contact dithranol therapy
Duration of treatment,  
weeks, mean ± SD
10.8 ± 3.8 11.9 ± 4.8 11.4 ± 4.3 0.48
Total number of visits at the 
day care centre, mean ± SD
16.8 ± 6.1 12.1 ± 4.3 14.5 ± 5.7 0.014
Frequency of telemedicine 
contacts, mean ± SD
- 7.1 ± 3.6 - -
Frequency of phone contacts, 
mean ± SD
0.5 ± 0.7 1.7 ± 1.7 1.1 ± 1.4 0.01
Max concentration of 
dithranol cream, median 
(IQR)
0.2 
(0.2 – 0.3)
0.3 
(0.2 – 0.4)
0.2 
(0.2 – 0.4)
0.16
Quality of life
Baseline CDLQI, mean ± SD 8.6 ± 3.9 10.8 ± 6.6 9.6 ± 5.4 0.28
End of treatment CDLQI, 
mean ± SD
4.8 ± 4.4 4.4 ± 4.5 4.4 ± 4.4 0.29
Absolute change in CDLQI 
score, mean ± SD
-4.1 ± 4.3 -6.1 ± 5.6 - 5.1 ± 5.0 0.25
SD, standard deviation; IQR, interquartile range; PASI, Psoriasis Area and Severity Index; 95% CI, 95% 
confidence interval, CDLQI, Children’s Dermatology Life Quality Index. *between regular day care and 
day care with telemedicine. Significant P-values are shown in bold.
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was an absence of a wash-out period of topical treatments, and patients were not 
randomized to regular day care or telemedicine, which might introduce a bias. 
In conclusion, short-contact dithranol therapy is an effective and safe treatment in 
paediatric psoriasis, as demonstrated in this first prospective study. The introduction 
of telemedicine in addition to regular day care resulted in a reduction of visits, while 
preserving good results. Whether these results can be conserved while reducing the 
number of visits even more, should be investigated. By combining telemedicine with 
regular day care, this effective and very safe treatment option will become appropriate 
for a larger group of children with psoriasis.
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Introduction
Psoriasis is a common inflammatory skin disease that manifests in 30-50% of patients 
in the first 2 decades of life.1,2 Treatment of psoriasis in childhood is often challenging, 
and there is a substantial unmet need for alternative treatment options to broaden the 
therapeutic armamentarium for paediatric psoriasis.3 Fumaric acid esters (FAE) may 
be an alternative option for paediatric psoriasis.4 
FAE are small molecules that are thought to improve psoriasis by a broad range of 
immunomodulatory effects.5,6 FAE were licensed in Germany in 1994 for severe 
plaque psoriasis in adults and in 2008 for moderate plaque psoriasis. In adults the 
efficacy of FAE is comparable to that of methotrexate,7 and the long-term safety 
profile is favourable.8 Data on paediatric use of FAE is relatively scarce, with only 3 
case reports published to date.9-11
In this study, we aimed to expand the current knowledge on the use of FAE in paediatric 
psoriasis by assessing the effectiveness and safety of FAE in 14 children with psoriasis.
Patients and methods
Study design and study population 
This is a retrospective analysis of patients with psoriasis aged < 18 years treated with 
oral FAE. All patients were treated by dermatologists, and were identified through 
databases or registries from several Dutch university and regional hospitals. 
Treatment regimen
Treatment with FAE was administrated according to local and Dutch guidelines with 
one of three standardized Dutch FAE-formulations. Routine laboratory testing and 
urine analysis were performed before the start of treatment and at fixed intervals 
during treatment.6 FAE were given according to the progressive dosing regimen 
applied in adult patients, starting at dimethylfumarate 30 mg, with an incremental 
increase up to a maximum daily dosage of 720 mg based upon clinical response and 
tolerability.6 Patients were allowed topical psoriasis treatments in addition to FAE, 
including topical steroids, vitamin D analogues and dithranol. 
Data collection
We extracted clinical data from the patient’s medical records. Effectiveness was 
based on the treating physician’s notes and with the psoriasis area and severity index 
(PASI) when available. 
Abstract
Background 
Fumaric acid esters (FAE) are used as an effective and safe oral treatment for plaque 
psoriasis in adult patients, but little is known about their efficacy and safety in children 
with psoriasis. 
Objective
To assess the effectiveness and safety of FAE in the treatment of paediatric psoriasis.
Methods
A retrospective analysis of 14 paediatric psoriasis patients (age < 18 years) treated 
with FAE between 2004 and 2012 at several Dutch university and regional clinics. 
Patients were identified through databases or registries. 
Results
The median age at start of FAE treatment was 15 years (range 8 – 17 years). The 
median duration of FAE treatment was 10 months (range 1 – 80 months), and the 
median maintenance dosage per day was 360 mg dimethylfumarate (range 240 – 
600 mg). Five patients (36%) achieved a complete clearance of their psoriasis, one 
patient (7%) had a good improvement, three patients (21%) had a partial response, 
and five patients (36%) were non-responders. FAE treatment was well-tolerated, but 
two patients (14%) discontinued FAE, one with severe diarrhoea and one with flushing 
of the skin. Five patients (36%) had transient, slightly abnormal laboratory values of 
liver-function tests or leukocytes that did not necessitate FAE dosage reduction or 
treatment discontinuation. No serious adverse events occurred.
Conclusion
In this retrospective case series FAE seemed to be an effective and safe treatment for 
children with psoriasis. FAE may be an attractive therapeutic alternative to the 
currently used systemic immunosuppressive agents for paediatric psoriasis patients. 
Further studies are needed to evaluate the suitability of FAE in paediatric psoriasis.
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after having been treated for 1 and 4 months, respectively. One patient with a complete 
resolution of her psoriasis discontinued FAE after 20 months of treatment. 
 
Effectiveness
Five of the 14 patients (36%) achieved a complete clearance of their psoriatic skin lesions 
with FAE treatment. One (7%) patient had a good improvement with an 82% reduction 
in PASI after 4 months of treatment. A partial response was seen in three patients 
(21%), one of whom had a PASI reduction of 69% following 6 months of treatment. 
Five patients (36%) did not sufficiently respond to FAE, or their psoriasis deteriorated. 
Of these, two patients had a 27% and a 31% increase in PASI, respectively. 
Tolerability
The most common reported subjective adverse events were abdominal cramps 
(n=5), diarrhoea (n=4), and flushing of the skin (n=2), which in most cases were 
tolerable and transient of nature. However, one patient discontinued FAE because of 
Results
Patient characteristics
The study population consisted of 14 children with chronic plaque psoriasis (Table 1). 
The median disease duration was 5 years (range 1 – 10 years). The majority of the 
patients (93%) had received prior phototherapy and/or systemic treatment. The median 
age at start of FAE treatment was 15 years (range 8 – 17 years). 
Treatment duration and dosage of fumaric acid esters
The median duration of FAE treatment was 10 months (range 1 – 80 months). The 
median maintenance dosage per day was 360 mg dimethylfumarate (range 240 – 
600 mg). Six patients were maintained on FAE at time of data closure, with a median 
treatment duration of 26 months (range 4 – 80 months). Five patients discontinued FAE 
after a median duration of 8 months (range 2 – 17 months) because of an insufficient 
clinical response. Two patients discontinued FAE because of subjective side-effects 
Table 1  Overview of clinical characteristics, treatment course and outcome of 
children with psoriasis treated with fumaric acid esters (FAE)
Patient Sex Type of 
psoriasis
Disease 
duration 
(years)
Previous 
systemic 
treatments/ 
phototherapy
Age at 
start 
of FAE  
(years)
Highest 
daily dose 
of FAE 
(mg)
Maintenance 
daily dose  
of FAE (mg)
Duration  
of treatment
(months)
Responsea Adverse 
events
Laboratory 
deviations
Reason for 
discontinuation
Follow-up
1 b M Plaque 6 UV-B 8 240 c 240 c 8 No response; PASI 
increase from 9.8 to 12.4 
(+27%)
Diarrhoea None Insufficient clinical 
response
Treated with MTX
2 F Plaque 
and 
palmo-
plantar
7 UV-B, PUVA 12 600 c 480-600 c 33 
(ongoing)
Complete response None None NA FAE continued
3 M Plaque 9 UV-B 13 360 c 360 c 12 No response; PASI 10 at 
end of treatment
None Reduction in  
neutrophils
Insufficient clinical 
response
Treated with MTX
4 F Plaque 1 UV-B 13 240 d 240 d 6
(ongoing)
Partial response;
PASI reduction from 16.4 to 
5.1 (-69%)
Flushing of 
the skin
Not reported NA FAE continued 
5 M Plaque 5 UV-B, acitretin  13 720 e 600 e 17 Partial response Bronchitis Reduction in 
lymphocytes, 
increase in 
neutrophils 
Insufficient clinical 
response
Treated with MTX, 
etanercept
6 F Plaque 8 UV-B, acitretin, 
MTX
15 720 c NA 4 Partial response Abdominal 
cramps 
Increase in 
eosinophils, 
proteinuria 
Insufficient clinical 
response
Treated with 
etanercept, MTX
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Table 1  Continued
Patient Sex Type of 
psoriasis
Disease 
duration 
(years)
Previous 
systemic 
treatments/ 
phototherapy
Age at 
start 
of FAE  
(years)
Highest 
daily dose 
of FAE 
(mg)
Maintenance 
daily dose  
of FAE (mg)
Duration  
of treatment
(months)
Responsea Adverse 
events
Laboratory 
deviations
Reason for 
discontinuation
Follow-up
7 f F Plaque 4 UV-B 15 480 d 120-240 d 20 Complete response Abdominal 
complaints
None Sufficient clinical 
response
Remission of 
psoriasis at 1-year 
of follow-up
8 M Plaque 
and 
guttate
7 UV-B 15 360 c 120-360 c 80
(ongoing)
Complete response None None NA FAE continued
9 M Plaque 3 UV-B 16 720 e 480 e 18 
(ongoing)
Complete response Abdominal 
cramps
Increase in ALT, 
increase in AST, 
increase in GGT, 
increase in serum 
creatinine
NA FAE continued 
10 M Plaque 
and 
guttate
1 None 16 480 c 240 e 33
(ongoing)
Complete response None None NA FAE continued 
11 M Plaque 2 MTX 16 720 c NA 2 No response; PASI 
increase from 7.5 to 9.8 
(+31%) 
Diarrhoea, 
flatulence
Increase in ALT Insufficient 
response
Not reported
12 F Plaque 3 UV-B 17 120 e NA 1 No response;
PASI increase from  
3.2 to 3.9 (+22%)
Abdominal 
pain, 
diarrhoea, 
severe 
flushing of 
the skin 
None Subjective adverse 
events
Treated with 
topical treatment
13 F Plaque 4 UV-B, MTX 17 720 e NA 4 No response Nausea, 
abdominal 
complaints
Increase in ALT Subjective adverse 
events
Treated with 
adalimumab 
14 F Plaque 10 UV-B, MTX, 
cyclosporin
17 270 d NA 4
(ongoing)
Good response;
PASI reduction from  
6.5 to 1.2 (-82%) 
Diarrhoea, 
fatigue
Not reported NA FAE continued 
ALT, alanine aminotransferase; AST, aspartate transaminase; F, female; FAE, fumaric acid esters; GGT, 
Gamma-glutamyltransferase; M, male; MTX, methotrexate; NA, not applicable; PUVA, psoralen and 
ultraviolet-A photochemotherapy; UV-B, Ultraviolet-B phototherapy. a Complete response: a complete 
resolution of the psoriatic skin lesions; Good response: at least 75% improvement of the psoriasis; 
Partial response: 50-75% improvement or in case of initial improvement but later deterioration of the 
psoriasis; Insufficient response: in case of less than 50% improvement; No response in case of 
worsening of psoriasis. b FAE in combination with topical treatment (1% dithranol once daily). 
c FAE-formulation with enteric-coated tablets of 30 mg dimethylfumarate and 120 mg dimethylfumarate 
(De Magistrale Bereider’, Oud-Beijerland, the Netherlands). d FAE-formulation with enteric-coated slow- 
release tablets of 30 mg dimethylfumarate and 120 mg dimethylfumarate (‘Mierlo-Hout’, Helmond, the 
Netherlands). e FAE-formulation with enteric-coated tablets of 105 mg (30 mg dimethylfumarate plus 75 mg 
calcium-monoethylfumarate) and 215 mg (120 mg dimethylfumarate plus 95 mg calcium- mono-
ethylfumarate) (De Magistrale Bereider’, Oud-Beijerland, the Netherlands). f This patient was described 
previously by us in a Dutch journal.11
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In long-term observational studies FAE was associated with a favourable side-effect 
profile without any indications of an increased risk of infections, malignancies or 
serious side-effects.8,15 It is tempting to speculate whether the favourable long-term 
safety profile as observed in adults also applies in children. The adverse events and 
changes in laboratory tests in this study are comparable with previous findings in 
adult patients. 
The number of dermatologists treating paediatric psoriasis with FAE is limited.16 In the 
Dutch guidelines FAE are not recommended because of insufficient evidence. To 
improve evidence on the use of FAE in children with psoriasis, further randomized 
controlled trials are needed to evaluate the efficacy of FAE in children with psoriasis 
and to compare the efficacy of FAE with of other systematic treatments such as 
methotrexate. Also, long-term observational studies are needed to assess the safety 
profile of FAE in children.
In conclusion, we report the effectiveness and safety of FAE in a retrospective series 
of 14 children with plaque psoriasis. FAE may be considered an alternative systemic 
treatment option in paediatric psoriasis.
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abdominal complaints. Another patient discontinued FAE because of a severe 
episode of flushing with diffuse reddening of the skin, a burning sensation, epistaxis, 
and an inability to stand on her feet following 6 hours after the first intake of 120 mg 
FAE; however, this resolved quickly with oral steroids (prednisone) and oral histamine 
antagonist (fexofenadine). 
Safety
Abnormal laboratory tests were observed in five patients (36%). Most of these 
involved slightly elevated liver-function tests (n=3). In all patients the elevations were 
less than twice of the upper limit of normal value (ULN). Other changes in laboratory 
tests included mild, temporary shifts in leukocyte counts. One patient developed a 
mild increase in serum creatinine levels up to 93 µmol/L (ULN 90 µmol/L). A mild 
proteinuria (1+) was reported in another patient, but disappeared within 4 weeks. In 
all cases the abnormal laboratory values normalized without any intervention and 
while continuing FAE treatment. There were no serious adverse events reported. 
Discussion
This is the first case series in which the effectiveness and safety of FAE are described 
in children with chronic plaque psoriasis. Our findings demonstrated positive effects 
of FAE and the treatment was well-tolerated.  
Several limitations need to be considered. Our retrospective study lacked a predefined 
study protocol and a control group, and uniform objective disease assessment 
scores such as PASI were not available for all patients. Nevertheless, we classified 
treatment responses based on the physicians’ notes, which would for a large part 
reflect the changes during treatment. Furthermore, patients were treated relatively 
long time with FAE. The median treatment duration was 10 months and seven patients 
were treated continuously for at least 1 year. 
 
The literature on FAE in children is limited. There have been three case reports on FAE 
in paediatric psoriasis,9,10,12 and one report on granulomatous cheilitis 13 and pityriasis 
rubra pilaris.14 Compared with the very limited experience in children, the literature on 
FAE in adult patients is much larger. About 50 to 70% of adult psoriasis patients 
treated with FAE achieve a 75% improvement in PASI score following 16 weeks of 
treatment,6 while 8 to 44% do not respond. These data are in line with the results in 
this study, in which 43% of the children achieved a complete or almost complete 
clearance of their psoriasis and 36% were non-responders.
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Introduction
Psoriasis is a chronic, remitting and relapsing scaly inflammatory skin disease that 
affects 1 – 3% of the population.1 Although it can occur at all ages, approximately a 
third of affected patients with psoriasis recall signs of disease before adulthood.2 
Treatment can provide temporary remission of physical symptoms but not a cure. 
Skin disease in children can have detrimental effects on the quality of life (QoL), 
disrupting family and social relationships, interfering with playing, sport and affecting 
normal development.3 In 1995 the Children’s Dermatology Life Quality Index (CDLQI) 
was developed to allow QoL assessment of children with skin conditions.4 Data about 
QoL in paediatric psoriasis are limited. Only a few cross-sectional studies demonstrated 
the negative influence of psoriasis on the QoL in children by means of the CDLQI.4-8 
Longitudinally, only one randomized controlled trial described a significant positive 
effect of etanercept therapy on QoL in moderate to severe paediatric plaque psoriasis.8
The influence of treatments in daily clinical practice on QoL of children with psoriasis 
is important in clinical decision-making. As this has never been investigated before, 
the current prospective observational study assessed the QoL in paediatric psoriasis 
by means of the CDLQI, in a cohort of patients treated in daily clinical practice. In 
order to assess what aspects of QoL were mainly influenced by psoriasis treatments, 
the 10 items of the CDLQI questionnaire were analysed as well.
Materials and Methods
Study population
Data were obtained from a prospective observational paediatric psoriasis registry, 
called Child-CAPTURE (Continuous Assessment of Psoriasis Treatment Use Registry). 
The Child-CAPTURE included all patients under the age of 18 years, with the diagnosis 
of psoriasis, who had attended the dermatology outpatient clinic at the Radboud 
University Nijmegen Medical Center, between September 2008 and October 2011. 
Patients were referred by general practitioners and dermatologists. At the initial visit 
patient characteristics were recorded including: age, gender, age at onset, family 
history and duration of psoriasis. During visits at the out-patient clinic, patients are 
actively asked if they have joint pain and when needed patients are referred to a 
paediatric rheumatologist.
Treatments
Patients were treated according to the treatment algorithm as published by de Jager 
et al.9 A rough summary of this algorithm is as follows: first, calcipotriene with or without 
Abstract
Background
Paediatric psoriasis has a negative effect on the quality of life (QoL). The influence of 
treatments on QoL of these children has never been investigated before in a 
prospective observational study. 
Objective
To assess the Children’s Dermatology Life Quality Index (CDLQI) in a cohort of 
patients with paediatric psoriasis and to evaluate the influence of treatments in daily 
clinical practice on CDLQI. 
Methods
We conducted a prospective observational study of children with psoriasis from a 
registry containing daily clinical practice data. Before and after treatment, QoL was 
assessed by the CDLQI and disease severity was documented by the Psoriasis Area 
and Severity Index (PASI). Three clusters of treatments were analysed: topical, 
dithranol and systemic therapy. 
Results
In total, 125 patients were enrolled in the registry. Cross-sectionally, a mean ± SD 
CDLQI score of 7.5 ± 5.0 and a mean ± SD PASI score of 7.0 ± 5.8 were recorded. 
Itching and problems with treatment had the highest impact on the children’s QoL. 
Longitudinally, 85 patients were analysed with a total of 137 treatment episodes. All 
treatments contributed to a significant decline in total CDLQI score, with the largest 
decrease seen in dithranol and systemic treatments. A significant correlation was 
found between ΔCDLQI and ΔPASI for all treatment modalities. The highest positive 
impact of treatments was found in a decline of itch and sleep disturbance. 
Conclusions
In this first prospective observational study on CDLQI in paediatric psoriasis, a 
positive influence of treatments in daily clinical practice on QoL was demonstrated.
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Results
Cohort characteristics and baseline 
In total, 125 patients were enrolled in the Child-CAPTURE registry. One patient was 
diagnosed with psoriatic arthritis. None of the paediatric psoriasis patients were 
hospitalized. Patient characteristics of the study population are reported in Table 1. 
The mean ± SD age at baseline was 10.7 ± 3.9 years, with a female preponderance 
(63.2%). The mean ± SD age at onset of psoriasis was 7.4 ± 3.9 years. Before visiting 
our clinic the patients had a mean ± SD duration of their psoriasis of 39.2 ± 37.0 
months (range 1 – 154). A large proportion of patients (70.4%) had one or more family 
members affected with psoriasis. At the initial visit, patients had a mean ± SD 
psoriasis severity score (PASI) of 7.0 ± 5.8 and documented a mean ± SD CDLQI 
of 7.5 ± 5.0. A significant positive correlation between PASI and CDLQI of r = 0.31 
(P = 0.001) was found. Boys and girls had a comparable mean score in total CDLQI 
(7.5 vs. 7.6; P = 0.89). The mean ± SD CDLQI of patients under the age of 12 (n=68; 
7.0 ± 4.5) and patients aged 12 years and above (n=53; 8.2 ± 5.6) did not significantly 
differ (P = 0.173). No significant correlation was found between duration of the 
psoriasis and total CDLQI score (P = 0.48).     
topical corticosteroids, followed by dithranol. Methotrexate is considered to be the first 
systemic treatment of choice, followed by etanercept. Based on the above-mentioned 
treatments a division into three clusters was made: topical (only topical treatment 
including topical corticosteroids, calcipotriol/betamethasone dipropionate, vitamin D 
analogues, calcineurin inhibitors and salicylic acids), dithranol (anthralin) and systemic 
therapy (including methotrexate, etanercept, acitretin and ciclosporin). Dithranol therapy 
was given in a day clinic setting. According to the Dutch guidelines for psoriasis, 
phototherapy for paediatric psoriasis is only limited recommended.10 A treatment 
episode was defined as the time between the start and the end of a treatment in one 
of the three clusters. The discontinuation of a treatment episode was either because 
of clearance or almost clearance of psoriasis, or because the treatment was not 
effective enough. A patient could have more than one treatment episode in different 
treatment clusters because of switch to another therapy. 
Outcome measures
At every visit, the patient’s quality of life, disease severity and type of treatment were 
documented. To quantify the impact of psoriasis on the children’s QoL, a validated 
Dutch version of the CDLQI was used (10 items; range 0 – 30).4,11 Clinical severity of 
psoriasis was assessed by a clinician using Psoriasis Area and Severity Index (PASI; 
range 0 – 72).12 Higher scores indicated more impairment in QoL and more severe 
psoriasis. Responders were defined as patients with a lower PASI at the end of a 
treatment episode compared to the start of that treatment episode. Non-responders 
were patients with an equal or higher PASI at the end of a treatment episode compared 
to the start of that treatment episode.
Analysis
At baseline descriptive statistics were provided using mean and standard deviation 
(SD). To demonstrate differences between the subgroups, an independent samples 
t-test was performed. Correlation coefficients were calculated with the Pearson 
correlation test. For each cluster of treatments, differences in scores of CDLQI and 
PASI were calculated before and after a treatment episode. These different scores 
were analysed using mixed models to accommodate the dependencies caused by 
the repeated measurements on some of the patients. To test effects of treatment on 
the CDLQI scores, models were fitted with and without these factors and likelihood 
ratio test were performed. The level of significance was considered to be 0.05. The 
statistical analyses were performed using SPSS software 16.0 (SPSS Inc., Chicago, 
IL, U.S.A.), R2.13 13 and the nlme package.14
Table 1  Patient characteristics
Number of patients 125
Age, years, mean ± SD (range) 10.7 ± 3.9 (3 – 17)
Boys/girls, n(%) 46/79 (36.8/63.2)
Psoriasis history
Age at onset, years, mean ± SD (range) 7.4 ± 3.9 (0 – 16)
Duration of psoriasis, months, mean ± SD (range) 39.2 ± 37.0 (1 – 154)
Familial history of psoriasis, n (%) 88 (70.4%)
Psoriasis baseline assessments
CDLQI, mean ± SD (range) 7.5 ± 5.0 (0 – 25)
PASI, mean ± SD (range) 7.0 ± 5.8 (0 – 33.3)
SD, standard deviation; CDLQI, Children’s Dermatology Life Quality Index; PASI, Psoriasis Area and 
Severity Index.
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Figure 1 shows the cross-sectional distribution of the 10 items of the CDLQI, reflecting 
that two items documented the highest mean ± SD scores: itch (1.27 ± 0.89) and 
problems with treatment (1.16 ± 0.89). On the other hand, friendships seem to be 
least affected by psoriasis (mean ± SD 0.18 ± 0.52). Analyses of the 10 separate 
items of the CDLQI demonstrated no significant differences between boys and girls. 
Adolescents (≥12 years), had significantly more problems with issues of clothes 
(mean ± SD 0.7 ± 0.93) and with sport (mean ± SD 0.91 ± 0.95) than patients under 
the age of 12 years (mean ± SD 0.28 ± 0.67, P = 0.001 and 0.38 ± 0.71, P < 0,0001 
respectively). No other items of the CDLQI showed a significant difference between 
those two age-groups.     
Influence of treatments in daily clinical practice on the quality of life
The longitudinally analysed cohort, consisting of 85 patients, had a total of 137 
treatment episodes. Sixty-nine patients went through 81 treatment episodes with 
topical treatment. Twenty-seven patients received in total 31 treatment episodes of 
dithranol short-contact therapy. The systemic treatments consisted of 25 treatment 
episodes in 19 patients: 16 with methotrexate, seven with etanercept, one with 
acitretin and one with ciclosporin. In our cohort only five patients were treated with 
phototherapy, this number was too small to analyse the influence of this treatment on 
quality of life. If all treatments were taken together, a significant improvement in total 
CDLQI score of -2.7 (95% confidence interval (CI) -3.7 to -1.7; P < 0.005) with a mean 
change in PASI of -2.1 (95% CI -3.1 to -1.1; P < 0.005) was found before and after a 
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Figure 1  Mean scores ± SD of the 10 items of the Children’s Dermatology Life 
Quality Index (CDLQI) for 125 patients at their initial visit.
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Analyses of the influence of all treatments on the 10 items of the CDLQI showed a 
significant decline in eight of the 10 items (Fig. 2). The highest positive impacts 
were found in an improvement of itch (mean -0.4; 95% CI -0.6 to -0.2; P < 0.005) and 
sleep disturbance (mean -0.4; 95% CI -0.6 to -0.2; P < 0.005). The items relating 
to friendship and changing clothes did not decline significantly (P = 0.068 and 
P = 0.052). There were no significant differences in the influence of the treatments 
on the 10 items of the CDLQI when comparing the younger (< 12 years) and older 
group (≥ 12 years). 
Discussion
Paediatric psoriasis causes a significant negative impact on mental health and 
QoL of those affected.5-8,15 This first prospective, cross-sectional and longitudinal, 
observational study confirmed the negative impact of paediatric psoriasis on QoL, 
and also demonstrated a positive influence of treatments in daily clinical practice on 
the CDLQI in a cohort of children with psoriasis, with the highest impact on itch and 
sleep disturbance.
Previous studies have reported cross-sectional mean CDLQI scores between 5.05 
and 10.0 in children with psoriasis.4-8 The total mean CDLQI score in our cross- 
sectional analyses was 7.5, which is in line with the mean scores found in other 
studies. The 10 items of the CDLQI were only once reported before in paediatric 
psoriasis.7 Our results confirm the fact that the items itch and problems with treatment 
had the highest impact on the children’s QoL. In addition, we found that the 
adolescents (≥ 12 years) had significantly more problems with issues of clothes and 
sport, as compared to the younger children (< 12 years). We did not find a difference 
in the 10 separate items of the CDLQI when comparing boys and girls. 
A cross-sectional correlation between CDLQI and PASI has been analysed in two 
studies before.6,7 De Jager et al. demonstrated a significant moderate correlation in 
39 children with psoriasis; on the other hand a Swedish group did not show a 
significant correlation in 45 patients. In the present paper the cross-sectional 
correlation between CDLQI and PASI in 125 patients was 0.31 (P = 0.001). Strikingly, 
the correlation between ΔCDLQI and ΔPASI in this longitudinal study was remarkably 
higher (r = 0.48, P < 0.05). 
Longitudinally, 85 patients were analysed with a total of 137 treatment episodes. This 
study is the first to describe prospective data in daily clinical practice in paediatric 
psoriasis. A significant decline in total CDLQI score was found for all treatments, with 
the highest improvement in CDLQI for dithranol, followed by systemic and other 
treatment episode (Table 2). Analyses of the three clusters of treatments demonstrated 
the highest improvement in CDLQI for dithranol, with a mean change of -4.0 (95% 
CI     -6.1 to -1.8, P < 0.005) and a mean alteration in PASI of -5.3 (95% CI -8.1 to -2.5, 
P < 0.005), followed by systemic treatments with a mean ΔCDLQI of -3.6 (95% CI -6.4 
to -0.9, P = 0.014) and a ΔPASI of   -4.4 (95% CI -6.9 to -2.0, P < 0.005). Topical 
treatment demonstrated a mean ΔCDLQI of -2.2 (95% CI -3.6 to -0.9, P < 0.005) with 
a mean ΔPASI of -0.5 (95% CI -1.4 – 0.4, P = 0.26). A comparison of ΔCDLQI for these 
three clusters of treatments with the likelihood ratio test was not significant in our 
population (P = 0.38), in contrast to ΔPASI which is very significant (P < 0.0001). The 
ΔCDLQI correlated significantly with ΔPASI for all treatments together, r = 0.48 (P < 0.05). 
Also in all the three different clusters of treatments significant correlations between 
ΔCDLQI and ΔPASI were found: topical r = 0.48 (P < 0.05), dithranol r = 0.46 (P < 0.05) 
and systemic r = 0.55 (P < 0.05). Subgroup analysis comparing patients who stopped 
treatment because of success (responders) with patients who stopped treatment 
because of ineffectiveness (non-responders) showed only a significant improvement in 
CDLQI in responders for all three treatment clusters (P < 0.005). This is in contrast to 
non-responders, in whom no significant improvement in CDLQI was found (P-values 
between 0.17 and 0.54).
Figure 2   Mean score the 10 items of the Children’s Dermatology Life Quality Index 
(CDLQI) before and after treatment in 137 treatment episodes for all 
treatments together. 
For all items the upper black bar is before treatment and the striped bar is after treatment. 
* p – value < 0.05. † items with the highest improvement.
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topical treatments. However, a conclusion about the superiority of one of these three 
treatment clusters with respect to influencing the CDLQI cannot be made, because 
the likelihood ratio test between the treatment clusters was not significant. Only one 
other longitudinal study described the influence of a treatment on QoL of children 
with psoriasis.8 This study, however, was designed as a randomized controlled trial 
and the only treatment modality was etanercept. Therefore, the results of this study 
can hardly be compared with the present study, in which daily clinical practice data 
were analysed. 
In conclusion, the present study is the first prospective observational study in which 
the positive influence of different treatments in daily clinical practice on the CDLQI 
was demonstrated in a cohort of children with psoriasis. The largest influence on the 
CDLQI was achieved by dithranol and systemic treatments. The highest positive 
impact of all treatments was found in a decline of itch and sleep disturbance.
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Introduction
In children, the scalp is a predilection site for psoriasis and a few studies demonstrated 
that the scalp is most often the initial site affected.1-4 Scalp involvement is reported 
between 47.0 – 88.9% of all children with psoriasis.5-8 Scalp involvement can be a 
particular burden for psoriasis patients because of the visibility of the lesions and it is 
difficult to apply therapy.9 Chen et al. developed and validated the Scalpdex, a quality 
of life (QoL) questionnaire special for adults with scalp dermatitis (psoriasis and 
seborrheic dermatitis).10 This instrument can be used to determine which aspect of the 
scalp dermatitis bothers patients the most and to evaluate the influence of therapeutic 
intervention on this QoL.
The impact of scalp psoriasis on QoL, especially in children with psoriasis, has not 
been investigated. Although a skin-specific questionnaire exists to measure QoL in 
children with skin diseases of the whole body (Children’s Dermatology Life Quality 
Index, CDLQI),11 there is no specific instrument to assess the influence of scalp 
psoriasis on QoL in children. 
This study aims to validate the Scalpdex in children with scalp psoriasis. This Children’s 
Scalpdex in Psoriasis (CSP) was assessed for its reliability, responsiveness and validity. 
The validation of an additional QoL questionnaire for children with scalp psoriasis will 
make it possible to focus on the symptoms and emotional and psychological impact 
of scalp psoriasis in children and to assess the influence of treatments.   
Materials and methods
Instrument development
The content of the questions of the CSP were based on the validated Scalpdex 
questionnaire.10 The Scalpdex was developed based on focus sessions with adult 
patients with scalp psoriasis and seborrheic dermatitis. Fourteen scalp dermatitis- 
specific items were formulated from these in-depth interviews and also nine items 
from the Skindex were included.12 This questionnaire comprised of 23 items, which 
were clustered and tested by factor analyses into three scales, labelled ‘symptoms’, 
‘functioning’ and ‘emotions’. 
For the CSP, the Scalpdex items were translated into Dutch and discussed in a 
steering group, comprising of two dermatologists, one paediatric dermatologist and 
one psychologist with a broad expertise in questionnaires for children with psoriasis. 
When necessary, the questions were modified slightly in order to make them more 
Abstract 
This study validated the Scalpdex, a quality of life questionnaire for adults with scalp 
dermatitis, in children with scalp psoriasis. The reliability, responsiveness and validity 
of the three scales (symptoms, functioning and emotions) of this 22-item questionnaire 
were analysed in a cohort of children with scalp psoriasis (age range 6 – 18 years). 
A total of 94 children completed the questionnaire once, and 53 children a second 
time, after treatment of their scalp psoriasis. The Children’s Scalpdex in Psoriasis 
(CSP) demonstrated reliability with internal consistency (Cronbach α, 0.69 – 0.91). 
The CPS scales proved sensitive to change in the expected direction for children 
whose scalp psoriasis improved. Moderate effect sizes were observed between both 
visits for all three the scales of the CSP (Cohen’s d, 0.44 – 0.58). In conclusion, CSP 
is a reliable, responsive and valid questionnaire which is the first to illustrate the 
specific influence of scalp psoriasis on the quality of life in children. 
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coefficient equal to or larger than 0.70 is considered to be acceptable.15 For construct 
validity, first the confirmatory factor analysis was performed to test whether the three 
constructs of the Scalpdex (symptoms, functioning and emotions) are similar in the 
CSP. Thereafter, the correlations between the mean scale scores of the CSP and the 
CDLQI and the scalp psoriasis severity scores by patient and physician were 
examined using Spearman’s rank correlation coefficient. It was hypothesized that 
CSP would be positively correlated with all the different scalp psoriasis severity 
scores and have higher correlations than the CDLQI with the scalp severity scores. 
For the discriminant validity, we hypothesized that the CDLQI, a skin-specific 
questionnaire for the whole body, is not sensitive enough to measure responsiveness 
over time for changes in the QoL specific to scalp psoriasis. Cohen’s D was calculated 
for responsiveness of both the CSP and CDLQI. Responsiveness of the CSP and 
CDLQI questionnaire was tested by calculating the change in the mean scale scores 
(symptoms, functioning and emotions) of the CSP and the change in total CDLQI of 
the patients who completed the questionnaire twice. Cohen’s D was used to calculate 
within-group effect sizes, to indicate the standardized differences between two 
means at the two occasions, before and after treatment of the scalp psoriasis, for 
both the CSP and CDLQI. Cohen’s D is defined as the difference between two means, 
divided by the standard deviation (SD). A Cohen’s D of 0.2 was considered to indicate 
a small effect, 0.5 to indicate a medium effect, and effects higher than 0.8 to indicate 
large effects.16 The paired t-test was applied to the baseline answers and the answers 
of the second time-point for three groups: those who improved according to the 
opinion of the physician (PhGA scalp) or their own opinion (PaGA scalp); those who 
showed no change of their scalp psoriasis and those whose scalp conditioned 
worsened. Statistical analyses were performed in SPSS software 18.0 (SPSS Inc., 
Chicago, IL, U.S.A.) and Mplus version 6.11.  
Results
Study sample
Patient characteristics of the study cohort are reported in Table 1. A total of 94 
children, mean age 12.4 ± 3.3 years, completed the questionnaire once. The majority 
of the patients were female (59.6%). Patients had a mean duration of psoriasis of 
3.7 ± 3.5 years and a mean psoriasis severity (PASI) of 4.8 ± 2.8. Both patients 
(PaGA scalp) and physician (PhGA scalp) reported a median scalp psoriasis severity 
of 2 (range 1 – 5). Fifty-three patients completed the questionnaire a second time. 
comprehensive for children. The item; ‘The cost of caring for my scalp condition 
bothers me’, was not included, because the steering group agreed that children are 
not likely to be concerned about this topic. The CSP thus comprises of 22 items, 
which consists of three major constructs, ‘symptoms’, ‘functioning’ and ‘emotions’, 
which is in line with the original Scalpdex. All items enquired about the past four 
weeks. Responses to the questions were based on a 5-point Likert-type scale 
(‘never’= 0, ‘rarely’= 25, ‘sometimes’= 50, ‘often’= 75, and ‘all the time’= 100). A lower 
score represents a better QoL. The responses to item 19, ‘I feel that my knowledge 
about caring for my scalp psoriasis is adequate’, were reverse scored. Scale scores 
were the average of responses to items in a given scale. If necessary, patients aged 
between 6 and 12 years were allowed to complete the questionnaire with the help of 
the child’s parent or guardian. The CSP will takes 5 – 10 minutes to complete. 
Sample population
The department of dermatology of the Radboud University Nijmegen Medical Center 
has a prospective observational paediatric psoriasis cohort (<18 years) from daily 
clinical practice, called the Child-CAPTURE (Continuous Assessment of Psoriasis 
Treatment Use Registry). All children between 6 and 18 years who visited the 
department between March 2011 and May 2012 with more than 5% scalp area 
involvement completed in the questionnaire at baseline. Patients were treated for 
their scalp psoriasis according to the physician’s opinion. The following patient 
 characteristics were recorded: age, gender, age at onset, family history and duration 
of psoriasis.
Outcome measures
At baseline, and if applicable at a second visit, the 22-items of the CSP were 
completed (range 0 – 100). In addition, patient’s QoL was evaluated with the validated 
Dutch version of the Children’s Dermatology Life Quality Index, CDLQI (10 items: 
range 0 – 30).11,13 For both questionnaires, higher scores indicate worse QoL. It is 
hypothesized that the CSP is better than the CDLQI questionnaire to assess explicit 
the impact of scalp psoriasis on the QoL in children. Severity of scalp psoriasis 
was established by the Physician Global Assessment of the Scalp (PhGA scalp; 
range 0 – 5) and Patient Global Assessment of the Scalp (PaGA scalp; range 0 – 5). 
Clinical severity of psoriasis of the whole body was assessed by a clinician using 
the Psoriasis Area and Severity Index (PASI; range 0 – 72).14  
Statistical analyses
The CSP was tested for reliability, responsiveness and validity. Reliability was assessed 
by Cronbach’s α at scale level. This expresses the internal consistency; whether the 
items in the scale are correlated, and thus measuring the same concept. A Cronbach’s α 
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functioning r = 0.46 (P < 0.001) and emotions r = 0.46 (P < 0.001). PhGA scalp also 
showed a significant positive correlations with the three scales; symptoms r = 0.44 
(P < 0.001), functioning r = 0.32 (P = 0.002), and emotions r = 0.27 (P = 0.009). The 
CDLQI correlated less significant positive with both PhGA scalp (r = 0.21; P = 0.05) 
and PaGA scalp (r = 0.30; P = 0.004) compared with the CSP scales.
Item Analysis
Mean ± SD item scores of the CSP demonstrated that the following three items were 
most affected (Table 2): ‘I am bothered by the persistence/reoccurrence of my scalp 
psoriasis’ (55.3 ± 33.4), ‘My scalp psoriasis itches’ (52.9 ± 31.5) and ‘I feel that my 
knowledge about caring for my scalp psoriasis is adequate’ (51.9 ± 34.0). The item 
with the lowest mean score was the question: “My scalp psoriasis affects the colour 
of clothes I wear” (9.8 ± 20.2). In Table 2 the mean scores of all items are listed. In 8 
out of 22 CSP items (36.4%) versus 8 out of 10 CDLQI items (80%), at least 50% of the 
patients answered never.
Reliability 
Internal consistency reliability of the three scales was analysed with Cronbach’s α. 
For all the three scales the internal consistency were relatively high (‘symptoms’ = 0.69; 
‘functioning’ = 0=74, ‘emotions’ = 0.91). 
Construct validity
Confirmative factor analysis demonstrated an acceptable fit for the three-factor 
model. This indicates that the three scales of the Scalpdex (symptoms, functioning 
and emotions) can also be used in our CSP. Correlations were calculated between 
the scale scores of the CSP and the scores of scalp psoriasis severity, PhGA and 
PaGA (Table 3). The highest significant positive correlations for all scales were 
demonstrated between PaGA scalp and the three scales; symptoms r = 0.51 (P < 0.001), 
Table 1  Patient characteristics (n=94)
Variables
Age, years, mean ± SD (range) 12.4 ± 3.3 (6 – 17) 
Boys/girls, n(%) 38/56 (40.4/59.6)
Psoriasis history, mean ± SD (range)
Age at onset, years 8.3 ± 4.2 (0 – 17)
Duration of psoriasis, years 3.7 ± 3.5 (0 – 13) 
Psoriasis baseline assessments
PASI psoriasis, mean ± SD 4.8 ± 2.8
PhGA Scalp, median (range) 2 (1 – 5) 
PaGA Scalp, median (range) 2 (1 – 5)
SD, standard deviation; PASI, Psoriasis Area and Severity Index; PhGA, Physician Global Assessment; 
PaGA, Patient Global Assessment.
Table 2  Mean score of the items of the Children’s Scalpdex in Psoriasis (n=94)
Item Scale a Mean score 
± SDb 
1. My scalp psoriasis hurts S 23.9 ± 26.7
2. My scalp psoriasis makes me feel sad E 23.1 ± 27.5
3. My scalp psoriasis itches S 52.9 ± 31.5 c
4. I am ashamed of my scalp psoriasis E 28.2 ± 31.2
5. I am embarrassed by my scalp psoriasis E 14.9 ± 23.6
6. I am angry/frustrated by my scalp psoriasis E 28.5 ± 29.6
7. I am humiliated by my scalp psoriasis E 13.8 ± 23.7
8. My scalp psoriasis bleeds S 26.1 ± 26.9
9. I am annoyed by my scalp psoriasis E 43.1 ± 36.7
10. I am bothered by the appearance of my scalp psoriasis E 31.4 ± 32.8
11. My scalp psoriasis makes me feel self-conscious E 17.3 ± 24.6
12. I am bothered that my scalp psoriasis is incurable E 41.5 ± 35.3
13. My scalp psoriasis affects how to wear my hair (hairstyle, hats) F 20.7 ± 31.2
14. I am bothered by people’s questions about my scalp 
psoriasis
E 34.0 ± 30.2
15. My scalp psoriasis affects the colour of clothes I wear F 9.8 ± 20.2
16. I am bothered by the persistence/reoccurrence of my  
scalp psoriasis
E 55.3 ± 33.4 c 
17. I feel stressed about my scalp psoriasis E 12.8 ± 21.0
18. Caring for my scalp psoriasis is inconvenient for me F 39.9 ± 34.8
19. I feel that my knowledge about caring for my scalp psoriasis 
is adequate
E 51.9 ± 34.0 c
20. My scalp psoriasis makes my daily life difficult F 20.5 ± 25.4
21. My scalp psoriasis makes me feel different from others E 22.6 ± 28.4
22. My scalp condition makes it hard to go to the hairdresser F 22.3 ± 32.7
a Scales: symptoms (S), emotions (E) and functioning (F). b Item scores; 0 ‘never’, 25 ‘rarely’, 50 ‘sometimes’, 
75 ‘often’ and 100 ‘all the time’. c Three items with the highest mean scores.
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Responsiveness and discriminant validity
A total of 53 patients completed the questionnaire a second time and were analysed 
for the responsiveness. Because patients were seen in daily clinical practice, the 
period of time between the first and second visit varied between one and seven 
months (mean ± SD; 4.3 ± 1.8). First, effect sizes with Cohen’s D were calculated 
between the two time points for both CSP and CDLQI. Cohen’s D for CSP showed 
moderate effect sizes (symptoms = 0.44; functioning = 0.58 and emotions = 0.51), 
whereas no effect size was found for the CDLQI (Cohen’s D = -0.03).
To evaluate the responsiveness of the CSP and the CDLQI with respect to changes in 
severity of scalp psoriasis, patients were divided into three groups. The first group 
consisted of patient with a worsening of their scalp psoriasis, either according to the 
physician (Table 4), or according to the patient’s own opinion (Table 5). The second 
and third group reported no change in severity or an improvement of their scalp 
psoriasis, respectively. Significant changes in all three scales of the CSP were found 
in the group with an improvement of their scalp psoriasis (P ≤ 0.001). This effect was 
found in improvements based on both PhGA and PaGA with a moderate size effect, 
Cohen’s D between 0.66 and 0.98. Patients with worsening of the scalp condition 
based on alterations in PhGA scalp showed a significant increase in mean score for 
the scale ‘symptoms’ (14.6 ± 13.8; P = 0.004), but not for the other two scales. It is 
notable that patients with the same scalp condition at both visits based on PhGA 
scalp showed a significant improvement for the emotions scale (-9.3 ± 11.0). All other 
alterations in both PaGA and PhGA scalp and the other scales demonstrated no 
significant increase or decrease in mean scores.  
Interestingly, for patients in whom the scalp psoriasis improved from both physician 
and patient’s point of view (Table 4 and 5) the skin-specific CLDQI questionnaire 
Table 3  Correlations between scalp psoriasis severity scores and  
Children’s Dermatology Life Quality Index and the Children’s in  
Scalpdex Psoriasis scales
Children’s Scalpdex in Psoriasis scales CDLQI
Symptoms Functioning Emotions
PhGA 0.44** 0.32** 0.27** 0.21*
PaGA 0.51** 0.46** 0.46** 0.30**
CDLQI, Children’s Dermatology Life Quality Index; PhGA, Physician Global Assessment; PaGA, Patient 
Global Assessment. * P < 0.05; ** P < 0.01.
Ta
b
le
 4
  M
ea
n 
sc
al
e 
sc
or
es
 fo
r C
hi
ld
re
n’
s 
S
ca
lp
de
x 
in
 P
so
ria
si
s 
an
d 
C
hi
ld
re
n’
s 
D
er
m
at
ol
og
y 
Li
fe
 Q
ua
lit
y 
In
de
x 
ba
se
d 
on
 
al
te
ra
tio
ns
 in
 P
hy
si
ci
an
 G
lo
ba
l A
ss
es
sm
en
t o
f t
he
 s
ca
lp
S
co
re
s,
 m
ea
n 
±
 S
D
S
ca
lp
 C
on
d
iti
on
S
ca
le
V
is
it 
1
V
is
it 
2
Δ
 (
S
D
)
P
–v
al
ue
C
oh
en
’s
 D
C
hi
ld
re
n’
s 
S
ca
lp
d
ex
 in
 P
so
ria
si
s
W
or
se
 (
n=
12
)
S
ym
pt
om
s
22
.9
 ±
 2
5.
4
37
.5
 ±
 2
1.
5
14
.6
 (1
3.
8)
0.
00
4
-0
.6
2
Fu
nc
tio
ni
ng
16
.2
 ±
 2
2.
4
19
.6
 ±
 2
0.
7
3.
4 
(1
1.
5)
0.
34
-0
.1
6
E
m
ot
io
ns
27
.4
 ±
 2
2.
2
37
.1
 ±
 2
7.
4
9.
7 
(1
7.
2)
0.
08
-0
.3
9
S
am
e 
(n
=
15
)
S
ym
pt
om
s
30
.6
 ±
 2
6.
7
23
.9
 ±
 2
2.
5
-6
.7
 (2
2.
3)
0.
27
0.
27
Fu
nc
tio
ni
ng
17
.0
 ±
 1
7.
7
13
.0
 ±
 1
3.
9
-4
.0
 (1
1.
8)
0.
21
0.
25
E
m
ot
io
ns
24
.5
 ±
 1
9.
7
15
.2
 ±
 1
6.
0
-9
.3
 (1
1.
0)
0.
00
6
0.
52
B
et
te
r 
(n
=
26
)
S
ym
pt
om
s
35
.9
 ±
 1
7.
1
19
.9
 ±
 1
5.
5
-1
6.
0 
(1
9.
3)
<
 0
.0
01
0.
98
Fu
nc
tio
ni
ng
20
.4
 ±
 1
5.
4
8.
7 
±
 1
0.
3
-1
1.
7 
(1
3.
4)
<
 0
.0
01
0.
89
E
m
ot
io
ns
24
.9
 ±
 1
6.
0
14
.5
 ±
 1
4.
6
-1
0.
4 
(1
4.
0)
0.
00
1
0.
68
C
hi
ld
re
n’
s 
D
er
m
at
ol
og
y 
Li
fe
 Q
ua
lit
y 
In
d
ex
W
or
se
 (
n=
12
)
-
5.
5 
±
 5
.6
6.
8 
±
 3
.9
1.
3 
(4
.8
)
0.
36
-0
.2
6
S
am
e 
(n
=
15
)
-
5.
0 
±
 5
.3
5.
4 
±
 4
.3
0.
4 
(4
.4
)
0.
29
-0
.0
8
B
et
te
r 
(n
=
26
)
-
3.
5 
±
 3
.4
6.
8 
±
 4
.6
3.
3 
(5
.1
)
0.
03
-0
.8
2
S
D
, s
ta
nd
ar
d 
de
vi
at
io
n.
 S
ig
ni
fic
an
t P
-v
al
ue
s 
ar
e 
sh
ow
n 
in
 b
ol
d.
CHAPTER 4 QUALITY OF LIFE
124 125
4
showed a significant increase in mean total CDLQI score (more impairment in QoL) 
(Table 4, n=26, PhGA scalp: ΔCDLQI 3.3 ± 5.1, P = 0.03; Table 5, n=27, PaGA scalp: 
ΔCDLQI 2.5 ± 5.7, P = 0.03). Because of this fact, we analysed the course of psoriasis 
severity on other parts of the body for the patients in whom the scalp psoriasis 
improved. Surprisingly, the psoriasis severity of the entire body, expressed by the 
PASI, increased in this group (PhGA scalp: ΔPASI 3.1 ± 4.2, P = 0.001; PaGA scalp: 
ΔPASI 3.2 ± 4.7, P 0.001), whilst the scalp psoriasis improved.   
Discussion
The results of this study show that the CSP is a reliable, responsive and valid 
questionnaire. It is the first instrument to focus on scalp psoriasis in children, 
illustrating the specific influence of scalp psoriasis on QoL. This QoL questionnaire 
makes it possible to assess the symptoms and emotional and psychological impact 
of paediatric scalp psoriasis. For this group of children, the development of this 
questionnaire is important for clinical research, decision making and evaluation of 
therapeutic interventions. In this study the questionnaire was validated for children 
with scalp psoriasis. However, it is highly likely that this questionnaire can also be 
used for other paediatric scalp conditions. 
This study is performed in a paediatric psoriasis cohort, drawn from daily clinical 
practice, called the Child-CAPTURE. This registry was set up in 2008 and aims to 
record clinical and QoL data from children with psoriasis every time they visit our 
outpatient clinic. For this study there was no wash-out period, and all patients were 
treated for their psoriasis according to the physician’s opinion. Therefore, the psoriasis 
severity at baseline of this study was mild.   
In our cohort of children with scalp psoriasis the items ‘my scalp itches’ and ‘I am 
bothered by the persistence/reoccurrence of my scalp condition’ are the two items 
with the highest scores. This is in line with the original Scalpdex, in which Chen et al.10 
also demonstrated that adults with scalp dermatitis (psoriasis and seborrheic 
dermatitis) reported most problems with these items as well. In contrast to adults, 
however, children report more bleeding of their scalp, and they are more troubled by 
people’s questions about their scalp psoriasis. On the other hand, the children are 
less embarrassed and frustrated by their scalp psoriasis than adults are by their 
scalp condition and the children feel that their knowledge about caring for the scalp 
psoriasis is adequate, more so than the adults. The reliability of the CSP scales were 
relatively high (Cronbach’s α, 0.69 – 0.91), which is slightly better than the reliability 
reported by Chen et al. for the Scalpdex (Cronbach’s α, 0.62 – 0.80).10
Ta
b
le
 5
  M
ea
n 
sc
al
e 
sc
or
es
 fo
r C
hi
ld
re
n’
s 
S
ca
lp
de
x 
in
 P
so
ria
si
s 
an
d 
C
hi
ld
re
n’
s 
D
er
m
at
ol
og
y 
Li
fe
 Q
ua
lit
y 
In
de
x 
ba
se
d 
on
 
al
te
ra
tio
ns
 in
 P
at
ie
nt
 G
lo
ba
l A
ss
es
sm
en
t o
f t
he
 s
ca
lp
S
co
re
s,
 m
ea
n 
±
 S
D
S
ca
lp
 C
on
d
iti
on
S
ca
le
V
is
it 
1
V
is
it 
2
Δ
 (
S
D
)
P-
va
lu
e
C
oh
en
’s
 D
C
hi
ld
re
n’
s 
S
ca
lp
d
ex
 in
 P
so
ria
si
s 
W
or
se
 (
n=
10
)
S
ym
pt
om
s
21
.7
 ±
 2
6.
7
31
.7
 ±
 2
0.
0
10
.0
 (1
8.
3)
0.
12
-0
.4
2
Fu
nc
tio
ni
ng
13
.5
 ±
 2
3.
6
12
.5
 ±
 1
9.
8
-1
.0
 (7
.7
)
0.
69
0.
05
E
m
ot
io
ns
21
.1
 ±
 2
2.
3
26
.3
 ±
 2
7.
8
5.
2 
(1
6.
1)
0.
34
-0
.2
1
S
am
e 
(n
=
16
)
S
ym
pt
om
s
29
.7
 ±
 1
9.
7
31
.3
 ±
 2
5.
0
1.
6 
(1
6.
7)
0.
71
-0
.0
7
Fu
nc
tio
ni
ng
17
.8
 ±
 1
6.
9
16
.6
 ±
 1
4.
9
-1
.2
 (1
5.
9)
0.
76
0.
08
E
m
ot
io
ns
25
.0
 ±
 1
6.
2
23
.2
 ±
 1
9.
8
-1
.8
 (1
3.
2)
0.
60
0.
10
B
et
te
r 
(n
=
27
)
S
ym
pt
om
s
36
.1
 ±
 2
1.
4
18
.8
 ±
 1
4.
7
-1
7.
3 
(2
1.
4)
<
 0
.0
01
0.
94
Fu
nc
tio
ni
ng
20
.7
 ±
 1
5.
6
9.
8 
±
 1
2.
0
-1
0.
9 
(1
.8
)
<
 0
.0
01
0.
78
E
m
ot
io
ns
27
.1
 ±
 1
8.
3
15
.4
 ±
 1
7.
3
-1
1.
7 
(1
5.
3)
0.
00
1
0.
66
C
hi
ld
re
n’
s 
D
er
m
at
ol
og
y 
Li
fe
 Q
ua
lit
y 
In
d
ex
W
or
se
 (
n=
10
)
-
3.
6 
±
 4
.6
5.
8 
±
 4
.1
2.
2 
(4
.3
)
0.
14
-0
.5
0
S
am
e 
(n
=
16
)
-
5.
3 
±
 4
.0
6.
3 
±
 4
.3
1.
1 
(3
.9
)
0.
29
-0
.2
4
B
et
te
r 
(n
=
27
)
-
4.
2 
±
 4
.8
6.
7 
±
 4
.5
2.
5 
(5
.7
)
0.
03
-0
.5
4
S
D
, s
ta
nd
ar
d 
de
vi
at
io
n.
 S
ig
ni
fic
an
t P
-v
al
ue
s 
ar
e 
sh
ow
n 
in
 b
ol
d.
CHAPTER 4 QUALITY OF LIFE
126 127
4
Construct validity was tested by calculating confirmative factor analyses. These 
analyses supported the three scales in the CSP, as used in the Scalpdex; namely, 
symptoms, functioning and emotions. The scores of the three scales of the CSP 
showed a significant positive correlation with both patient- and physician- reported 
scalp severity; this is in line with the hypothesis for the construct validity. Interestingly, 
the scales have higher correlations with patient’s perception of the severity of the 
scalp psoriasis than with the physician’s opinion. The correlation between both 
patient- and physician-reported scalp severity and the CDLQI was less strong. 
Responsiveness analysis proved that the three scales of the CSP are sensitive to 
change in the expected direction in the children whose scalp psoriasis improved. In 
contrast to the improvement of CSP and scalp psoriasis of these children, the CDLQI 
and PASI deteriorated. This suggests that the CDLQI is not specific enough to reflect 
the QoL of particularly children with scalp psoriasis.  
In conclusion, the Children’s Scalpdex in Psoriasis proved to be reliable, responsive 
and valid for the assessment of QoL of children with scalp psoriasis. The CSP can be 
used as a targeted questionnaire in the evaluation of outcome assessments and the 
effect of therapeutic interventions on QoL in children with scalp psoriasis. 
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Introduction 
Psoriasis is a chronic, inflammatory skin disease, which affects 2% of the general 
population.1 Approximately 30% of patients with psoriasis report onset during 
childhood.2,3 Research in children with psoriasis demonstrated that these patients report 
itch, pain, and feelings of shame or stigmatization.4 In conjunction with standard 
dermatological care, several educational and training programs have been developed 
for adult patients with psoriasis, which have resulted in improved knowledge and 
coping.5-11 To our knowledge, only one study outlined an inpatient educational 
program for children and adolescents with psoriasis which resulted in improved 
disease management and self-estimated long-term skin condition and reduced 
psychosocial impairment.12 
In the present paper, we describe the development and design of the first multi-
disciplinary training program for outpatient children with psoriasis and their parents. 
In a case-study design, the program is illustrated and evaluated.
Methods
Development of the program
To design the training program a steering group was assembled, consisting of two 
dermatologists, two psychologists and two dermatology nurse specialists. First, 
systematic semi-structured interviews were held with 15 children with psoriasis and 
their parents.4 Based on content analysis the following items were found to be 
important for the children with psoriasis: information about psoriasis and treatments, 
itch, coping with psoriasis in daily life and contact with other fellow suffers. Their 
parents reported to be relevant: information about psoriasis and treatment, scratch 
behaviour and coping with psoriasis in daily life. Next, the literature on educational 
and training programs for skin conditions was reviewed and parts of these evidence- 
based programs were used for the development of the present training program.12-14
Procedure and Assessments
To be included in the program, the diagnosis of psoriasis had to be clinically confirmed 
by a dermatologist and the patient had to be under the age of 18 years. Due to 
different phases of cognitive and emotional development of children, the program 
was designed for two age-related groups: primary school children (6 – 12 years) and 
adolescents visiting secondary school (12-18 years). Assessments were made pre- 
and post-treatment, and after three months of follow up. 
Abstract
Objective
To describe and illustrate in a case-study design the development and design of a 
multidisciplinary training program for outpatient children and adolescents with 
psoriasis and their parents. 
Methods
For the development of the program, a steering group was assembled, systematic 
semi-structured interviews were held and the literature was reviewed. 
Results
Aim of the training program was to strengthen patients and their parents in coping 
with and diminishing psoriasis-related problems in an outpatient setting. The program 
included treatment modules of medical information and skin care, itch and scratch 
problems, psychological issues in coping with the psoriasis, sleep hygiene, and 
relapse prevention. Descriptive results in the case patient showed improvement of all 
outcome variables in the expected direction.  
Conclusion
This is the first multidisciplinary training program for outpatient children and 
adolescents with psoriasis and their parents. It aims at improving coping skills and 
self-management and could be a promising addition to regular treatment.
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children were instructed to register the frequency and kind of ointments used to 
improve daily skin care routines with a reward system.  
Itch and scratch responses: session 2
In session 2, patients and parents learned that itching and scratching frequently lead to a 
vicious itch-scratch cycle. In addition, it was discussed how to deal with (triggering factors 
of) itching and scratching, prevention of itching and alternatives for scratching behaviour. 
For homework, the children were asked to register their itch and scratch behaviour and 
implement and evaluate alternative measures to cope with itch and scratching. 
Psychological issues and sleep hygiene: session 3
During the last session psychological issues concerning coping strategies with 
regard to social encounters and self-esteem were discussed. The children practiced 
(without parents) with role plays how to cope with reactions from other children, 
promoting a positive self- and body-image. At the same time, the parents discussed 
how to deal with transfer of responsibilities for self-management during the development 
of the child. Furthermore, sleep hygiene was discussed and patients and parents 
learned to use relaxation exercises. For homework, the children completed an exercise 
on long-term goals and relapse prevention. 
Follow-up session: session 4
In the follow-up session, all previous issues were passed in review. Patients and 
parents discussed the most important items they learned during the program. Finally, 
relapse prevention exercise and future goals were discussed. 
Outcome measures
The primary end points were differences in patient’s quality of life, intensity and 
duration of itch and scratch responses, illness cognitions, and impact on family life. 
Disease severity was a secondary end point. 
The patient’s quality of life was assessed with the Children’s Dermatology Life Quality 
Index (CDLQI).15 Itch and scratch responses were assessed with the Impact of 
Chronic Skin Disease on Daily Life (ISDL).16 Illness cognitions were assessed using 
two chronic-disease related cognitions of the ISDL: helplessness and acceptance.16,17 
Disease-related impact on family life was assessed with the Stein Impact on Family 
Scale (SIFS) and the Dermatitis Family Impact (DFI).18,19 
Clinical evaluation of skin severity was performed by a dermatologist using three 
different parameters: Psoriasis Area and Severity Index (PASI; range 0 – 72), Physician 
Global Assessment (PGA; range 0 – 5) and Body Surface Area (BSA; range 0 – 100). 
Higher scores indicated a more severe psoriasis. 
Results
Design of the program 
The goal of the program was to support patients and their parents with coping and 
diminishing the consequences of psoriasis in daily life. All sessions were delivered by 
three trainers: a dermatologist, a clinical psychologist/cognitive behaviour therapist 
and a dermatology nurse specialist. The program consisted of three sessions, once 
every two weeks, plus one follow-up session four weeks after the last meeting. 
Duration was 2.5 h including a short break. A small group-size (four to five participants 
with one or both parents) was determined in order to create a confidential environment. 
Children and their parents were given a booklet containing information about the 
program’s content and homework assignments. At the end of each session, homework 
was given and explained to promote the transfer of what was learned into daily life. 
This required approximately one hour a week. Referral addresses were offered if 
further counselling seemed to be indicated after the program. Table 1 provides a 
schematic overview of the specific topics of each session.  
Medical information and skin care: session 1
In the first session the dermatologist explained basic medical information about 
psoriasis, including basic pathogenetic mechanisms, clinical symptoms and 
treatment. Furthermore, information about compositions and ingredients of skin care 
products and recommendation for daily skin care were offered. For homework, the 
Table 1  Structure and content of training program for children and adolescents 
with psoriasis
Session Topic
1 Medical information about psoriasis
Daily skin care
2 Triggering factors for itch and scratching
Dealing with itching and scratching
3 Coping with psoriasis, including social encounters and self-esteem
Sleep hygiene and relaxation exercises
4 Long-term goals and relapse prevention
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improved patient’s quality of life, reduced itching and scratching, enhanced illness 
cognitions, decreased impact on family life and improved disease severity. At 3 months 
of follow-up, these results improved even further. 
Discussion
 
In this paper, the development and design of the first multidisciplinary training 
program for outpatient children and adolescents with psoriasis and their parents was 
described. The goal of this program was to support patients and their parents with 
coping and diminishing the consequences of psoriasis in daily life. 
Other programs for children with skin conditions have shown to be successful in 
improving coping and catastrophizing.13 However, only one study had so far investigated 
the efficacy of an inpatient intervention in paediatric psoriasis.12 In contrast to the 
aforementioned program, we choose an outpatient setting in order to make the 
program more feasible and improve the transfer to daily practice. Furthermore, itch 
and scratch behaviour were introduced since this is a complaint that is often reported 
by children with psoriasis.4 In addition, in order to aspire the most optimal effect and 
the lowest burden for the patient and their parents, the number of meetings in our 
program was kept as low as possible. Therefore, our program comprised of three 
sessions and one follow-up session with a duration of 2.5 h per meeting. This is in 
contrast to other programs for children in which the number and duration of the 
sessions varied between a single 2-h workshop, and 10 lessons of 45 minutes in a 
4- to 6-week period of rehabilitation.12,13,20,21 The results of the case patient – who 
represents the average problems of children or adolescents with psoriasis attending 
the training program – showed that this intervention is promising. 
However, although the results of the case study suggest that the program can be 
promising, it does not prove the efficacy of this training program. Therefore, the 
efficacy of this program had to be evaluated in the future when more patient are 
included.  
In summary, this is the first multidisciplinary training program for outpatient children 
and adolescents with psoriasis and their parents. The program could be a promising 
addition to regular treatment.
Case presentation 
We present a representative case of a 6-year-old girl who was diagnosed with 
psoriasis since she was five years old. At the start of the program, the severity of her 
psoriasis was moderate (PASI 11.3). Treatment existed of topical corticosteroids 
alternating with a vitamin D analogue, which was not adjusted during the program 
and follow-up. The following treatment goals were set: more frequent use of topical 
ointments, learn how to deal with itch and scratching, learn how to cope with the 
psoriasis in general for both the patient and parents. 
At the end of the training, the patient and her mother reported that it was especially 
important to keep using the reward system to maintain the use of topical treatment 
and reduce conflicts. Furthermore, both declared that the itch-scratching problems 
were diminished and also the psoriasis was improved (PASI 6.6). The assessment 
of the outcome variables with questionnaires supported these descriptive results 
(Table 2). All outcome variables improved in the expected direction, more specifically; 
Table 2  Results of the case study patient for the outcome measures pre- and 
post-treatment and at 3-months follow-up
Pre-treatment Post-treatment Follow-up
Quality of life Children 
CDLQI 11 7 0
Itch and Scratching 
ISDL – Itch 12.4 6.2 3.0
ISDL – Scratch 8 5 3
Illness cognitions
Helplessness 8 6 6
Acceptance 12 15 19
Family impact
DFI 7 0 0
SIFS 4 2 0
Disease severity
PASI 11.3 6.6 0.4
PGA 3 2 1
BSA 10.0 6.0 0.5
BSA = body surface area; CDLQI: Children’s Dermatology Life Quality Index; DFI = Dermatitis Family 
Impact; ISDL: Impact of Chronic Skin Disease on Daily Life; PASI = Psoriasis Area and Severity Index; 
PGA = Physician Global Assessment; SIFS = Stein Impact on Family Scale.
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5.1 Summary and general discussion
The aim of this thesis was to achieve more insight in genetic, therapeutic and 
psychological aspects of paediatric psoriasis. Therefore, five aims were formulated in 
Chapter 1 divided into three parts; genetics, treatments and quality of life. In this 
concluding chapter a summary of the major conclusions of the current thesis will be 
given and discussed in the light of a holistic understanding of paediatric psoriasis. 
Thereafter, clinical implications and directions for future research will be outlined. 
The majority of the data was extracted from the Child-CAPTURE registry, a prospective 
observational daily clinical practice registry containing data of children with psoriasis 
(aged < 18 years) seen at the outpatient clinic of the department of Dermatology of 
the Radboud University Medical Center in Nijmegen.
Genetics
Aim 1: To explore the genetic features of paediatric onset psoriasis 
A lot of genetic studies have been performed within the field of psoriasis. However, 
limited data about the association of psoriasis risk genes and age at onset of psoriasis 
(specifically onset < 18 years) are available. Therefore, the possible associations of 
seven known psoriasis risk genes (Human Leukocyte Antigen (HLA)-C*06, deletion 
of Late Cornified Envelope 3B and 3C genes (LCE3C_LCE3B-del) and psoriasis- 
associated single nucleotide polymorphisms (SNPs) in interleukin(IL)-23 receptor 
(IL23R), interleukin-12B (IL12B), endoplasmic reticulum aminopeptidase 1 (ERAP1), 
interferon induced with helicase C domain 1 (IFIH1) and TRAF3-interacting protein 2 
(TRAF3IP2) loci) in paediatric onset psoriasis (< 18 years) and adult onset (≥ 18 years) 
were investigated and described in Chapter 2.1 and 2.2. In our relatively small cohort 
(151 patients) we demonstrated that paediatric onset psoriasis compared to controls 
without psoriasis was associated with genes involved in epidermal barrier function 
(LCE3C_LCE3B-del) and adaptive immunity (HLA-C*06 and SNPs in the IL23R 
and ERAP1 loci). We showed in our cohort of 85 adult onset psoriasis patients 
compared to healthy controls associations with LCE3C_LCE3B-del and HLA-C*06. 
When comparing paediatric onset psoriasis with adult onset psoriasis we found an 
association for only HLA-C*06 in the paediatric onset cohort. Based on our data 
shown in Chapter 2.1 and 2.2, we think that in paediatric onset psoriasis heritable 
factors may play an even more important role than in adult onset psoriasis. However, 
a limitation of our studies presented in Chapter 2.1 and 2.2 is the relatively small 
number of patients. Although our genetic study in a cohort of 151 paediatric onset 
psoriasis patients was one of the first to describe these associations in children with 
psoriasis, the number of patients is limited compared to the large genome wide 
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IFIH1 and ERAP1. We are the first to describe these genetic associations with psoriasis 
severity (in this specific group) in a genetically relatively small cohort and this finding 
requires replication in larger cohorts. IFIH1 encodes for the interferon-induced with 
helicase C domain 1 (innate immune system), which triggers type I interferon in 
response to microbial infection,13 and variants are associated with type I diabetes 
mellitus.14 ERAP1 encodes an amino peptidase, with regulates the quality of peptides 
bound to major histocompatibility class I molecules, such as HLA-C*06.15 Previous 
studies in mainly adults with psoriasis demonstrated the psoriasis risk factors 
HLA-C*06 and LCE3C_LCE3B-del to be associated with severe psoriasis.7,16-18 
Recently Lysell et al. showed that HLA-C*06 positive patients had more often facial 
lesions and guttate phenotype and were mostly pubertal children.9 
In our cohort, nail psoriasis was more often seen in HLA-C*06-negative patients. This 
association was previously reported in larger studies, however unstratified for age at 
onset.17,18 Why HLA-C*06 negative patients tend to have nail psoriasis more often, is 
still unclear.
We assumed an association between HLA-C*06 and family history of psoriasis in 
patients with early onset psoriasis based on data of previous studies which 
demonstrated an association between a positive family history of psoriasis and early 
onset of psoriasis (onset < 30 or 40 years), and HLA-C*06 and early onset psoriasis.5-7,18 
Remarkably, we found that family history (first and up to third degree relatives) was 
clearly not associated with HLA-C*06 in our specific group of early onset psoriasis 
(< 18 years). The large proportion of patients with a positive family history in HLA-C*06 
negative patients (and the lack of correlation between the two) indicates that other 
genes, either alone or in epistasis, may have significant effects on heritability. 
Previous genetic studies suggest a role for the LCE3 genes in skin barrier function.1 
We hypothesized that a compromised skin barrier function plays a role in psoriasis 
susceptibility. Therefore, we investigated in Chapter 2.2 and 2.3 the possible association 
between the Koebner phenomenon in psoriasis patients and LCE3C_LCE3B-del. 
Koebner phenomenon is the appearance of psoriasis lesions after damage of the 
uninvolved skin, which is seen in approximately 25% of all psoriasis patients.19 
We could not confirm our hypothesis that there is an association between 
LCE3C_LCE3B-del and Koebner phenomenon in (paediatric) psoriasis patients. 
The biological role of LCE3B and LCE3C deletion in development and/or maintenance 
of psoriasis remains to be explained. 
In conclusion, in our cohort severe psoriasis was associated with the SNPs tagging 
IFIH1 and ERAP1. Remarkably, we found no significant associations between family 
history of psoriasis and the allele frequency of the psoriasis, even HLA-C*06 showed 
association studies (GWAS), that often comprise more than thousands of patients. 
In the full cohort (paediatric and adult onset) we confirmed the known genetic 
interaction between HLA-C*06 and LCE3C-LCE3B-del.1-3 Because of this interaction 
it is not surprising that the associations with ERAP1 (which also interacts with 
HLA-C*06)2 and LCE3C_LCE3B-del were detected in our relatively small cohort of 
paediatric onset psoriasis with such high HLA-C*06 allele frequency. 
Several studies previously showed an association between HLA-C*06 and an early 
age at onset of psoriasis.4-8 A Swedish cohort demonstrated that ERAP1 was 
associated with a psoriasis onset between 10 and 20 years.8 They also demonstrated 
the strongest association with HLA-C*06 for these pubertal children.8-10 In our cohort 
we could not replicate these associations in this specific age group (between 10 and 
20 years), but found an association between age at onset before 10 years and the 
SNP in the IL12B locus (Chapter 2.2). Recently, Nikamo et al. published that regulatory 
elements in the IL22 promotor are associated with onset of psoriasis before puberty 
(< 10 years).10 
In conclusion, in our cohort associations were found for paediatric onset psoriasis 
with ERAP1, IL23R, LCE3C_LCE3B-del and HLA-C*06. Based on our results and the 
reported associations in the literature, it seems that that in paediatric onset psoriasis 
heritable factors may play an even more important role than in adult onset psoriasis. 
For the future, we hope that our published data will motivate other centers to carefully 
register patient characteristics (age at onset) in order to replicate and extend our 
data. Further clarification of genetic factors at an early stage may lead to a better long 
term management of paediatric psoriasis and could contribute to the development of 
more targeted therapies for paediatric onset psoriasis.   
Aim 2: To detect genotype-phenotype associations in children with psoriasis. 
Psoriasis is a complex and heterogeneous disease, which varies in clinical presentation 
(phenotype) and genomic predisposition (genotype). In fact, heterogeneity is an 
outstanding feature of a variety of subtypes. To better understand paediatric psoriasis 
we investigated in Chapter 2.2 and 2.3 associations between known genetic risk 
factors for psoriasis (HLA-C*06, ERAP1, LCE3C_LCE3B-del, TRAF3IP2, IL23R, IL12B 
and IFIH1) and different parameters such as family history of psoriasis, age at onset 
and phenotype traits (psoriasis severity, nail psoriasis and Koebner phenomenon). 
In Chapter 2.2 we demonstrated that severe psoriasis (defined: patients that ever 
reached Psoriasis Area and Severity Index (PASI) ≥ 10, Physician Global Assessment 
(PGA) ≥ 3 or Body Surface Area (BSA) ≥ 10)11,12 was associated with the SNPs tagging 
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in this study was defined as an assessment of the investigator global assessment 
(IGA) and patient global assessment (PaGA) of clear or almost clear. In 85% (IGA) 
and 87% (PaGA) of patients treatment success was achieved at the end of the 
treatment.22 They reported that calcipotriol/betamethasone dipropionate scalp 
formulation was well tolerated in adolescents with at least moderate scalp psoriasis 
with few adverse events (6%) and no serious adverse events reported.22 The reported 
adverse drug reactions were: application-site pruritus, headache, acne, dermatitis 
acneiform, blood calcium decrease, blood parathyroid hormone increase and urine 
calcium decrease. In randomized controlled trials in adults in 68 - 83% of the patients 
a complete clearance or very mild residual lesions of scalp psoriasis were found after 
8 weeks of once daily treatment,23-27 with a comparable low number of adverse events 
(up to 7.0%).24-27 
A direct comparison of our results with prior studies is not possible because of 
different outcome measures and different treatment regimes. In the study of Gooderham 
et al. no striae were observed, probably because of the short period of follow-up. It 
should be kept in mind that adverse events in our study were based on patients’ own 
experience or observations of the physician and, not actively reported and collected 
as in randomized, controlled trials. In addition, patients had no wash-out period in our 
study and may be less motivated to use their scalp formulation compared to patients 
participating in clinical trials, which probably leads to poor adherence.28,29 We did not 
collected laboratory data about systemic absorption of the formulation. The number 
of patients in our study was too small to draw firm conclusions about safety. 
Dithranol is one of the oldest topical therapeutics for psoriasis which is unjustifiably 
on the verge of falling into oblivion. Based on the available literature about the 
effectiveness and safety of dithranol in paediatric psoriasis, it can be considered in 
case first line topicals such as calcipotriol and topical corticosteroids failed.30 In 
addition, our group previously demonstrated in a retrospective study that dithranol 
can be regarded as an efficacious and safe treatment option for paediatric psoriasis.31 
In Chapter 3.2 we prospectively investigated the effectiveness and safety of 
short-contact dithranol therapy in paediatric psoriasis in daily clinical practice and 
besides we compared the addition of telemedicine to regular day care. Dithranol 
short-contact therapy demonstrated to be effective with a mean reduction in PASI 
score of -69.3%. Previous studies with this treatment in children with psoriasis did not 
report objective severity scores to evaluate outcome effects.31,32 In adults, a PASI 
improvement of –63.3% was demonstrated in a randomized controlled trial.33 As 
treatment with dithranol short-contact therapy involves a complex treatment schedule, 
best results were obtained when it is administered in a day care centre setting, with 
regular visits.34 Contact by means of telemedicine may reduce the burden of travelling 
to the hospital. We demonstrated that the addition of telemedicine (instead of a visit 
no significant association. Further research is needed to elucidate the relationships 
between psoriasis susceptibility genes and clinical phenotypes. An intriguing 
question is to what extend the above mentioned genetic parameters represent a 
prognostic marker for the march of psoriasis from childhood to adulthood. The 
advances in the understanding of genotype–phenotype associations are the 
possibilities of stratification of psoriasis, targeted patient management and predict 
clinical outcomes. 
Treatments
Aim 3: To investigate the effectiveness and safety of different treatments in 
children with psoriasis in daily clinical practice. 
In this thesis we have prospectively investigated the effectiveness and safety of 
calcipotriol/betamethasone dipropionate scalp formulation for children with scalp 
psoriasis in Chapter 3.1. In addition in Chapter 3.2, the effectiveness and safety of 
short-contact dithranol therapy for chronic paediatric plaque psoriasis was 
prospectively studied. A retrospective analysis in which the effectiveness and safety 
of fumaric acid esters (FAE) in paediatric patients with psoriasis was performed in 
Chapter 3.3.
Evidence on efficacy and safety of (topical) treatments for paediatric psoriasis is 
lacking. In Chapter 3.1 the effectiveness and safety of calcipotriol/betamethasone 
dipropionate scalp formulation in daily clinical practice was prospectively described 
in children with scalp psoriasis. This scalp formulation (applied in the first two weeks 
daily and subsequently three times a week) proved to be effective with a 32.1% 
improvement of Psoriasis Scalp Severity Index (PSSI) at week 12 and a maintenance 
of this effect until 48 weeks of follow-up. Subanalysis of patients pre-treated with 
salicylic acid for two nights (prescribed depending on the severity of scaling in the 
opinion of the physician) showed to have an additive effect in the first 12 weeks in this 
subgroup. A response rate of at least 50% PSSI improvement at week 12 compared 
to baseline was found in 29.9% of the patients (n=21). In 22.2% of the children (n=16) 
clearance (PSSI=0) was achieved after a median treatment duration of 19 weeks. 
Three overweight patients (4.1%) developed striae of the skin (arms, trunk and legs), 
which were possibly related to the scalp formulation. However, the overweight in 
combination with an increase in bodyweight may also in its own right cause striae 
distensae.20,21 In our study, no serious adverse events were reported. Apart from our 
study, only one recent publication (Gooderham et al.) addressed the use of 
calcipotriol/betamethasone dipropionate scalp formulation in adolescents with scalp 
psoriasis (12 – 17 years).22 This study mainly focussed on safety and in addition 
effectiveness of this scalp formulation once daily up to 8 weeks. Treatment success 
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abnormal laboratory values of liver-function test or mild, temporary shifts in leukocyte 
counts. In all patients the abnormal laboratory values normalized without any 
intervention or treatment discontinuation. No serious adverse events have been 
reported in our case series. The adverse events and changes in laboratory test in our 
study are in line with adult patients with psoriasis treated with FAE.40 
Further prospective studies are needed to evaluate the efficacy and safety of FAE in 
children with psoriasis and to compare the efficacy of FAE with other systemic 
treatments such as methotrexate. At this moment, a prospective multicenter study is 
being performed in Germany addressing the efficacy and safety of FAE in paediatric 
psoriasis.41 In addition, we are still collecting long-term prospective data about 
effectiveness and safety of FAE in the Child-CAPTURE registry. 
In conclusion, the present studies suggested that in real clinical practice calcipotriol/
betamethasone dipropionate scalp formulation seems to be effective and safe. 
Dithranol short-contact treatment has a so far underestimated value as the vast 
majority of patients improved substantially. Ditranol should, therefore, be offered as a 
treatment to children with psoriasis that do not respond to first line topical treatments. 
The use of telemedicine in addition to regular day care dithranol treatment created 
the opportunity to treat patients who live far away from the hospital, and therefore 
made it available for larger groups of patients. Our study on FAE challenged 
methotrexate as first line systemic treatment in paediatric psoriasis. Due to the low 
number of patients studied, further, preferably comparative studies are required. 
Quality of life 
Aim 4: To achieve more insight in the quality of life of children with psoriasis.
Skin disease in children can have detrimental effects on the quality of life (QoL).42 
Data about the QoL in children with psoriasis are limited.42-44 In Chapter 4.1 we 
investigated in a cross-sectional and longitudinal study the influence of psoriasis on 
the QoL of children. Cross-sectionally, we demonstrated in 125 patients with psoriasis 
a mean Children’s Dermatology Life Quality Index (CDLQI) score of 7.5. Previous 
studies have reported cross-sectional mean CDLQI scores between 5.05 and 10.0 in 
children with psoriasis.42,44-47 Our results demonstrated that the items itch and 
problems with treatment had the highest impact on the children’s QoL. In addition, we 
found that the adolescents (≥ 12 years) had significantly more problems with issues 
of clothes and sport, as compared to younger children (< 12 years). We showed that 
all treatment clusters (topical, dithranol and systemic treatment) induce a decline in 
CDLQI score. Treatment of paediatric psoriasis thus improved QoL. Subanalysis for 
different treatment clusters demonstrated that a conclusion about the superiority of 
one of these three treatment clusters with respect to influencing the CDLQI could not 
to the day care centre) can be of additional value as it is less time consuming. 
Effectiveness did not significantly differ between patients with only regular day care 
and patients with day care in combination with telemedicine (PASI reduction: -67.2% 
regular day care vs. -71.3% day care with telemedicine). Patients in the telemedicine- 
assisted group had obviously a lower number of visits to the day care centre. The only 
adverse event reported in our study was irritation of the skin (mean number of irritation 
events during treatment 3.6), with no differences in frequency between the group of 
patients with only regular day care and the group of patients with day care with 
telemedicine. The maximum biological effect of dithranol is achieved just below the 
level of irritation of the surrounding uninvolved skin.35 Compared with other 
retrospective studies, we found a relatively high frequency of irritation.31,32 The 
reported frequency in other studies might have been biased due to their retrospective 
design, or our application time may be too long, because no studies investigated 
which application schedule of short-contact dithranol therapy is the most sufficient. 
For the future it might be interesting to investigate the intensity of the irritation. None 
of the patients or parents reported unwanted staining of their bathroom or furniture. 
From this study we can conclude that short-contact dithranol therapy is a very 
effective and safe treatment option in paediatric psoriasis and well beyond the 
efficacy of currently available first line topicals. The introduction of telemedicine in 
addition to regular day care resulted in a reduction of visits, while preserving good 
results. It is interesting to investigate whether these results can be preserved when 
decreasing the number of day care visits even further. Dithranol short-contact therapy 
can be popularized to larger populations of children with psoriasis by combining 
telemedicine with regular day care. 
FAE is a systemic treatment that has been used in adult patients with psoriasis for 
more than 25 years, mainly in German speaking countries.36 FAE is not licensed in 
the Netherlands. The literature on FAE in paediatric psoriasis is sparse, with only a 
few case reports suggesting effectiveness in children.37-39 In Chapter 3.3 we retro-
spectively described the first published case series regarding the effectiveness and 
safety of FAE in 14 children with psoriasis. We reported a median duration of FAE 
treatment of 10 months with a median age at start of 15 years. In 36% of the patients 
a complete response of their psoriasis was achieved, 7% of the patients had a good 
improvement, 21% of the patients had a partial response and 36% of the patients 
were non-responders. Literature in adults with psoriasis treated with FAE demonstrated 
a 75% improvement in PASI score in about 50-70% of the patients.40 A limitation in our 
retrospective study is the fact there were no PASI scores available for all patients. 
Gastrointestinal complaints (abdominal complains, diarrhoea and nausea) and 
flushing of the skin are the most frequent reported adverse drug reactions during 
treatment with FAE in our study. We reported in 36% of the patients transient, slightly 
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assessments and the effect of therapeutic interventions on QoL in children with scalp 
psoriasis. In Chapter 3.1 we demonstrated that calcipotriol/betamethasone dipropionate 
scalp formulation had a positive influence on the QoL measured by the CSP 
questionnaire after three months of treatment.
Aim 5: To develop together with the medical psychologist a multidisciplinary 
training program for children with psoriasis.  
Patient education programs focussing on psychological interventions in adult 
psoriasis patients have been developed and resulted in improved of knowledge and 
coping.49-55 In Chapter 4.3 we described the development and design of the first 
multidisciplinary training program for outpatient children with psoriasis and their 
parents. This program was developed in collaboration with two medical psychologists 
specialised in the field of dermatology. For the development of the program, literature 
was reviewed, a steering group was assembled and systematic semi-structured 
interviews were held. The aim of the training program was to strengthen patients and 
their parents in coping with and diminishing psoriasis related problems in an 
outpatient setting. The program included treatment modules of medical information 
and skin care, itch and scratch problems, psychological issues in coping with 
psoriasis, sleep hygiene and relapse prevention. To our knowledge, only one study 
described an educational program for children and adolescents with psoriasis, 
however this is in an inpatient setting.56 In contrast to this inpatient program, our 
program is in an outpatient setting in order to make the program more feasible and 
improve the transfer to daily practice. Based on the systematic semi-structured 
interviews and in agreement with the steering group, the subjects itch and scratch 
behaviour were introduced in our program since these subjects were often reported 
by children with psoriasis.43 The number of meetings in our program was kept as low 
as possible, in order to achieve the most optimal effect and the lowest burden for the 
patient and their parents. Therefore, our program consists of three sessions and one 
follow-up session with a duration of 2 ½ h per meeting. This is in contrast to other 
programs for children in which the number and duration of the sessions varied 
between a single 2-h workshop, and 10 lessons of 45 minutes in a 4- to 6-week 
period of rehabilitation.56-59 
Till now, 23 patients participated in the program. It is already known that the program 
is highly appreciated by both the children and their parents. The efficacy of this 
training program will be evaluated soon in a pilot study. It could be a promising 
addition to the standard dermatological care for paediatric psoriasis patients.
be made. Analyses of the influence of all treatments together on the 10 items of the 
CDLQI showed that the highest positive impacts were found in an improvement of 
itch and sleep disturbance. Only one previous study investigated the influence of 
treatment in children with psoriasis on the QoL.47 Because this study was a randomized 
controlled trial with etanercept, results of this study can hardly be compared with our 
daily clinical practice study. Our study demonstrated that children and adolescents 
with psoriasis still experience a negative impact on their QoL despite (successful) 
treatment. Therefore, it is important to focus on psychological aspects in conjunction 
to the standard dermatological care. Educational programs can support children 
and adolescents to cope with psoriasis. This important subject is highlighted and 
discussed in aim 5.  
In conclusion, paediatric psoriasis has a negative influence on the QoL of those 
affected. Especially itch and problems with the treatment itself bothered the children 
most. Treatments did influence the quality of life in a positive way, especially with a 
reduction of itch and an improvement in sleep. However, even after successful 
treatments, QoL is still impaired.
In Chapter 4.2 we described the development and validation of a specific instrument 
to assess the influence of scalp psoriasis on QoL in children, the Children’s Scalpdex 
in Psoriasis (CSP). The content of the CSP questions was based on the validated 
Scalpdex questionnaire.48 In our cohort of children with scalp psoriasis the items “my 
scalp itches” and “I am bothered by the persistence/reoccurrence of my scalp 
condition” were the two items with the highest scores, which is in line with the original 
Scalpdex in adults with scalp dermatitis (psoriasis and seborrhoeic dermatitis).48 The 
reliability of the CSP scales (symptoms, emotions, functioning) was relatively high 
(Cronbach’s α 0.69–0.91), and slightly better than the reliability reported by the 
original Scalpdex (Cronbach’s α 0.62–0.80).48 The scores of the three scales of the 
CSP showed a significant positive correlation with both patient- and physician-report-
ed scalp severity. Responsiveness analysis proved that the three scales of the CSP 
are sensitive to change in the expected direction in the children whose scalp psoriasis 
improved.
In conclusion, the results of this study showed that the CSP is a reliable, responsive 
and valid questionnaire. It is the first instrument to focus on scalp psoriasis in children, 
illustrating the specific influence of scalp psoriasis on QoL, with itch and reoccurrence 
of the condition being the most important issues in scalp psoriasis. In this study the 
questionnaire was validated for children with scalp psoriasis. However, it is highly 
likely that this questionnaire can also be used for other paediatric scalp conditions. 
The CSP can be used as a targeted questionnaire in the evaluation of outcome 
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• Short-contact dithranol therapy in paediatric psoriasis patients demonstrated a 
mean reduction in PASI score of -69.3%.
• Patients with regular day-care and day-care with telemedicine showed a comparable 
effectiveness of short-contact dithranol therapy. 
• The only adverse event reported in short-contact dithranol therapy was irritation of 
the skin, with no differences in frequency between the group of patients with only 
regular day care and the group of patients with day care with telemedicine.
• In 14 children with psoriasis treated with FAE, we found in 36% of these patients a 
complete response, 7% a good improvement, 21% a partial response and 36% of 
the patients were non-responders.
• Gastrointestinal complaints and flushing of the skin were the most frequent 
reported adverse drug reactions during treatment with FAE in paediatric psoriasis. 
We reported in 36% of the patients transient, slightly abnormal laboratory values of 
liver-function test or mild, temporary shifts in leukocyte counts.
Quality of life (Chapter 4)
• Paediatric psoriasis caused a significant negative impact on QoL of those affected.
• A positive influence of psoriasis treatments in daily clinical practice on the QoL in 
a cohort of children with psoriasis was demonstrated, with most improvement 
found in a reduction of itch and a reduction of sleep disturbance.
• The CSP questionnaire showed to be a reliable, responsive and valid questionnaire. 
It is the first instrument to focus on the influence of scalp psoriasis on the QoL of 
children with psoriasis.
• The development and design of a multidisciplinary training program for outpatient 
children and adolescents with psoriasis and their parents was described and 
illustrated.
5.3   Implications for current clinical practices  
and future perspectives
This thesis approaches the paediatric psoriasis patient in a holistic manner including 
genetic, therapeutic and psychological aspects. 
As has been demonstrated in this thesis, paediatric psoriasis might be a genetically 
different subgroup from adult psoriasis but also the therapeutic and psychological 
aspects of this vulnerable subgroup differ from adult psoriasis. By knowing the 
genetic and phenotypic profile of a paediatric patient the course of psoriasis might 
be better predicted. Future studies might focus on the genetic profile in combination 
with the effect of a treatment, to identify a predictor of treatment response paediatric 
5.2 Main conclusions of this thesis
The present thesis comprises genetics, treatment responsiveness, and quality of life 
in paediatric psoriasis. The main conclusions are listed below: 
Genetics (Chapter 2)
• Our complete psoriasis cohort (paediatric and adult onset) compared to 
controls without psoriasis demonstrated significant associations with HLA-C*06, 
LCE3C_LCE3B-del and SNPs in the ERAP1 and IL23R loci.
• In the complete psoriasis cohort we showed an interaction between HLA-C*06 
and LCE3C_LCE3B-del.
• Paediatric onset psoriasis compared to controls without psoriasis was associated 
with genes involved in epidermal barrier function (LCE3C_LCE3B-del) and 
adaptive immunity (HLA-C*06 and SNPs in the ERAP1 and IL23R loci).
• In paediatric onset psoriasis heritable factors might play an even more important 
role than in adult onset psoriasis.
• An onset of psoriasis < 10 years of age was significant associated with the 
psoriasis risk allele of SNP in the IL12B locus.
• No significant associations were found between family history of psoriasis and the 
allele frequency of the psoriasis risk factors. Even HLA-C*06 showed no significant 
associations.
• In our cohort severe psoriasis was associated with the SNPs tagging IFIH1 and 
ERAP1.
• In HLA-C*06 negative patients a significant increase of nail involvement was found
• None of the investigated risk factors showed a significant association with 
Koebnerization in our cohort.
Treatments (Chapter 3)
• Calcipotriol/betamethasone dipropionate scalp formulation in paediatric scalp 
psoriasis in daily clinical practice demonstrated to be effective with a 32.1% 
improvement of PSSI at week 12 and a maintenance of this effect until 48 weeks of 
follow-up.
• Subanalysis of patients pre-treated with salicylic acid for two nights demonstrated 
the highest improvements in the first 12 weeks. 
• At week 12, the response rate of at least 50% PSSI improvement compared to 
baseline was found in 29.9% (n=21) of the patients. 
• Clearance (PSSI = 0) was achieved in 22.2% of the patients (n=16) after a median 
treatment duration of 19 weeks.
• In 4.1% of the patients (n=3) striae of the skin (arms, trunk and legs) were observed, 
which were possibly related to the scalp formulation.
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and thus develop an individualized tailored approach. Recently Talamonti et al. 
demonstrated HLA-C*06 as a pharmacogenetic marker of response to ustekinumab 
in adults with psoriasis.60 The collection of the genetic profile and treatment effectiveness 
data by means of patient registries in daily clinical practice can be of additional value 
in the field of pharmacogenetics.    
The treatment of a paediatric psoriasis patient is complicated by a gap of evidence in 
safety and efficacy data. Many potential psoriasis treatments do not have an official 
label for paediatric use, forcing dermatologist to use them off-label. Registries can 
provide safety and effectiveness data and represent daily clinical practice. In contrast 
to randomized controlled trials, daily clinical practice registries include non-ideal and 
high-risk patients and it is possible to collect long term follow-up data. In addition to 
regular treatment, it is important to focus on the impact of psoriasis on the QoL of a 
child. An educational program can be of additional value to strengthen children and 
their parents in coping with and diminishing psoriasis related problems.
In order to collect more evidence on the genetics, efficacy and safety of treatments 
and psychological aspects of paediatric psoriasis, larger numbers of patients are 
necessary. By means of a large, prospective international registry, efficacy and safety 
data could be collected, as well as DNA samples, other biologic markers and QoL 
measurements. In this thesis, a first step in the holistic approach of the paediatric 
psoriasis patient has been made. The publications in this thesis will be helpful in the 
daily clinical practice of physicians treating paediatric psoriasis. In addition, these 
articles hopefully encourage other research groups to collaborate, and construct a 
prospective, international registry for paediatric psoriasis.
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6.1 Samenvatting en discussie
Het doel van dit proefschrift was om meer inzicht te krijgen in genetische, therapeutische 
en psychologische aspecten van kinderen met psoriasis. In Hoofdstuk 1 werden vijf 
doelen geformuleerd, verdeeld over drie onderwerpen; genetica, behandelingen en 
kwaliteit van leven. In dit hoofdstuk worden de belangrijkste conclusies van dit proefschrift 
samengevat en bediscussieerd. Tot slot worden toepassingen voor de dagelijkse 
klinische praktijk beschreven en suggesties voor toekomstig onderzoek gedaan.
In dit proefschrift werd het grootste gedeelte van de gegevens verkregen uit de 
Child-CAPTURE database. Dit is een prospectieve observationele database die 
gegevens bevat van kinderen met psoriasis (ontstaan < 18 jaar) die verwezen werden 
naar de polikliniek dermatologie van het Radboudumc in Nijmegen. De data zijn een 
weergave van behandelingen uit de dagelijkse praktijk.
Genetica
Doel 1: Onderzoeken naar genetische kenmerken van kinderen met psoriasis.
Op het gebied van psoriasis zijn veel genetische onderzoeken verricht. Er zijn echter 
weinig gegevens beschikbaar over de associatie van genetische risicofactoren voor 
psoriasis en de leeftijd waarop  psoriasis zich voor het eerst presenteert. Vooral naar 
een associatie tussen genetische risico factoren en leeftijd van ontstaan voor het 18e 
levensjaar werd nauwelijks onderzoek gedaan. Daarom werden in Hoofstuk 2.1 en 2.2 de 
mogelijke associaties onderzocht tussen zeven bekende genetische risicofactoren 
voor psoriasis (HLA*C06, LCE3C_LCE3B-del, IL23R, IL12B, ERAP1, IFIH1 en TRAF3-IP2) 
en het ontstaan van psoriasis op de kinderleeftijd (< 18 jaar) en volwassen leeftijd 
(≥ 18 jaar). We hebben laten zien, (in ons relatief kleine cohort van 151 patiënten), dat 
psoriasis ontstaan op de kinderleeftijd is geassocieerd met genetische risicofactoren 
voor psoriasis die betrokken zijn in epidermale barrière functie (LCE3C_LCE3B-del) 
en het verworven afweersysteem (HLA*C06, IL23R en ERAP1) vergeleken met een 
controle groep zonder psoriasis Als de groep van patiënten met psoriasis ontstaan 
op de kinderleeftijd wordt vergeleken met een groep patiënten waarbij de psoriasis 
op volwassen leeftijd is ontstaan, wordt in de kinderleeftijd groep een duidelijke 
associatie met HLAC6 gevonden ten opzichte van de volwassen groep. Worden 
patiënten met psoriasis vanaf volwassen leeftijd vergeleken met een controle groep 
zonder psoriasis, dan worden associaties met LCE3C_LCE3B-del en HLA*C06 gevonden. 
We bevestigden een eerder beschreven interactie tussen de psoriasis risicogenen 
HLA*C06 en LCE3C_LCE3B-del in de totale groep van psoriasis patiënten.1-3 
Een beperking van onze studies is het relatieve kleine aantal onderzochte patiënten. 
Onze genetische studie van 151 patiënten met psoriasis vanaf de kinderleeftijd is de 
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deze bevindingen  worden gerepliceerd in een groter cohort. Eerdere studies die 
voornamelijk bij patiënten met psoriasis vanaf volwassen leeftijd werden uitgevoerd, 
hebben een associatie aangetoond tussen een ernstige psoriasis en de genetische 
risicofactoren HLA-C*06 en LCE3C_LCE3B-del.7,11-13 Recent heeft een Zweedse 
groep aangetoond dat voornamelijk kinderen in de puberleeftijd HLA-C*06 positieve 
patiënten zijn die vaker plekken in het gezicht hebben en een guttata fenotype.9 
In ons cohort werd nagelpsoriasis vaker gezien in HLA-C*06 negatieve patiënten. 
Deze associatie is eerder beschreven in grotere studies, echter niet gespecificeerd 
voor leeftijd van ontstaan van psoriasis.12,13 Het is niet duidelijk waarom HLA-C*06 
negatieve patiënten vaker nagelpsoriasis hebben. 
Eerdere studies hebben een associatie beschreven tussen een positieve familie 
anamnese voor psoriasis en psoriasis vanaf jonge leeftijd (ontstaan voor 30e of 40e 
levensjaar), en tevens de associatie tussen en HLA-C*06 positiviteit en psoriasis 
vanaf jonge leeftijd.5-7,13 Op basis van deze studies veronderstelden we een sterke 
associatie te kunnen vinden, bij patiënten met psoriasis vanaf kinderleeftijd, tussen 
HLA-C*06 en een positieve familie anamnese voor psoriasis. Wij vonden dat een 
positieve familie anamnese (eerste tot en met derdegraads familieleden) niet 
geassocieerd was met HLA-C*06 in onze specifieke groep van kinderpsoriasis 
(ontstaan voor 18e jaar). Ook de andere onderzochte genetische risicofactoren voor 
psoriasis waren niet geassocieerd met familie anamnese voor psoriasis. Mogelijk 
spelen andere genen een belangrijke rol bij de erfelijkheid van psoriasis. 
Eerdere studies suggereerden een rol voor de LCE3 genen in de huid barrière unctie.1 
Op deze studies baseerden wij onze hypothese dat een verminderde barrièrefunctie 
(LCE3C_LCE3B-del) van de huid mogelijk een oorzaak zou kunnen zijn voor het 
ontstaan van psoriasis.1 Koebner fenomeen is het ontstaan van psoriasis plekken na 
beschadiging van de niet aangedane huid. Dit komt voor bij ongeveer een kwart van 
de psoriasis patiënten.14 In Hoofdstuk 2.2 en 2.3 hebben we de relatie tussen 
LCE3C_LCE3B-del en het optreden van Koebner fenomeen in psoriasis patiënten 
onderzocht. Uit dit onderzoek bleek dat LCE3C_LCE3B-del het optreden van Koebner 
fenomeen in ons patiënten cohort niet verklaart. 
Concluderend kunnen we stellen dat in ons cohort met kinderen met psoriasis een 
ernstigere psoriasis was geassocieerd met de genetische risicofactoren voor 
psoriasis IFIH1 en ERAP1. We konden geen associatie aantonen tussen familie 
anamnese voor psoriasis en genetische risicofactoren voor psoriasis (zelfs niet voor 
HLA-C*06) en niet tussen LCE3C_LCE3B-del en het optreden van Koebner fenomeen. 
Verder onderzoek is nodig om de relatie tussen genetische risicofactoren voor 
een van de eerste studies die deze associaties heeft onderzocht en beschreven in 
deze specifieke leeftijdsgroep. Zoals gezegd is het aantal geïncludeerde patiënten 
beperkt, zeker in vergelijking met grote genoom wijde associatie studies, waarin vaak 
duizenden patiënten worden geïncludeerd. 
De associatie tussen HLA-C*06 en jonge leeftijd van ontstaan van psoriasis was al 
wel eerder in de literatuur beschreven.4-8 Een Zweeds cohort toonde aan dat ERAP1 
is geassocieerd met psoriasis ontstaan tussen 10 en 20 jaar.8 Zij vonden in deze 
groep van pubers de sterkste associatie met HLA-C*06.8-10 In ons cohort konden 
deze associaties in deze specifieke leeftijdsgroep (tussen 10 en 20 jaar) niet 
gerepliceerd worden, maar wij vonden wel een associatie met leeftijd van ontstaan 
voor 10e levensjaar en genetische variatie in het IL12B gen (Hoofdstuk 2.2). 
Concluderend kunnen we stellen dat in ons cohort associaties werden gevonden 
tussen kinderpsoriasis en de psoriasis risicogenen ERAP1, IL23R, LCE3C_LCE3B-del 
en HLA-C*06. Gebaseerd op onze resultaten beschreven in Hoofdstuk 2.1 en 2.2 en 
eerdere publicaties lijken erfelijke factoren mogelijk een belangrijkere rol te spelen bij 
psoriasis ontstaan op kinderleeftijd dan psoriasis die op latere leeftijd is ontstaan. 
Voor de toekomst hopen we dat onze bevindingen andere centra motiveren om 
patiënt karakteristieken te registreren en DNA te verzamelen om op die manier onze 
bevindingen te repliceren en hopelijk nieuwe associaties te vinden. Opheldering van 
de genetisch factoren in een vroege fase zou kunnen leiden tot een beter lange 
termijn management van kinderpsoriasis en zou kunnen bijdragen aan de ontwikkeling 
van meer gerichte behandeling voor kinderpsoriasis.
Doel 2: Detecteren van genotype-fenotype associaties in kinderen  
met psoriasis.
Psoriasis is een complexe heterogene ziekte, met een variatie in klinische presentatie 
(fenotype) en genoom predispositie (genotype). Om psoriasis beter te kunnen begrijpen 
hebben we in Hoofdstuk 2.2 en 2.3 associaties onderzocht tussen bekende genetische 
risicofactoren voor psoriasis (zoals beschreven bij doel 1) en verschillende parameters 
zoals familie anamnese voor psoriasis, leeftijd van ontstaan en klinische kenmerken 
(ernst van psoriasis, nagelpsoriasis en Koebner fenomeen).
In Hoofdstuk 2.2 hebben we laten zien dat een ernstige psoriasis was geassocieerd 
met de genetische risicofactoren voor psoriasis IFIH1 en ERAP1. Onze studie is de 
eerste die deze genetische associaties met ernstige psoriasis heeft beschreven in 
deze specifieke groep van kinderpsoriasis patiënten. Deze studie vond echter plaats 
in een klein cohort, zeker voor genetica begrippen. Het zou daarom goed zijn dat 
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onze groep aangetoond dat ditranol korte contact therapie kan worden gezien als 
een effectieve en veilige behandeling bij kinderen met psoriasis.18 We hebben in 
Hoofdstuk 3.2 prospectief onderzoek gedaan naar de effectiviteit en veiligheid van 
ditranol korte contact therapie bij kinderen met psoriasis. Daarbij hebben we ook 
onderzocht of er een verschil is in effectiviteit en veiligheid tussen patiënten die alleen 
via dagbehandeling behandeld werden  en patiënten waarbij de dagbehandeling 
deels vervangen werd door telezorg. Wij hebben aangetoond dat ditranol korte 
contact therapie bij kinderen met psoriasis effectief is, met 69,3% verbetering van de 
ernst score van de psoriasis (gemeten met behulp van de PASI score). Er werd geen 
verschil gevonden in effectiviteit tussen patiënten met alleen dagbehandeling en 
patiënten met dagbehandeling in combinatie met telezorg. Eerdere studies naar de 
behandeling van ditranol bij kinderen met psoriasis beschreven geen objectiveer-
bare scores als uitkomstmaat.18,19 In het verleden is aangetoond dat de beste 
resultaten met ditranol korte contact therapie worden bereikt wanneer het wordt 
toegepast in een dagbehandeling setting met regelmatige bezoeken.20 Contacten 
met behulp van telezorg kan de belasting van regelmatige bezoeken aan het 
ziekenhuis verminderen. Wij hebben aangetoond dat toevoeging van telezorg (ter 
vervanging van een bezoek aan de dagbehandeling) van toegevoegde waarde kan 
zijn, aangezien het minder tijdsintensief is. De groep patiënten met telezorg had 
logischerwijs minder bezoeken aan de dagbehandeling. De enige bijwerking die in 
onze studie werd gerapporteerd was irritatie van de huid. Er werd geen verschil 
gevonden in de frequentie van irritatie tussen beide patiëntgroepen. Vergeleken met 
eerdere retrospectieve studies vonden wij een relatief hoge frequentie van irritatie van 
de huid.18,19 De frequentie van irritatie in andere studies zou mogelijk niet correct 
kunnen zijn vanwege het retrospectieve karakter of, onze applicatietijd zou te lang 
kunnen zijn. Er zijn echter nog geen studies geweest die hebben onderzocht welk 
applicatie schema van ditranol korte contact therapie het meest effectief is. Uit onze 
gegevens concluderen we dat ditranol korte contact therapie een zeer effectieve en 
veilige behandeling is. De introductie van telezorg als gedeeltelijke vervanging van 
bezoeken aan de dagbehandeling zorgt voor een vermindering van het aantal 
bezoeken met behoud van goed resultaat. Het is interessant om te onderzoeken of 
het aantal bezoeken aan de dagbehandeling nog verder omlaag zou kunnen. Door 
de toevoeging van telezorg aan de reguliere dagbehandeling kan ditranol korte contact 
therapie beschikbaar worden voor een grotere groepen kinderen met psoriasis. 
Fumaarzuur is een systemische behandeling die al meer dan 25 jaar wordt voor- 
geschreven aan volwassen patiënten met psoriasis in voornamelijk Duits sprekende 
landen.21 Fumaarzuur is officieel niet geregistreerd in Nederland. Er zijn enkele case 
reports gepubliceerd over het gebruik van fumaarzuur bij kinderen met psoriasis.22-24 
In Hoofdstuk 3.3 beschrijven we retrospectief de eerste case serie over de effectiviteit 
psoriasis en de verschillende klinische fenotypen beter te verklaren. Door meer 
duidelijkheid te krijgen over de associatie tussen genotype en fenotype ontstaat de 
mogelijkheid om psoriasis te kunnen stratificeren, doelgerichte behandelingen te 
geven en mogelijk klinische resultaten te voorspellen. 
Behandelingen
Doel 3: Het onderzoeken van de effectiviteit en veiligheid van verschillende 
behandelingen van kinderpsoriasis in de dagelijkse klinische praktijk.
Er is weinig bewijs over de effectiviteit en veiligheid van (lokale) behandelingen voor 
kinderpsoriasis. In dit proefschrift hebben we prospectief de effectiviteit en veiligheid 
van calcipotriol/betamethason hoofdgel bij kinderen met psoriasis op het behaarde 
hoofd onderzocht in Hoofdstuk 3.1. Deze hoofdgel bleek effectief te zijn, met op 
week 12 een 32,1% verbetering van de ernst score van psoriasis op de behaarde 
hoofdhuid (Psoriasis Scalp Severity Index (PSSI)). Dit effect bleef behouden tot een 
follow-up duur van 48 weken. Twee nachten voorbehandeling met salicylzuur ter 
ontschilfering van de behaarde hoofdhuid (voorgeschreven op basis van de mening 
van de behandelend arts) toonde een positief additioneel effect op de PSSI in de 
eerste 12 weken. Op week 12 werd er in 29,9% van de patiënten (n=21) een 50% 
verbetering in de PSSI gevonden ten opzichte van start van de behandeling. Bij 
22,2% van de patiënten (n=16) werd er een PSSI score van 0 bereikt na een 
gemiddelde behandelduur van 19 weken. Drie patiënten (met overgewicht) (4,1%) 
ontwikkelden striae van de huid (armen, romp en benen), dit was mogelijk gerelateerd 
aan het gebruik van de hoofdgel. In onze studie werden er geen ernstige bijwerkingen 
gerapporteerd. Een vergelijking van onze studie met andere studies is niet mogelijk 
omdat er verschillende uitkomstmaten zijn gebruikt en verschillende behandelregime 
zijn toegepast. In onze studie is het bijwerkingenprofiel gebaseerd op zelf gerapporteerde 
bijwerkingen van de patiënten, en observaties door arts. Er is niet actief naar 
geïnformeerd, zoals dat in gerandomiseerd onderzoek met een controlegroep vaak 
wordt gedaan. Verder kregen de patiënten in onze studie geen wash-out periode 
voor aanvang van de behandeling. Bovendien waren onze patiënten in de dagelijkse 
praktijk mogelijk minder gemotiveerd om de behandeling te gebruiken ten opzichte 
van patiënten die deelnemen aan gerandomiseerd onderzoek.15,16 Gezien het 
beperkte aantal patiënten in onze studie, is het niet mogelijk om harde conclusies te 
trekken met betrekking tot de veiligheid van calcipotriol/betamethason hoofdgel bij 
kinderen met psoriasis op het behaarde hoofd. 
Ditranol is een van de oudste lokale behandelingen voor psoriasis. Deze behandeling 
kan worden overwogen indien behandeling met calcipotriol en lokale corticoste-
roïden onvoldoende effectief zijn.17 In een eerdere retrospectieve studie werd door 
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Kwaliteit van leven
Doel 4: Meer inzicht verkrijgen in de kwaliteit van leven van kinderen  
met psoriasis.
Huidziekten kunnen een negatieve impact hebben op de kwaliteit van leven (KvL) bij 
kinderen.26 Gegevens over de impact van psoriasis op de KvL bij kinderen zijn 
beperkt.26-28 In Hoofdstuk 4.1 onderzochten we cross-sectioneel en longitudinaal de 
invloed van psoriasis op de KvL van kinderen met behulp van de ‘Children’s 
Dermatology Life Quality Index’ (CDLQI) vragenlijst (score 0 tot 30; hogere score 
betekent een slechtere KvL). In een groep van 125 kinderen met psoriasis vonden we 
cross-sectioneel een gemiddelde CDLQI score van 7,5. Eerdere cross-sectionele 
studies bij kinderen met psoriasis beschreven een gemiddelde CDLQI score tussen 
de 5 en 10.26,28-31 Onze resultaten toonden dat de items ” jeuk” en “problemen met de 
behandeling“ de meeste impact op de KvL van de kinderen hadden. Verder zagen 
we dat de adolescenten (≥ 12 jaar) significant meer problemen hadden met kleding 
en sporten in vergelijking met jongere kinderen (< 12 jaar). Behandelingen (lokaal, 
ditranol en systemische) zorgen voor een daling in de CDLQI score (verbetering van 
KvL). De grootste positieve impact werd gevonden in een verbetering van de 
jeukklachten en vermindering van slaapproblemen. 
Slechts één eerdere studie had (tot onze publicatie) de invloed van een behandeling 
op de kwaliteit van leven van kinderen met psoriasis onderzocht.31 Omdat dit een 
gerandomiseerde gecontroleerde studie betrof, konden deze resultaten niet worden 
vergeleken met onze resultaten uit de dagelijkse klinische praktijk. 
Onze studie toonde dat kinderen en adolescenten met psoriasis een negatieve 
impact op de kwaliteit van leven ervaren ondanks (succesvolle) behandeling. Het is 
daarom belangrijk om ook op psychologische aspecten te focussen naast de standaard 
dermatologische zorg. Educatie programma’s kunnen kinderen en adolescenten 
ondersteunen bij het leren omgaan met psoriasis. Dit belangrijke onderwerp wordt 
besproken in doel 5.
Concluderend kan gezegd worden dat kinderpsoriasis  een negatieve impact op de 
KvL heeft. De kinderen irriteren zich het meest aan de jeuk en problemen met de 
voorgeschreven behandeling. Behandeling heeft een positieve invloed op de KvL, 
voornamelijk door een vermindering van jeukklachten en een verbetering van de 
slaapproblemen. Echter ondanks een succesvolle behandeling blijven deze kinderen 
een verminderde KvL hebben.
In Hoofdstuk 4.2 beschrijven we de ontwikkeling en validatie van een specifieke 
vragenlijst om de invloed van psoriasis op het behaarde hoofd op de KvL van 
kinderen te meten, de ‘Children’s Scalpex in Psoriasis’ (CSP). De inhoud van de 
en veiligheid van fumaarzuur in 14 kinderen met psoriasis. We vonden een mediane 
leeftijd van 15 jaar bij start van de behandeling en een mediane duur van behandeling 
van 10 maanden. We vonden in 36% van de patiënten een complete respons, 7% een 
goede verbetering, 21% een gedeeltelijke respons en 36% van de patiënten was 
non-responder. Bij volwassenen patiënten met psoriasis behandeld met fumaarzuur 
wordt in 50% tot 70% van de patiënten een 75% verbetering van de PASI score (score 
voor de ernst van psoriasis) beschreven.25 Een beperking van onze retrospectieve 
studie is dat we geen PASI scores beschikbaar hadden voor alle patiënten. De 
meeste gerapporteerde bijwerkingen in onze studie waren maag-darm klachten 
(buikklachten, diarree en misselijkheid) en opvliegers. In 36% van de patiënten werden 
licht afwijkende leverfunctie waarden of een tijdelijke verschuiving in leukocyten 
aantal gevonden. Bij alle patiënten normaliseerden de laboratorium waarden zonder 
interventie of onderbreking van de behandeling. In onze serie van patiënten werden 
geen ernstige bijwerkingen gerapporteerd. De bijwerkingen en laboratorium onderzoeken 
gevonden in onze studie komen overeen met volwassen patiënten met psoriasis 
behandeld met fumaarzuur.25 Onze resultaten suggereren dat fumaarzuur een 
veelbelovende systemische behandelingsmogelijkheid kan zijn bij kinderen met 
psoriasis. Verder onderzoek is nodig om de effectiviteit en veiligheid van fumaarzuur 
in kinderpsoriasis te evalueren en de effectiviteit te vergelijken met andere systemische 
behandelingen zoals methotrexaat. Wij zijn nog steeds bezig om lange termijn 
prospectieve data te verzamelen in de Child-CAPTURE database over de effectiviteit 
en veiligheid van fumaarzuur. 
Gebaseerd op de bovenstaande drie studies kunnen we concluderen dat calcipotriol/
betamethason hoofdgel bij kinderen met psoriasis op het behaarde hoofd effectief 
en veilig lijkt te zijn. Ditranol korte contact therapie bij kinderen met psoriasis effectief 
is en zou daarom kunnen worden aangeboden indien kinderen met psoriasis niet of 
onvoldoende reageren op eerstelijn lokale behandelingen. De vervanging van een 
deel van de dagbehandeling door telezorg, zorgt ervoor dat deze behandeling 
beschikbaar wordt voor kinderen die verder weg van het ziekenhuis wonen. Daardoor 
kan deze behandeling mogelijk worden voor een grotere groep patiënten. Onze 
studie naar fumaarzuur bij kinderen met psoriasis toonde dat dit een veelbelovende 
systemische behandeling kan zijn. Vanwege het lage aantal patiënten onderzocht 
zijn aanvullende studies nodig bij. Het is interessant om de effectiviteit van fumaarzuur 
uitgebreider te onderzoeken en eventueel te vergelijken met methotrexaat. 
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bekend is er één andere studie die een educatie programma beschrijft voor kinderen 
en adolescenten met psoriasis, echter is dit in een klinische setting.40 Ons programma 
is daarentegen in een poliklinische setting opgesteld,om het programma beter 
uitvoerbaar te maken. De onderwerpen die tijdens de training aan bod komen zijn 
informatie over de huidaandoening en mogelijke behandelvormen, regelmatige 
huidverzorging, het leren omgaan met jeuk en krabgedrag en leren omgaan met de 
gevolgen van de huidaandoening in het dagelijks leven. Het aantal bijeenkomsten in 
ons programma is zo laag mogelijk gehouden om het meest optimale effect te 
bereiken bij de laagste belasting voorde patiënt en ouders. Het programma bestaat 
uit drie sessies en een follow-up sessie met een duur van 2,5 uur per bijeenkomst.
Tot nu toe hebben er 23 patiënten deelgenomen aan het programma. Kinderen en 
ouders stellen het programma zeer op prijs. Het effect van het programma wordt 
binnenkort geëvalueerd in een pilot studie. Het programma kan veel belovend zijn in 
aanvulling op standaard dermatologische zorg voor kinderen met psoriasis. 
6.2 De belangrijkste conclusies van dit proefschrift
Genetica (Hoofdstuk 2)
•	 In ons cohort van psoriasis (kinder- en volwassen leeftijd) vergeleken met controle 
groep zonder psoriasis werden significante associaties gevonden met HLA-C*06, 
LCE3C_LCE3B-del, ERAP1 en IL23R.
•	 Psoriasis ontstaan op kinderleeftijd vergeleken met controlegroep zonder psoriasis 
was geassocieerd met genetische risicofactoren voor psoriasis LCE3C_LCE3B-del, 
HLA-C*06, ERAP1 en IL23R.
•	 Erfelijke factoren zouden mogelijk een belangrijkere rol spelen bij psoriasis ontstaan 
op de kinderleeftijd dan psoriasis die op latere leeftijd is ontstaan.
•	 Psoriasis ontstaan voor het 10e levensjaar was in ons cohort geassocieerd met de 
genetische risicofactor voor psoriasis IL12B.
•	 Er konden geen associaties worden aangetoond tussen een positieve familie 
anamnese voor psoriasis en genetische risicofactoren voor psoriasis.
•	 In ons cohort was een ernstigere psoriasis geassocieerd met de genetische 
risicofactoren IFIH1 en ERAP1.
•	 Er werd vaker nagelpsoriasis gezien bij patiënten die HLA-C*06 negatief waren.
•	 Geen van de onderzochte genetische risicofactoren voor psoriasis toonde een 
significante associatie met het Koebner fenomeen. 
Behandelingen (Hoofdstuk 3)
•	 Calcipotriol/betamethason hoofdgel in de dagelijkse praktijk was effectief met een 
32,1% verbetering in PSSI score op week 12; dit effect werd gehandhaafd tot 48 
weken follow-up.
vragenlijst is gebaseerd op de gevalideerde Scalpdex vragenlijst.32 In ons cohort van 
kinderen met psoriasis op het behaarde hoofd scoorden de volgende 2 items het 
hoogst; ‘mijn behaarde hoofd jeukt’ en ‘Ik erger me aan de psoriasis op mijn behaarde 
hoofdhuid’. Dit komt overeen met de oorspronkelijke Scalpdex vragenlijst bij 
volwassenen met huidaandoeningen op behaarde hoofd (psoriasis en seborroïsch 
eczeem).32 De betrouwbaarheid van de drie CSP schalen (symptomen, emoties en 
functioneren) was relatief hoog, en iets beter dan de betrouwbaarheid gerapporteerd 
bij de oorspronkelijke Scalpdex. De scores van de drie schalen van de CSP toonden 
een significante positieve correlatie met patiënt en arts gerapporteerde ernst van 
psoriasis op behaarde hoofd. Analyses toonden dat de drie schalen van de CSP 
vragenlijst gevoelig zijn om te veranderen in de te verwachten richting bij de kinderen 
waarbij de psoriasis op het behaarde hoofd verbetert. 
Concluderend kunnen we stellen dat onze studie toonde dat de CSP een betrouwbare, 
responsieve en valide vragenlijst is. Het is de eerste vragenlijst die zich richt op de 
invloed van psoriasis op het behaarde hoofd op de KvL bij kinderen. In onze studie 
was de vragenlijst gevalideerd voor kinderen met psoriasis op het behaarde hoofd. 
Deze vragenlijst zou mogelijk ook gebruikt kunnen worden voor andere aandoeningen 
op het behaarde hoofd bij kinderen. De CSP kan gebruikt worden als een specifieke 
vragenlijst voor de evaluatie van resultaten en effect van therapeutische interventie 
op de KvL bij kinderen met psoriasis op het behaarde hoofd. In Hoofdstuk 3.1 
toonden we dat calcipotriol/betamethason hoofdgel een positieve invloed heeft op 
de KvL na drie maanden behandelen, gemeten met de CSP vragenlijst. 
Doel 5: Het ontwikkelen van een multidisciplinair trainingsprogramma voor 
kinderen met psoriasis samen met de medisch psycholoog. 
Er zijn diverse patiënt educatie programma’s ontwikkeld voor volwassen patiënten 
met psoriasis gericht op psychologische interventie. Deze programma’s resulteerden 
in een verbetering van kennis en coping.33-39 In Hoofdstuk 4.3 beschreven we de 
ontwikkeling en het ontwerp van het eerste poliklinische multidisciplinaire training-
sprogramma voor kinderen met psoriasis en hun ouders. Dit programma is ontwikkeld 
samen met twee medisch psychologen gespecialiseerd op het gebied van de 
dermatologie. Voor de ontwikkeling van dit programma werd literatuur onderzoek 
gedaan, een stuurgroep samengesteld en werden systematische semi-gestructuu-
reerde interviews gehouden. Het trainingsprogramma is gericht op het zo goed 
mogelijk leren omgaan met de huidaandoening. Onderwerpen die tijdens de training 
aan bod komen zijn informatie over de huidaandoening en mogelijke behandelvormen, 
regelmatige huidverzorging, het leren omgaan met jeuk en krabgedrag en leren 
omgaan met de gevolgen van de huidaandoening in het dagelijks leven. Voor zo ver 
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6.3  Implicaties voor de huidige klinische praktijk  
en toekomst perspectieven
Dit proefschrift heeft de kinderen en adolescenten met psoriasis benaderd vanuit 
een holistische visie, waarbij zowel naar genetische aspecten als behandelingen en 
psychologische aspecten werd gekeken.
In dit proefschrift is aangetoond, dat psoriasis ontstaan vanaf kinderleeftijd mogelijk 
een genetische subgroep is ten opzichte van psoriasis ontstaan vanaf volwassen 
leeftijd. Maar ook de behandelingen en psychologische aspecten van deze kwetsbare 
groep verschillen van volwassen patiënten met psoriasis. Door het genetische en 
fenotypische profiel van kinderpsoriasis in kaart te brengen, zou het beloop mogelijk 
beter voorspeld kunnen worden. Toekomstige studies zullen zich meer richten op het 
genetische profiel in combinatie met het effect van een behandeling, om een 
therapeutisch respons te kunnen voorspellen en daarmee een meer geïndividuali-
seerde aanpak op maat te kunnen ontwikkelen. De verzameling van het genetische 
profiel en effectiviteit data van behandelingen met behulp van patiënt registries in de 
dagelijkse klinische praktijk kan van toegevoegde waarde zijn op het gebied van 
farmacogenetica. 
De behandeling van psoriasis bij kinderen is complex door een gebrek aan data over 
veiligheid en effectiviteit van behandelingen. Veel psoriasis behandelingen hebben 
geen officiële registratie voor gebruik bij kinderen, waardoor dermatologen gedwongen 
worden tot off-label gebruik. Registries kunnen zorgen voor representatieve veiligheids- 
en effectiviteits- gegevens uit de dagelijkse praktijk. In tegenstelling tot gerandomi-
seerde gecontroleerde studies bevatten dagelijkse klinische praktijk registries de 
niet-ideale patiënten met comorbiditeiten en is het mogelijk om lange termijn data te 
verzamelen. Naast de standaard behandeling van psoriasis, is het belangrijk om ons 
te richten op de impact van de psoriasis op de KvL van een kind. Een educatie 
programma kan van toegevoegde waarde zijn om  kinderen en hun ouder(s) sterker te 
maken in het leren omgaan met, en verminderen van psoriasis gerelateerde problemen. 
Om meer bewijs te verzamelen over de genetische aspecten effectiviteit en veiligheid 
van behandelingen, en psychologische aspecten van kinderpsoriasis zijn grote groepen 
van patiënten nodig. Met behulp van een grote prospectieve internationale registry, 
kunnen effectiviteits- en veiligheidsdata worden verzameld, net als DNA, andere 
biologische markers en KvL metingen. In dit proefschrift is een eerste stap gemaakt 
in de holistische benadering van het kind en de adolescent met psoriasis. Hopelijk 
moedigt dit proefschrift andere onderzoeksgroepen aan om samen te werken in het 
opbouwen van een prospectieve, internationale registry voor kinderen met psoriasis.
•	 Patiënten die voorafgaand aan de behandeling werden  behandeld met salicylzuur 
gedurende twee nachten lieten de grootste verbetering zien in de eerste 12 weken.
•	 Op week 12 werd bij 29,9% van de patiënten (n=21) een 50% verbetering van de 
PSSI score gevonden ten opzichte van baseline.
•	 Bij 22,2% van de patiënten (n=16) werd een complete remissie (PSSI = 0) van de 
psoriasis op het behaarde hoofd gevonden na een gemiddelde behandelduur van 
19 weken. 
•	 Bij 4,1% van de patiënten (n=3) werden striae van de huid (armen, romp en benen) 
geobserveerd, welke mogelijk gerelateerd  zijn aan de calcipotriol/betamethason 
hoofdgel.
•	 Ditranol korte contact therapie bij kinderen met psoriasis is effectief,  met een 
gemiddelde verbetering van 69,3% in PASI score.
•	 Er werden vergelijkbare resultaten gevonden in effectiviteit bij patiënten met 
reguliere dagbehandeling en dagbehandeling in combinatie met telezorg.
•	 De enige gerapporteerde bijwerking bij ditranol korte contact therapie was irritatie 
van de huid, hierbij werd er geen verschil gevonden in frequentie van irritatie 
tussen patiënten met reguliere dagbehandeling en dagbehandeling in combinatie 
met telezorg.
•	 Bij 14 kinderen met psoriasis behandeld met fumaarzuur toonden we in 36% van 
de patiënten een complete respons, 7% een goede verbetering, 21% een 
gedeeltelijke respons en 36% van de patiënten was non-responder. 
•	 De meest gerapporteerde bijwerking tijdens behandeling met fumaarzuur bij 
kinderen met psoriasis was maag-darm klachten en opvliegers. 
Kwaliteit van leven (Hoofdstuk 4)
•	 Psoriasis bij kinderen heeft een negatieve invloed op de kwaliteit van leven. 
•	 Behandeling van kinderen met psoriasis in de dagelijkse klinische praktijk zorgt 
voor een positieve invloed op de kwaliteit van leven, waarbij e grootste verbetering 
gevonden wordt  in een vermindering van jeukklachten en minder slaapproblemen. 
•	 De Children’s Scalpdex in Psoriasis  is een betrouwbare, responsieve en valide 
vragenlijst. Dit is de eerste vragenlijst die zich richt op de invloed van psoriasis op 
het behaarde hoofd op de kwaliteit van leven van kinderen met psoriasis. 
•	 De ontwikkeling en het ontwerp van een multidisciplinaire poliklinisch training-
sprogramma voor kinderen en adolescenten met psoriasis en hun ouders werd 
beschreven en geïllustreerd.
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